EP1685094A1 - Acylurea connected and sulfonylurea connected hydroxamates - Google Patents
Acylurea connected and sulfonylurea connected hydroxamatesInfo
- Publication number
- EP1685094A1 EP1685094A1 EP04775672A EP04775672A EP1685094A1 EP 1685094 A1 EP1685094 A1 EP 1685094A1 EP 04775672 A EP04775672 A EP 04775672A EP 04775672 A EP04775672 A EP 04775672A EP 1685094 A1 EP1685094 A1 EP 1685094A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- optionally substituted
- group
- phenyl
- ethyl
- benzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007945 N-acyl ureas Chemical class 0.000 title abstract description 19
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title abstract description 19
- 229940100389 Sulfonylurea Drugs 0.000 title abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 262
- 238000002360 preparation method Methods 0.000 claims abstract description 104
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 71
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 63
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 63
- 230000000694 effects Effects 0.000 claims abstract description 42
- 238000011282 treatment Methods 0.000 claims abstract description 41
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 230000002062 proliferating effect Effects 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 22
- -1 sulfonylamino, sulfinylamino, phenoxy, benzyloxy Chemical group 0.000 claims description 203
- 229910052739 hydrogen Inorganic materials 0.000 claims description 87
- 125000000217 alkyl group Chemical group 0.000 claims description 77
- 206010028980 Neoplasm Diseases 0.000 claims description 62
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 55
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 54
- 125000003118 aryl group Chemical group 0.000 claims description 53
- 125000001072 heteroaryl group Chemical group 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 51
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 50
- 208000035475 disorder Diseases 0.000 claims description 45
- 125000002252 acyl group Chemical group 0.000 claims description 43
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 38
- 201000011510 cancer Diseases 0.000 claims description 37
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 37
- 229940002612 prodrug Drugs 0.000 claims description 36
- 239000000651 prodrug Substances 0.000 claims description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 34
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 33
- 125000000304 alkynyl group Chemical group 0.000 claims description 31
- 125000003545 alkoxy group Chemical group 0.000 claims description 30
- 125000001188 haloalkyl group Chemical group 0.000 claims description 29
- 125000003282 alkyl amino group Chemical group 0.000 claims description 28
- 125000004442 acylamino group Chemical group 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 25
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 24
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 24
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 24
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 18
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 18
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 18
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 18
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 18
- 208000026278 immune system disease Diseases 0.000 claims description 18
- 208000027866 inflammatory disease Diseases 0.000 claims description 18
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 17
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 17
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 17
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 16
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 16
- 125000001769 aryl amino group Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 16
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 15
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 15
- 125000000732 arylene group Chemical group 0.000 claims description 15
- 125000004104 aryloxy group Chemical group 0.000 claims description 15
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 15
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 206010060862 Prostate cancer Diseases 0.000 claims description 13
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 13
- 125000005549 heteroarylene group Chemical group 0.000 claims description 13
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 13
- 125000003107 substituted aryl group Chemical group 0.000 claims description 13
- VKVJIWVUYNTBEZ-UHFFFAOYSA-N 1,3-bis(3,5-dichlorophenyl)urea Chemical compound ClC1=CC(Cl)=CC(NC(=O)NC=2C=C(Cl)C=C(Cl)C=2)=C1 VKVJIWVUYNTBEZ-UHFFFAOYSA-N 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 12
- 125000001091 aminosulfinyl group Chemical group [H]N([H])S(*)=O 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 12
- 201000002528 pancreatic cancer Diseases 0.000 claims description 12
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 12
- 125000005717 substituted cycloalkylene group Chemical group 0.000 claims description 12
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 11
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 claims description 9
- 208000023105 Huntington disease Diseases 0.000 claims description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 9
- 206010038389 Renal cancer Diseases 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 230000033115 angiogenesis Effects 0.000 claims description 9
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000010536 head and neck cancer Diseases 0.000 claims description 9
- 201000010982 kidney cancer Diseases 0.000 claims description 9
- KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 claims description 9
- 230000004770 neurodegeneration Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 9
- 102100038715 Histone deacetylase 8 Human genes 0.000 claims description 8
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 8
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 7
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 claims description 7
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 claims description 6
- 229910020008 S(O) Inorganic materials 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- 150000002430 hydrocarbons Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- RPGQDNYTFIIQFG-UHFFFAOYSA-N n-[[6-(hydroxyamino)-6-oxohexyl]carbamothioyl]benzamide Chemical compound ONC(=O)CCCCCNC(=S)NC(=O)C1=CC=CC=C1 RPGQDNYTFIIQFG-UHFFFAOYSA-N 0.000 claims description 6
- VQLQZMGNGMOMPU-UHFFFAOYSA-N n-[[6-(hydroxyamino)-6-oxohexyl]carbamoyl]benzamide Chemical compound ONC(=O)CCCCCNC(=O)NC(=O)C1=CC=CC=C1 VQLQZMGNGMOMPU-UHFFFAOYSA-N 0.000 claims description 6
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 6
- 208000003120 Angiofibroma Diseases 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 206010017533 Fungal infection Diseases 0.000 claims description 5
- 102100039996 Histone deacetylase 1 Human genes 0.000 claims description 5
- 208000031888 Mycoses Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 230000003176 fibrotic effect Effects 0.000 claims description 5
- DEKDRKOBNHSPFL-UHFFFAOYSA-N n-[[6-(hydroxyamino)-6-oxohexyl]-(pyridin-2-ylmethyl)carbamoyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(=O)N(CCCCCC(=O)NO)CC1=CC=CC=N1 DEKDRKOBNHSPFL-UHFFFAOYSA-N 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 4
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- QSNIVZUEIYKLLL-UHFFFAOYSA-N N-[[1-[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]-2-phenylpropyl]carbamoyl]benzamide Chemical compound C(C1=CC=CC=C1)(=O)NC(NC(C1=CC=C(C=C1)C=CC(=O)NO)C(C)C1=CC=CC=C1)=O QSNIVZUEIYKLLL-UHFFFAOYSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 230000006882 induction of apoptosis Effects 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- OKHVAIWRKWXLGO-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-[2-(1h-indol-3-yl)ethyl]carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCC1=CNC2=CC=CC=C12 OKHVAIWRKWXLGO-UHFFFAOYSA-N 0.000 claims description 4
- WUKFQTZVXXYEAB-UHFFFAOYSA-N n-[[8-(hydroxyamino)-8-oxooctyl]carbamoyl]benzamide Chemical compound ONC(=O)CCCCCCCNC(=O)NC(=O)C1=CC=CC=C1 WUKFQTZVXXYEAB-UHFFFAOYSA-N 0.000 claims description 4
- 108010040003 polyglutamine Proteins 0.000 claims description 4
- 229920000155 polyglutamine Polymers 0.000 claims description 4
- XGEOJELIFQONSX-UHFFFAOYSA-N 4-[(benzoylcarbamoylamino)methyl]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CNC(=O)NC(=O)C1=CC=CC=C1 XGEOJELIFQONSX-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 3
- 208000003495 Coccidiosis Diseases 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims description 3
- 206010016212 Familial tremor Diseases 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 3
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010023076 Isosporiasis Diseases 0.000 claims description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
- 208000004554 Leishmaniasis Diseases 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 206010036105 Polyneuropathy Diseases 0.000 claims description 3
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 3
- 206010037075 Protozoal infections Diseases 0.000 claims description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 3
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 3
- 208000000389 T-cell leukemia Diseases 0.000 claims description 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000002903 Thalassemia Diseases 0.000 claims description 3
- 206010044074 Torticollis Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 3
- 241000223105 Trypanosoma brucei Species 0.000 claims description 3
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 229940095731 candida albicans Drugs 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 201000006517 essential tremor Diseases 0.000 claims description 3
- 208000024908 graft versus host disease Diseases 0.000 claims description 3
- 230000003394 haemopoietic effect Effects 0.000 claims description 3
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 3
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims description 3
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 3
- 230000001969 hypertrophic effect Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- FGOYVBQKFZYPBM-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-(2-pyrrolidin-1-ylethyl)carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCN1CCCC1 FGOYVBQKFZYPBM-UHFFFAOYSA-N 0.000 claims description 3
- BNCCUGNZFRIHPM-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-(3-hydroxypropyl)carbamoyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(=O)N(CCCO)CC1=CC=C(C=CC(=O)NO)C=C1 BNCCUGNZFRIHPM-UHFFFAOYSA-N 0.000 claims description 3
- LZQLHQNNAVPNSB-UHFFFAOYSA-N n-[[6-(hydroxyamino)-6-oxohexyl]-(3-phenylpropyl)carbamoyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(=O)N(CCCCCC(=O)NO)CCCC1=CC=CC=C1 LZQLHQNNAVPNSB-UHFFFAOYSA-N 0.000 claims description 3
- PKJAJLSDHXPRTC-UHFFFAOYSA-N n-[[7-(hydroxyamino)-7-oxoheptyl]-(pyridin-2-ylmethyl)carbamoyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(=O)N(CCCCCCC(=O)NO)CC1=CC=CC=N1 PKJAJLSDHXPRTC-UHFFFAOYSA-N 0.000 claims description 3
- BWWHWAGGQJPERW-UHFFFAOYSA-N n-[benzyl-[6-(hydroxyamino)-6-oxohexyl]carbamoyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(=O)N(CCCCCC(=O)NO)CC1=CC=CC=C1 BWWHWAGGQJPERW-UHFFFAOYSA-N 0.000 claims description 3
- WULXSBUNSWHIED-UHFFFAOYSA-N n-[benzyl-[7-(hydroxyamino)-7-oxoheptyl]carbamoyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(=O)N(CCCCCCC(=O)NO)CC1=CC=CC=C1 WULXSBUNSWHIED-UHFFFAOYSA-N 0.000 claims description 3
- GAXGGAUAKRJZDE-UHFFFAOYSA-N n-hydroxy-3-[3-[(4-methylphenyl)sulfonylcarbamoylamino]phenyl]prop-2-enamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1=CC=CC(C=CC(=O)NO)=C1 GAXGGAUAKRJZDE-UHFFFAOYSA-N 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 230000007824 polyneuropathy Effects 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000007056 sickle cell anemia Diseases 0.000 claims description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 3
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 3
- 208000003755 striatonigral degeneration Diseases 0.000 claims description 3
- 208000018724 torsion dystonia Diseases 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims description 2
- 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims description 2
- AXAPGPZYOIMDEL-UHFFFAOYSA-N 4-[[benzoylcarbamoyl(3-hydroxypropyl)amino]methyl]-n-hydroxybenzamide Chemical compound C=1C=CC=CC=1C(=O)NC(=O)N(CCCO)CC1=CC=C(C(=O)NO)C=C1 AXAPGPZYOIMDEL-UHFFFAOYSA-N 0.000 claims description 2
- LHZDBUASLUNYQT-UHFFFAOYSA-N 4-[[benzoylcarbamoyl(3-phenylpropyl)amino]methyl]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCCC1=CC=CC=C1 LHZDBUASLUNYQT-UHFFFAOYSA-N 0.000 claims description 2
- QSXFGNYJWQIJIG-UHFFFAOYSA-N 4-[[benzoylcarbamoyl(benzyl)amino]methyl]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CC1=CC=CC=C1 QSXFGNYJWQIJIG-UHFFFAOYSA-N 0.000 claims description 2
- DAGMADSESOVASR-UHFFFAOYSA-N 4-[[benzoylcarbamoyl(pyridin-3-ylmethyl)amino]methyl]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CC1=CC=CN=C1 DAGMADSESOVASR-UHFFFAOYSA-N 0.000 claims description 2
- FTWIUQYDPYFHIJ-UHFFFAOYSA-N 4-[[benzoylcarbamoyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCC1=CNC2=CC=CC=C12 FTWIUQYDPYFHIJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 206010023335 Keratitis interstitial Diseases 0.000 claims description 2
- 201000006904 interstitial keratitis Diseases 0.000 claims description 2
- YSPKMUBGBCMALY-UHFFFAOYSA-N n-[1h-benzimidazol-2-ylmethyl-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CC1=NC2=CC=CC=C2N1 YSPKMUBGBCMALY-UHFFFAOYSA-N 0.000 claims description 2
- XHGPBFXTZNFSCU-UHFFFAOYSA-N n-[2-(4-bromophenyl)ethyl-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCC1=CC=C(Br)C=C1 XHGPBFXTZNFSCU-UHFFFAOYSA-N 0.000 claims description 2
- BKNAQXNSWCMOHW-UHFFFAOYSA-N n-[2-(4-fluorophenyl)ethyl-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCC1=CC=C(F)C=C1 BKNAQXNSWCMOHW-UHFFFAOYSA-N 0.000 claims description 2
- LEFFMEJMFPMEIL-NRFANRHFSA-N n-[[(2s)-1-[[6-(hydroxyamino)-6-oxohexyl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]carbamoyl]benzamide Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCCCCCC(=O)NO)C(=O)NC(=O)C1=CC=CC=C1 LEFFMEJMFPMEIL-NRFANRHFSA-N 0.000 claims description 2
- GFTRQWVHWUKAFN-UHFFFAOYSA-N n-[[3-[2-(hydroxyamino)-2-oxoethyl]phenyl]carbamoyl]benzamide Chemical compound ONC(=O)CC1=CC=CC(NC(=O)NC(=O)C=2C=CC=CC=2)=C1 GFTRQWVHWUKAFN-UHFFFAOYSA-N 0.000 claims description 2
- VUXVREHFAAEDJQ-UHFFFAOYSA-N n-[[4-(hydroxyamino)-4-oxobutyl]carbamoyl]benzamide Chemical compound ONC(=O)CCCNC(=O)NC(=O)C1=CC=CC=C1 VUXVREHFAAEDJQ-UHFFFAOYSA-N 0.000 claims description 2
- RYPNLHGEXJRNBK-UHFFFAOYSA-N n-[[4-[2-(hydroxyamino)-2-oxoethyl]phenyl]carbamoyl]benzamide Chemical compound C1=CC(CC(=O)NO)=CC=C1NC(=O)NC(=O)C1=CC=CC=C1 RYPNLHGEXJRNBK-UHFFFAOYSA-N 0.000 claims description 2
- XYWNVCHWOQSERE-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1NC(=O)NC(=O)C1=CC=CC=C1 XYWNVCHWOQSERE-UHFFFAOYSA-N 0.000 claims description 2
- MMDUJWUFAAOKBB-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-(2-morpholin-4-ylethyl)carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCN1CCOCC1 MMDUJWUFAAOKBB-UHFFFAOYSA-N 0.000 claims description 2
- GWLVYOWRQBVVCP-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-(2-pyridin-2-ylethyl)carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCC1=CC=CC=N1 GWLVYOWRQBVVCP-UHFFFAOYSA-N 0.000 claims description 2
- DGYSGZJUXGIXGH-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-(2-pyridin-4-ylethyl)carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCC1=CC=NC=C1 DGYSGZJUXGIXGH-UHFFFAOYSA-N 0.000 claims description 2
- WNVRYYNSWMCUKM-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-(3-imidazol-1-ylpropyl)carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCCN1C=NC=C1 WNVRYYNSWMCUKM-UHFFFAOYSA-N 0.000 claims description 2
- PNKMVCHCSGGULD-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-(3-phenylpropyl)carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCCC1=CC=CC=C1 PNKMVCHCSGGULD-UHFFFAOYSA-N 0.000 claims description 2
- QENCLUDJNAMREJ-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-(pyridin-3-ylmethyl)carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CC1=CC=CN=C1 QENCLUDJNAMREJ-UHFFFAOYSA-N 0.000 claims description 2
- MWBMXGJMZUNDDN-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-[2-(1h-imidazol-5-yl)ethyl]carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCC1=CNC=N1 MWBMXGJMZUNDDN-UHFFFAOYSA-N 0.000 claims description 2
- XEBCJLKRZJZBNT-UHFFFAOYSA-N n-[[7-(hydroxyamino)-7-oxoheptyl]carbamoyl]benzamide Chemical compound ONC(=O)CCCCCCNC(=O)NC(=O)C1=CC=CC=C1 XEBCJLKRZJZBNT-UHFFFAOYSA-N 0.000 claims description 2
- NBXGYANALMIZBU-UHFFFAOYSA-N n-[benzyl-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CC1=CC=CC=C1 NBXGYANALMIZBU-UHFFFAOYSA-N 0.000 claims description 2
- MGZRGQZNOKXQRS-UHFFFAOYSA-N n-benzoyl-4-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]piperazine-1-carboxamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN1CCN(C(=O)NC(=O)C=2C=CC=CC=2)CC1 MGZRGQZNOKXQRS-UHFFFAOYSA-N 0.000 claims description 2
- AEGNJZPTYKCAPK-UHFFFAOYSA-N n-hydroxy-2-[3-[(4-methylphenyl)sulfonylcarbamoylamino]phenyl]acetamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1=CC=CC(CC(=O)NO)=C1 AEGNJZPTYKCAPK-UHFFFAOYSA-N 0.000 claims description 2
- SECKWRXKZXWLBF-UHFFFAOYSA-N n-hydroxy-3-[4-[(4-methylphenyl)sulfonylcarbamoylamino]phenyl]prop-2-enamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1=CC=C(C=CC(=O)NO)C=C1 SECKWRXKZXWLBF-UHFFFAOYSA-N 0.000 claims description 2
- JBZBXFXLTWOXPW-UHFFFAOYSA-N n-hydroxy-4-[[(4-methylphenyl)sulfonylcarbamoylamino]methyl]benzamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NCC1=CC=C(C(=O)NO)C=C1 JBZBXFXLTWOXPW-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- VVQQSBIAUPDIEN-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-(2-piperidin-1-ylethyl)carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCN1CCCCC1 VVQQSBIAUPDIEN-UHFFFAOYSA-N 0.000 claims 2
- VWDNEXLFRKWPPV-UHFFFAOYSA-N 4-[[benzoylcarbamoyl(2-pyridin-2-ylethyl)amino]methyl]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCC1=CC=CC=N1 VWDNEXLFRKWPPV-UHFFFAOYSA-N 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- PODKJBYCLYAZAE-UHFFFAOYSA-N n-benzoyl-4-[[4-(hydroxycarbamoyl)phenyl]methyl]piperazine-1-carboxamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1CCN(C(=O)NC(=O)C=2C=CC=CC=2)CC1 PODKJBYCLYAZAE-UHFFFAOYSA-N 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 9
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 83
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- 239000007858 starting material Substances 0.000 description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 64
- 238000005160 1H NMR spectroscopy Methods 0.000 description 61
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 58
- 238000004128 high performance liquid chromatography Methods 0.000 description 43
- 239000000243 solution Substances 0.000 description 38
- 239000000203 mixture Substances 0.000 description 37
- 238000002953 preparative HPLC Methods 0.000 description 37
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 35
- 239000012071 phase Substances 0.000 description 35
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 34
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 33
- 239000007787 solid Substances 0.000 description 30
- 239000002253 acid Substances 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 16
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 108010033040 Histones Proteins 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 238000010626 work up procedure Methods 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 102000006947 Histones Human genes 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000287 crude extract Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 229910017912 NH2OH Inorganic materials 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 7
- 208000032839 leukemia Diseases 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- LURYMYITPCOQAU-UHFFFAOYSA-N benzoyl isocyanate Chemical compound O=C=NC(=O)C1=CC=CC=C1 LURYMYITPCOQAU-UHFFFAOYSA-N 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000021736 acetylation Effects 0.000 description 5
- 238000006640 acetylation reaction Methods 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- YSLDOTFAFZJPOC-UHFFFAOYSA-N hydron;methyl 6-aminohexanoate;chloride Chemical compound Cl.COC(=O)CCCCCN YSLDOTFAFZJPOC-UHFFFAOYSA-N 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- ZPUSNAFOTQINNG-UHFFFAOYSA-N methyl 6-(benzoylcarbamoylamino)hexanoate Chemical compound COC(=O)CCCCCNC(=O)NC(=O)C1=CC=CC=C1 ZPUSNAFOTQINNG-UHFFFAOYSA-N 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 238000004701 1H-13C HSQC Methods 0.000 description 4
- ITSKBMVSIHQVTL-UHFFFAOYSA-N 6-amino-n-[(2,4-dimethoxyphenyl)methoxy]hexanamide Chemical compound COC1=CC=C(CONC(=O)CCCCCN)C(OC)=C1 ITSKBMVSIHQVTL-UHFFFAOYSA-N 0.000 description 4
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- FEIOASZZURHTHB-UHFFFAOYSA-N Methyl-p-formylbenzoate Natural products COC(=O)C1=CC=C(C=O)C=C1 FEIOASZZURHTHB-UHFFFAOYSA-N 0.000 description 4
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- KVXMLLMZXPRPNG-UHFFFAOYSA-N methyl 3-(4-formylphenyl)prop-2-enoate Chemical compound COC(=O)C=CC1=CC=C(C=O)C=C1 KVXMLLMZXPRPNG-UHFFFAOYSA-N 0.000 description 4
- ZHFFGGOZGASTTI-UHFFFAOYSA-N methyl 8-[(4-methylphenyl)sulfonylcarbamoylamino]octanoate Chemical compound COC(=O)CCCCCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 ZHFFGGOZGASTTI-UHFFFAOYSA-N 0.000 description 4
- DNMCSEZPFDMEHC-UHFFFAOYSA-N methyl 8-aminooctanoate;hydrochloride Chemical compound Cl.COC(=O)CCCCCCCN DNMCSEZPFDMEHC-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 238000006268 reductive amination reaction Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- YNMACZDIEKIZPV-UHFFFAOYSA-N 6-(benzoylcarbamoylamino)hexanoic acid Chemical compound OC(=O)CCCCCNC(=O)NC(=O)C1=CC=CC=C1 YNMACZDIEKIZPV-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960004424 carbon dioxide Drugs 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- HAMXTNQDKGNDTD-UHFFFAOYSA-N methyl 4-[(benzoylcarbamoylamino)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNC(=O)NC(=O)C1=CC=CC=C1 HAMXTNQDKGNDTD-UHFFFAOYSA-N 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- HNACNYOQQGUSRD-UHFFFAOYSA-N o-[(2,4-dimethoxyphenyl)methyl]hydroxylamine Chemical compound COC1=CC=C(CON)C(OC)=C1 HNACNYOQQGUSRD-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 239000011369 resultant mixture Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 3
- 229960000237 vorinostat Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- LLOKIGWPNVSDGJ-AFBVCZJXSA-N (3s,6s,9s,12r)-3,6-dibenzyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 LLOKIGWPNVSDGJ-AFBVCZJXSA-N 0.000 description 2
- CHMAEAFFKRYPQT-UHFFFAOYSA-N (7-methoxy-7-oxoheptyl)azanium;chloride Chemical compound Cl.COC(=O)CCCCCCN CHMAEAFFKRYPQT-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 2
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical compound O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- LLOKIGWPNVSDGJ-UHFFFAOYSA-N Trapoxin B Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 LLOKIGWPNVSDGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 2
- 230000006195 histone acetylation Effects 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Chemical group 0.000 description 2
- 229910052740 iodine Chemical group 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- QGRFNSDMEVMAAL-UHFFFAOYSA-N methyl 3-[4-[[benzoylcarbamoyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enoate Chemical compound C1=CC(C=CC(=O)OC)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCC1=CNC2=CC=CC=C12 QGRFNSDMEVMAAL-UHFFFAOYSA-N 0.000 description 2
- GZXPIROXKBEMNZ-UHFFFAOYSA-N methyl 6-(3-phenylpropylamino)hexanoate Chemical compound COC(=O)CCCCCNCCCC1=CC=CC=C1 GZXPIROXKBEMNZ-UHFFFAOYSA-N 0.000 description 2
- AEIVPHQHWKWPID-UHFFFAOYSA-N methyl 6-(benzenesulfonylcarbamoylamino)hexanoate Chemical compound COC(=O)CCCCCNC(=O)NS(=O)(=O)C1=CC=CC=C1 AEIVPHQHWKWPID-UHFFFAOYSA-N 0.000 description 2
- JJBHHGZELBBTPM-UHFFFAOYSA-N methyl 6-[[2-amino-3-(1h-indol-3-yl)propanoyl]amino]hexanoate Chemical compound C1=CC=C2C(CC(N)C(=O)NCCCCCC(=O)OC)=CNC2=C1 JJBHHGZELBBTPM-UHFFFAOYSA-N 0.000 description 2
- SVXNYYGLTHDHOA-UHFFFAOYSA-N methyl 6-[benzoylcarbamoyl(3-phenylpropyl)amino]hexanoate Chemical compound C=1C=CC=CC=1C(=O)NC(=O)N(CCCCCC(=O)OC)CCCC1=CC=CC=C1 SVXNYYGLTHDHOA-UHFFFAOYSA-N 0.000 description 2
- HCZCUPIIJZIZLV-UHFFFAOYSA-N methyl 7-(benzoylcarbamoylamino)heptanoate Chemical compound COC(=O)CCCCCCNC(=O)NC(=O)C1=CC=CC=C1 HCZCUPIIJZIZLV-UHFFFAOYSA-N 0.000 description 2
- QGLLSRQIQWJMQE-UHFFFAOYSA-N methyl 8-(benzoylcarbamoylamino)octanoate Chemical compound COC(=O)CCCCCCCNC(=O)NC(=O)C1=CC=CC=C1 QGLLSRQIQWJMQE-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- ZIVMINKJGFDTAA-UHFFFAOYSA-N n-[[6-[(2,4-dimethoxyphenyl)methoxyamino]-6-oxohexyl]-(pyridin-2-ylmethyl)carbamoyl]benzamide Chemical compound COC1=CC(OC)=CC=C1CONC(=O)CCCCCN(C(=O)NC(=O)C=1C=CC=CC=1)CC1=CC=CC=N1 ZIVMINKJGFDTAA-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 229940117803 phenethylamine Drugs 0.000 description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000014493 regulation of gene expression Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108010060596 trapoxin B Proteins 0.000 description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000013298 xenograft nude mouse model Methods 0.000 description 2
- MGHMWKZOLAAOTD-DEOSSOPVSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 MGHMWKZOLAAOTD-DEOSSOPVSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000002223 1H--13C heteronuclear multiple bond coherence Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- MALIONKMKPITBV-UHFFFAOYSA-N 2-(3-chloro-4-hydroxyphenyl)-n-[2-(4-sulfamoylphenyl)ethyl]acetamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)CC1=CC=C(O)C(Cl)=C1 MALIONKMKPITBV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- VLJQDHDVZJXNQL-UHFFFAOYSA-N 4-methyl-n-(oxomethylidene)benzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N=C=O)C=C1 VLJQDHDVZJXNQL-UHFFFAOYSA-N 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- FPCPONSZWYDXRD-UHFFFAOYSA-N 6-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCCCC(=O)O)C3=CC=CC=C3C2=C1 FPCPONSZWYDXRD-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 description 1
- PVFKDLNTGQYTCV-UHFFFAOYSA-N 7-amino-n-[(2,4-dimethoxyphenyl)methoxy]heptanamide Chemical compound COC1=CC=C(CONC(=O)CCCCCCN)C(OC)=C1 PVFKDLNTGQYTCV-UHFFFAOYSA-N 0.000 description 1
- FLOMFRDOHGATKK-UHFFFAOYSA-N 8-amino-n-[(2,4-dimethoxyphenyl)methoxy]octanamide Chemical compound COC1=CC=C(CONC(=O)CCCCCCCN)C(OC)=C1 FLOMFRDOHGATKK-UHFFFAOYSA-N 0.000 description 1
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000052567 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Human genes 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- WKLWATVFGBECFX-UHFFFAOYSA-N COC(C=CC1=CC=C(C=C1)C(NC(=O)NC(C1=CC=CC=C1)=O)C(C)C1=CC=CC=C1)=O Chemical compound COC(C=CC1=CC=C(C=C1)C(NC(=O)NC(C1=CC=CC=C1)=O)C(C)C1=CC=CC=C1)=O WKLWATVFGBECFX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010049678 Endometrial dysplasia Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 108091006463 SLC25A24 Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- CVCWYXDWUIYHSU-UHFFFAOYSA-N [6-[(2,4-dimethoxyphenyl)methoxyamino]-6-oxohexyl]carbamic acid Chemical compound COC1=CC=C(CONC(=O)CCCCCNC(O)=O)C(OC)=C1 CVCWYXDWUIYHSU-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OCKPROYBCPQWJO-UHFFFAOYSA-N acetyl isocyanate Chemical compound CC(=O)N=C=O OCKPROYBCPQWJO-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- SBGUYEPUJPATFD-UHFFFAOYSA-N bromo(tripyrrolidin-1-yl)phosphanium Chemical compound C1CCCN1[P+](N1CCCC1)(Br)N1CCCC1 SBGUYEPUJPATFD-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000007960 cellular response to stress Effects 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000003624 condensation of chromatin Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- YJDYYYJQGRCSQH-UHFFFAOYSA-N ethyl 4-(benzoylcarbamoylamino)butanoate Chemical compound CCOC(=O)CCCNC(=O)NC(=O)C1=CC=CC=C1 YJDYYYJQGRCSQH-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 102000045898 human HDAC1 Human genes 0.000 description 1
- 102000054168 human HDAC8 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- KDFBGNBTTMPNIG-UHFFFAOYSA-N hydron;2-(1h-indol-3-yl)ethanamine;chloride Chemical compound Cl.C1=CC=C2C(CCN)=CNC2=C1 KDFBGNBTTMPNIG-UHFFFAOYSA-N 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- CNAYRKBMBAWHCJ-UHFFFAOYSA-N methyl 3-[4-[(2-phenylethylamino)methyl]phenyl]prop-2-enoate Chemical compound C1=CC(C=CC(=O)OC)=CC=C1CNCCC1=CC=CC=C1 CNAYRKBMBAWHCJ-UHFFFAOYSA-N 0.000 description 1
- RNMMBFYQXXFIQZ-UHFFFAOYSA-N methyl 3-[4-[(2-pyridin-2-ylethylamino)methyl]phenyl]prop-2-enoate Chemical compound C1=CC(C=CC(=O)OC)=CC=C1CNCCC1=CC=CC=N1 RNMMBFYQXXFIQZ-UHFFFAOYSA-N 0.000 description 1
- YJBYVOSRTXXUGV-UHFFFAOYSA-N methyl 3-[4-[(3-hydroxypropylamino)methyl]phenyl]prop-2-enoate Chemical compound COC(=O)C=CC1=CC=C(CNCCCO)C=C1 YJBYVOSRTXXUGV-UHFFFAOYSA-N 0.000 description 1
- PNVRIZSYGNODHF-UHFFFAOYSA-N methyl 3-[4-[[benzoylcarbamoyl(3-hydroxypropyl)amino]methyl]phenyl]prop-2-enoate Chemical compound C1=CC(C=CC(=O)OC)=CC=C1CN(CCCO)C(=O)NC(=O)C1=CC=CC=C1 PNVRIZSYGNODHF-UHFFFAOYSA-N 0.000 description 1
- IVOHRHTVYLPHHF-UHFFFAOYSA-N methyl 3-[4-[[benzoylcarbamoyl(pyridin-3-ylmethyl)amino]methyl]phenyl]prop-2-enoate Chemical compound C1=CC(C=CC(=O)OC)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CC1=CC=CN=C1 IVOHRHTVYLPHHF-UHFFFAOYSA-N 0.000 description 1
- GIZCKBSSWNIUMZ-UHFFFAOYSA-N methyl 4-(aminomethyl)benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C(CN)C=C1 GIZCKBSSWNIUMZ-UHFFFAOYSA-N 0.000 description 1
- XJIVYTXCTMWGLR-UHFFFAOYSA-N methyl 4-(piperazin-1-ylmethyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1CCNCC1 XJIVYTXCTMWGLR-UHFFFAOYSA-N 0.000 description 1
- DFSACDXGVBVPBP-UHFFFAOYSA-N methyl 4-[(2-phenylethylamino)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNCCC1=CC=CC=C1 DFSACDXGVBVPBP-UHFFFAOYSA-N 0.000 description 1
- UALYZLRNEZUKES-UHFFFAOYSA-N methyl 4-[(2-pyridin-2-ylethylamino)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNCCC1=CC=CC=N1 UALYZLRNEZUKES-UHFFFAOYSA-N 0.000 description 1
- OWIOLLFXMYRMHT-UHFFFAOYSA-N methyl 4-[(3-hydroxypropylamino)methyl]benzoate Chemical compound COC(=O)C1=CC=C(CNCCCO)C=C1 OWIOLLFXMYRMHT-UHFFFAOYSA-N 0.000 description 1
- ISGMVERHDCZVLF-UHFFFAOYSA-N methyl 4-[(benzylamino)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNCC1=CC=CC=C1 ISGMVERHDCZVLF-UHFFFAOYSA-N 0.000 description 1
- XUKOPHPRNWAMEA-UHFFFAOYSA-N methyl 4-[(pyridin-3-ylmethylamino)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNCC1=CC=CN=C1 XUKOPHPRNWAMEA-UHFFFAOYSA-N 0.000 description 1
- GTHUJURUXXPRBV-UHFFFAOYSA-N methyl 4-[[benzoylcarbamoyl(3-hydroxypropyl)amino]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN(CCCO)C(=O)NC(=O)C1=CC=CC=C1 GTHUJURUXXPRBV-UHFFFAOYSA-N 0.000 description 1
- VEBJTZUDLNLYGG-UHFFFAOYSA-N methyl 4-[[benzoylcarbamoyl(pyridin-3-ylmethyl)amino]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CC1=CC=CN=C1 VEBJTZUDLNLYGG-UHFFFAOYSA-N 0.000 description 1
- ARJMPEYNEABWDC-UHFFFAOYSA-N methyl 6-[(4-methylphenyl)sulfonylcarbamoylamino]hexanoate Chemical compound COC(=O)CCCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 ARJMPEYNEABWDC-UHFFFAOYSA-N 0.000 description 1
- WENOSXOQCPRCOO-UHFFFAOYSA-N methyl 8-[[methyl-(4-methylphenyl)sulfonylcarbamoyl]amino]octanoate Chemical compound COC(=O)CCCCCCCNC(=O)N(C)S(=O)(=O)C1=CC=C(C)C=C1 WENOSXOQCPRCOO-UHFFFAOYSA-N 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- WZKOKGOAHBIPCI-UHFFFAOYSA-N n,n,4-trimethylbenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(C)C=C1 WZKOKGOAHBIPCI-UHFFFAOYSA-N 0.000 description 1
- UJYAZVSPFMJCLW-UHFFFAOYSA-N n-(oxomethylidene)benzenesulfonamide Chemical compound O=C=NS(=O)(=O)C1=CC=CC=C1 UJYAZVSPFMJCLW-UHFFFAOYSA-N 0.000 description 1
- XSMQPMILQREZJL-UHFFFAOYSA-N n-[(2,4-dimethoxyphenyl)methoxy]-6-(pyridin-2-ylmethylamino)hexanamide Chemical compound COC1=CC(OC)=CC=C1CONC(=O)CCCCCNCC1=CC=CC=N1 XSMQPMILQREZJL-UHFFFAOYSA-N 0.000 description 1
- FWQBQIPETMKPHV-UHFFFAOYSA-N n-[[3-(5-chloropyrimidin-2-yl)oxy-4-ethylphenyl]carbamoyl]-2-nitrobenzamide Chemical compound C1=C(OC=2N=CC(Cl)=CN=2)C(CC)=CC=C1NC(=O)NC(=O)C1=CC=CC=C1[N+]([O-])=O FWQBQIPETMKPHV-UHFFFAOYSA-N 0.000 description 1
- MKYYYLYKIUUBEX-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-(2-phenoxyethyl)carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCOC1=CC=CC=C1 MKYYYLYKIUUBEX-UHFFFAOYSA-N 0.000 description 1
- GYNMKNPUBTUEPF-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl-(2-pyridin-3-ylethyl)carbamoyl]benzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CN(C(=O)NC(=O)C=1C=CC=CC=1)CCC1=CC=CN=C1 GYNMKNPUBTUEPF-UHFFFAOYSA-N 0.000 description 1
- DTWNQVRCUQNICE-UHFFFAOYSA-N n-[[6-[(2,4-dimethoxyphenyl)methoxyamino]-6-oxohexyl]carbamothioyl]benzamide Chemical compound COC1=CC(OC)=CC=C1CONC(=O)CCCCCNC(=S)NC(=O)C1=CC=CC=C1 DTWNQVRCUQNICE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KWBACAMRZLPAJU-UHFFFAOYSA-N n-hydroxy-2-[4-[(4-methylphenyl)sulfonylcarbamoylamino]phenyl]acetamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1=CC=C(CC(=O)NO)C=C1 KWBACAMRZLPAJU-UHFFFAOYSA-N 0.000 description 1
- URDCAZJAQYTAOI-UHFFFAOYSA-N n-hydroxy-6-[(4-methylphenyl)sulfonylcarbamoylamino]hexanamide Chemical compound CC1=CC=C(S(=O)(=O)NC(=O)NCCCCCC(=O)NO)C=C1 URDCAZJAQYTAOI-UHFFFAOYSA-N 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- BUXTXUBQAKIQKS-UHFFFAOYSA-N sulfuryl diisocyanate Chemical compound O=C=NS(=O)(=O)N=C=O BUXTXUBQAKIQKS-UHFFFAOYSA-N 0.000 description 1
- 239000003930 superacid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003899 tartaric acid esters Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000004435 urinary system cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/54—Y being a carbon atom of a six-membered aromatic ring, e.g. benzoylureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/58—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/24—Derivatives of thiourea containing any of the groups, X being a hetero atom, Y being any atom
- C07C335/26—Y being a hydrogen or a carbon atom, e.g. benzoylthioureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to hydroxamate compounds that are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea or sulfonylurea containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase activities.
- chromatin a protein-DNA complex
- histones which are the protein components.
- Reversible acetylation of histones is a key component in the regulation of gene expression by altering the accessibility of transcription factors to DNA.
- increased levels of histone acetylation are associated with increased transcriptional activity, whereas decreased levels of acetylation are associated with repression of gene expression [Wade P.A. Hum. Mol. Genet. 10, 693-698 (2001), De Ruijter A.J.M. et al, Biochem. J., 370, 737-749 (2003)].
- HDACs histone deacetylases
- histone acetyltransferase Inhibition of HDACs results in the accumulation of acetylated histones, which results in a variety of cell type dependent cellular responses, such as apoptosis, necrosis, differentiation, cell survival, inhibition of proliferation and cytostasis.
- SAHA suberoylanilide hydroxamic acid
- Trichostatin A is a reversible inhibitor of mammalian HDAC.
- Trapoxin B is a cyclic tetrapeptide, which is an irreversible inhibitor of mammalian HDAC.
- HDAC inhibitors have become available for clinical evaluation [US6,552,065]. Additional
- HDAC inhibitors have been reported to interfere with neurodegenerative processes, for instance, HDAC inhibitors arrest polyglutamine-dependent neurodegeneration [Nature, 413(6857): 739-43, 18
- HDAC inhibitors have also been known to inhibit production of cytokines such as TNF, IFN, IL-1 which are known to be implicated in inflammatory diseases and/or immune system disorders. [J. Biol. Chem. 1990; 265(18): 10230-10237;
- HDAC inhibitors that would be expected to have useful, improved pharmaceutical properties in the treatment of diseases such as cancer, neurodegenerative diseases and inflammatory and/or immune system disorders.
- the present invention provides compounds of the Formula (I)
- R 1 is selected from the group consisting of H, d -C 6 alkyl and acyl
- M is selected from the group consisting of O, S, NH, NR 4 , NOH and NOR 4 ;
- R 2 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylk
- R 3 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, al
- G is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; each R 4 is independently selected from the group consisting of H, alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl; each of which may be optionally substituted; or a pharmaceutically acceptable salt or prodrug thereof.
- the present invention provides compounds having the Formula (2)
- R 1 is selected from the group consisting of H, Ci -C 6 alkyl and acyl
- L is a single bond or is a C C 5 hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -0-, -S-, -S(O)- and -S(0) 2 - and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C C 4 alkyl;
- Z is selected from the group consisting of a single bond, N(R 1 ), O, S, S(O) and S(O) 2 ;
- A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;
- B is selected from the group consisting of a single bond, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, .optionally substituted alkylheteroarylene, optionally substituted C C 3 alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene and optionally substituted -(CH 2 ) m -C(0)-N(R 4 )- (CH 2 ) n -, wherein n is an integer from 0 to 6, m is an integer from 0 to 6; M is selected from the group consisting of O, S, NH, NR 4 , NOH and NOR 4 ;
- R 2 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, ' arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino
- R 3 is independently selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino,
- G is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl; each R 4 is independently selected from the group consisting of H, alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl; each of which may be optionally substituted; or a pharmaceutically acceptable salt or prodrug thereof.
- R 1 is selected from the group consisting of H, C ⁇ -C 6 alkyl and acyl L is a single bond or is a CrC 5 hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -0-, -S-, -S(O)- and -S(0) 2 - and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C C 4 alkyl;
- Z is selected from the group consisting of a single bond, N(R 1 ), O, S, S(O) and S(0) 2 ;
- A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;
- B is selected from the group consisting of a single bond, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, optionally substituted alkylheteroarylene, optionally substituted d-C 3 alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene and optionally substituted -(CH 2 ) m -C(0)-N(R 4 )- (CH 2 ) n -, wherein n is an integer from 0 to 6, m is an integer from 0 to 6; M is selected from the group consisting of O,.S, NH, NR 4 , NOH and NOR 4 ;
- R 2 is selected from the group consisting of H, Ci -C 10 alkyl, alkenyi, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C 4 -C 9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g.
- R 3 is selected from the group consisting of H, Ci -C ⁇ 0 alkyl, alkenyi, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C 4 -C 9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g.
- R 4 is selected from the group consisting of C C alkyl, heteroalkyl, aryl, heteroaryl and acyl;
- X and Y are the same or different and are independently selected from the group consisting of H, halo, C C 4 alkyl, N0 2 , OR 4 , SR 4 , C(0)R 5 , and NR 6 R 7 ;
- R 5 is C C 4 alkyl
- R 6 and R 7 are the same or different and are independently selected from the group consisting of H, C C6 alkyl, C 4 -C 9 cycloalkyl, C 4 -C 8 heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroaryl alkyl.
- Particularly preferred compounds of Formula (2) are those of Formula (2b) and (2c).
- R 2 , X, Y, Z, A, B, R 3 and R 4 are the same as for Formula (2).
- G and R 2 are as for Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
- G and R 2 are as for Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
- G and R 2 are as for Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
- B is a single bond or CH 2
- B is attached to meta or para position of phenylene relative to L and G is selected from aryl, heteroaryl, alkyl and alkoxyalkyl.
- n is an integer from 1 to 8;
- G is selected from aryl, heteroaryl, alkyl and heteroalkyl.
- R 2 is selected from H, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, arylheteroalkyl, heteroarylalkyl, and heteroarylheteroalkyl.
- X is selected from H, halo, C C 4 alkyl, alkoxy, alkylamino; B is attached to meta or para position of phenylene relative to L.
- n is an integer from 1 to 8
- X is selected from H, halo, C C alkyl, alkoxy, alkylamino.
- R 1 is preferably H or C C 4 alkyl, more preferably H or methyl, most preferably H.
- M is preferably O or S, most preferably O.
- Q is preferably S(0) 2 or CO, most preferably CO.
- G is preferably optionally substituted aryl, more preferably optionally substituted phenyl, most preferably 4-methyl phenyl or phenyl.
- R 2 is preferably selected from the group consisting of H, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted arylheteroalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylheteroalkyl, optionally substituted cycloalkylalkyl and optionally substituted heterocycloalkylalkyl.
- R 2 is selected from the group consisting of H, 2-
- R 2 is selected from the group consisting of H, 2-(1H-indol-3- yl)-ethyl, 2-(2-methyl-1H-indol-3-yl)-ethyl, pyridin-3-ylmethyl, 3-hydroxy-propyl, 2-pyridin- 2-yl-ethyl, 2-pyridin-3-yl-ethyl, pyridin-2-ylmethyl, pyridin-3-ylmethyl, 2-pyridin-4-yl-ethyl, benzyl, 3-phenyl-propyl, 2-phenoxy-ethyl, 2-morpholino ethyl, 2-phenyl ethyl, 2-(4-bromo- phenyl)-ethyl, 2-(4-fluoro-phenyl)-ethyl, 3-imidazol-1 -yl-propyl, 2-(1 H-imidazol-4-yl)-ethyl,
- R 2 is selected from the group consisting of H, 2-(1 H- indol-3-yl)-ethyl, 2-(2-methyl-1 H-indol-3-yl)-ethyl, 2-phenyl ethyl, 2-piperidin-1 -yl-ethyl and 2-pyrrolidin-1 -yl-ethyl.
- R 3 is H.
- Z is preferably a single bond.
- A is preferably an optionally substituted arylene.
- A is selected from the group consisting of 1 ,4-phenylene and 1 ,3-phenylene. It is particularly preferred that A is 1 ,4-phenylene.
- B is selected from the group consisting of a single bond, methylene, ethylene, propylene, alkylarylene, and heteroalkylene.
- B is methylene.
- B is a bond.
- B is ethylene.
- B is propylene.
- the identities of B, A, Z and L are such that the group BAZL is a group of formula -(CH 2 ) n - wherein n is an integer from 1 to 7.
- identities of B, A, Z are such that the group BAZ is a group of formula -(CH 2 )- phenyl-
- identities of B, A, Z and L are such that the group BAZL is selected from the group consisting of
- each R 5 is independently selected from the group consisting of alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted;
- the embodiments disclosed are also directed to pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of such compounds, and pharmaceutically acceptable salts of such metabolites.
- Such compounds, salts, prodrugs and metabolites are at times collectively referred to herein as "HDAC inhibiting agents" or "HDAC inhibitors".
- HDAC inhibiting agents or "HDAC inhibitors”.
- the compounds disclosed are used to modify deacetylase activity, in some cases histone deacetylase activity and in some cases HDAC 8, or HDAC 1 activity.
- compositions each comprising a therapeutically effective amount of a HDAC inhibiting agent of the embodiments described with a pharmaceutically acceptable carrier or diluent for treating cellular proliferative ailments.
- effective amount indicates an amount necessary to administer to a host to achieve a therapeutic result, e.g., inhibition of proliferation of malignant cancer cells, benign tumor cells or other proliferative cells.
- the invention also relates to pharmaceutical compositions including a compound of the invention with a pharmaceutically acceptable carrier, diluent or excipient.
- the present invention provides a method of treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis including administration of a therapeutically effective amount of a compound of Formula (I).
- the method preferably involves administration of a compound of Formula (2) more preferably a compound of Formula (2a) or (2b) or (2c), most preferably a compound of (2e) to (2r).
- the disorder is preferably selected from the group consisting of but not limited to cancer (e.g. breast cancer, colon cancer, prostate cancer, pancreatic cancer, leukemias, lymphomas), inflammatory diseases/immune system disorders, angiofibroma, cardiovascular diseases (e.g. restenosis, arteriosclerosis), fibrotic diseases (e.g. liver fibrosis), diabetes, autoimmune diseases, chronic and acute neurodegenerative disease like disruptions of nerval tissue, Huntington's disease and infectious diseases like fungal, bacterial and viral infections.
- the disorder is a proliferative disorder.
- the proliferative disorder is preferably cancer.
- the cancer can include solid tumors or hematologic malignancies.
- the invention also provides agents for the treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis including a compound of Formula (I) as disclosed herein.
- the agent is preferably an anti-cancer agent.
- the agent preferably contains a compound of Formula (2) more preferably a compound of Formula (2a) or (2b) or (2c), most preferably a compound of (2e) to (2r).
- the invention also relates to the use of compounds of Formula (I) in the preparation of a medicament for the treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis.
- the disorder is preferably a proliferative disorder, most preferably a cancer.
- the compounds of the present invention surprisingly show low toxicity, together with a potent anti-proliferative activity.
- the invention provides a method of treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase including administration of a therapeutically effective amount of a compound of Formula (I).
- the invention provides a method of treatment of a disorder, disease or condition that are mediated by deacetylase activity such as histone deacetylase including administration of a therapeutically effective amount of a compound of Formula (I).
- the method preferably includes administration of a compound of Formula (2), more preferably a compound of Formula (2a) or (2b) or (2c), most preferably a compound of (2e) to (2r) as described herein.
- the disorder is preferably selected from the group consisting of but not limited to Proliferative disorders (e.g. cancer); Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesis, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Progressive supranuclear palsy, Pick's disease, Intracerebral haemorrhage Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration,
- Candida Albicans Bacterial infections, Viral infections, such as Herpes Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.
- Viral infections such as Herpes Simplex
- Protozoal infections such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.
- the invention also provides agents for the treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase including a compound of Formula (I) as disclosed herein.
- the agent is preferably an anti-cancer agent.
- the invention also relates to the use of compounds of Formula (I) in the preparation of a medicament for the treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase.
- the invention provides amethod of modifying deacetylase activity including contacting the deacetylase with a compound of Formula (I).
- the deacetylase activity is preferably histone deacetylase activity, even more preferably class I histone deacetylase activity.
- the histone deacetylase is preferably HDAC1 or HDAC8.
- the invention also provides a method for inhibiting cell proliferation including administration of an effective amount of a compound according to Formula (I).
- the invention provides a method of treatment of a neurodegenerative disorder in a patient including administration of a therapeutically effective amount of a compound of Formula (I).
- the method preferably includes administration of a compound of Formula (2) more preferably a compound of Formula (2a) or (2b) or (2c), most preferably a compound of (2e) to (2r) as described herein.
- the neurodegenerative disorder is preferably Huntington's Disease.
- the invention also provides agents for the treatment of neurodegenerative disorder including a compound of Formula (I) as disclosed herein.
- the agent is preferably anti- Huntington's disease agent.
- the invention also relates to the use of compounds of Formula (I) in the preparation of a medicament for the treatment of a neurodegenerative disorder.
- the neurodegenerative disorder is preferably Huntington's Disease.
- the invention provides a method of treatment of an inflammatory disease and/or immune system disorder in a patient including administration of a therapeutically effective amount of a compound of Formula (I).
- the method preferably includes administration of a compound of Formula (2) more preferably a compound of Formula (2a) or (2b) or (2c), most preferably a compound of (2e) to (2r) as described herein.
- the inflammatory disease and/or immune system disorder is rheumatoid arthritis.
- the inflammatory disease and/or immune system disorder is Systemic Lupus Erythematosus.
- the invention also provides agents for the treatment of inflammatory disease and/or immune system disorder including a compound of Formula (I) as disclosed herein.
- the invention also relates to the use of compounds of Formula (I) in the preparation of a medicament for the treatment of inflammatory disease and/or immune system disorder.
- the inflammatory disease and/or immune system disorder is rheumatoid arthritis.
- the inflammatory disease and/or immune system disorder is Systemic Lupus Erythematosus.
- the present invention provides the use of a compound of Formula (I) to modify deacetylase activity, preferably histone deacetylase activity, even more preferably HDACI or HDAC8.
- the invention also provides the use of a compound of Formula (I) to treat cancer.
- the cancer is selected from a group including but not limited to breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.
- the present invention also provides the use of a compound of Formula (I) in the preparation of a medicament for the treatment of hematologic malignancies.
- the hematologic malignancy is preferably selected from the group consisting of B-cell lymphoma, T-cell lymphoma and leukemia.
- the invention also provides a method for the treatment of a hematologic malignancy including administration of an effective amount of a compound of Formula (I).
- the invention also provides an agent for the treatment of hematologic malignancy including a compound of Formula (I).
- the invention also provides the use of a compound of Formula (I) in the preparation of a medicament for the treatment of solid tumors.
- the solid tumor is preferably selected from the group consisting of breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.
- the invention also provides a method of treatment of a solid tumor including administration of an effective amount of a compound of Formula (I).
- the solid tumor is preferably selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer and brain cancer.
- the invention also provides agents for the treatment of solid tumors including a compound of Formula (I).
- the invention provides for the use of a compound of Formula (I) in the preparation of a medicament for the induction of cell death such as apoptosis of tumor cell.
- the invention also provides a method of inhibiting tumor cell proliferation including the administration of a compound according to Formula (I).
- the invention also provides a method of inhibiting the activity of histone deacetylase including contacting the histone deacetylase with an effective amount of a compound according to Formula (I).
- the invention also provides the use of a compound of Formula (I) in the manufacture of medicaments for the induction of apoptosis of tumor cells.
- the invention provides a method of inducing apoptosis in tumor cells including administration of an effective amount of a compound of Formula (I).
- hydroxamate compounds for example acylurea/sulfhonylurea containing hydroxamic acid in one of the substituents, that may be inhibitors of deacetylases, including but not limited to inhibitors of histone deacetylases.
- the hydroxamate compounds may be suitable for prevention or treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis when used either alone or together with a pharmaceutically acceptable carrier, diluent or excipient.
- a pharmaceutically acceptable carrier diluent or excipient.
- An example of such a disorder is cancer.
- 'cancer' is a general term intended to encompass the vast number of conditions that are characterised by uncontrolled abnormal growth of cells.
- the compounds of the invention will be useful in treating various cancers including but not limited to bone cancers including Ewing's sarcoma, osteosarcoma, chondrosarcoma and the like, brain and CNS tumors including acoustic neuroma, neuroblastomas, glioma and other brain tumors, spinal cord tumors, breast cancers, colorectal cancers, colon cancer, advanced colorectal adenocarcinomas, endocrine cancers including adenocortical carcinoma, pancreatic cancer, pituitary cancer, thyroid cancer, parathyroid cancer, thymus cancer, multiple endocrine neoplasma, gastrointestinal cancers including stomach cancer, esophageal cancer, small intestine cancer, Liver cancer, extra hepatic bile duct cancer, gastrointestinal carcinoid tumor, gall bladder cancer, genitourinary cancers including testicular cancer, penile cancer, prostate cancer, gynaecological cancers including cervical cancer,
- Preferred cancers that may be treated by the compounds of the present invention include but are not limited to breast cancer, colon cancer, pancreatic cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer and brain cancer.
- Preferred cancers that may be treated by compounds of the present invention include but are not limited to B-cell lymphoma (e.g. Burkitt's lymphoma), leukemias (e.g. Acute promyelocytic leukemia), cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma.
- B-cell lymphoma e.g. Burkitt's lymphoma
- leukemias e.g. Acute promyelocytic leukemia
- CCL cutaneous T-cell lymphoma
- peripheral T-cell lymphoma e.g., peripheral T-cell lymphoma.
- Preferred cancers that may be treated by compounds of the present invention include but are not limited to solid tumors and hematologic malignancies.
- the compounds may also be used in the treatment of a disorder involving, relating to, or associated with dysregulation of histone deacetylase (HDAC).
- HDAC histone deacetylase
- HDAC activity is known to play a role in triggering disease onset, or whose symptoms are known or have been shown to be alleviated by HDAC inhibitors.
- disorders of this type that would be expected to be amenable to treatment with the compounds of the invention include the following but not limited to: Proliferative disorders (e.g.
- Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesis, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Progressive supranuclear palsy, Pick's disease, intracerebreal haemorrphage, Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateralsclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration, Rubeotic glaucoma, Intersititial keratitis, Diabetic retinopathy
- Systemic Lupus Erythematosus Disease involving angiogenesis including cancer, psoriasis, rheumatoid arthritis; Psychological disorders including bipolar disease, schizophrenia, mainia, depression and dementia; Cardiovascular Diseases including heart failure, restenosis and arteriosclerosis; Fibrotic diseases including liver fibrosis, cystic fibrosis and angiofibroma; Infectious diseases including Fungal infections, such as
- Candida Albicans Bacterial infections, Viral infections, such as Herpes Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.
- Viral infections such as Herpes Simplex
- Protozoal infections such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.
- hydroxamate compounds of the present invention have the following structure (I):
- R 1 is selected from the group consisting of H, Ci -C 6 alkyl and acyl
- M is selected from the group consisting of O, S, NH, NR 4 , NOH and NOR 4 ;
- R 2 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl; heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, al
- R 3 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, al
- G is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; each R 4 is independently selected from the group consisting of H, alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted; or a pharmaceutically acceptable salt or prodrug thereof.
- R 1 is selected from the group consisting of H, C-i -C 6 alkyl and acyl;
- L is a single bond or is a C C 5 hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -0-, -S-, -S(O)- and -S(0) 2 - and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C C alkyl;
- Z is selected from the group consisting of a single bond, N(R 1 ), O, S, S(O) and S(0) 2 ;
- A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;
- B is selected from the group consisting of a single bond, optionally substituted acylamino, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, optionally substituted alkylheteroarylene, optionally substituted C ⁇ -C 3 alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene and optionally substituted -(CH2) m -C(0)-N(R )-(CH 2 ) n -, wherein n is an integer from 0 to 6, m is an integer from 0 to 6;
- M is selected from the group consisting of O, S, NH, NR 4 , NOH and NOR 4 ;
- R 2 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylk
- R 3 is independently selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino,
- G is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl; each R 4 is independently selected from the group consisting of H, alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted; or a pharmaceutically acceptable salt or prodrug thereof.
- the compounds of Formula (2) are compounds of
- R 1 is selected from the group consisting of H, Ci -C ⁇ alkyl and acyl
- L is a single bond or is a C C 5 hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -O-, -S-, -S(O)- and -S(0) 2 - and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C 1 -C 4 alkyl;
- Z is selected from the group consisting of a single bond, N(R 1 ), O, S, S(O) and S(O) 2 ;
- A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;
- B is selected from the group consisting of a single bond, optionally substituted acyl amino, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, optionally substituted alkylheteroarylene, optionally substituted C C 3 alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene and optionally substituted -(CH 2 ) m -C(0)-N(R 4 )-(CH 2 ) n -, wherein n is an integer from 0 to 6, m is an integer from 0 to 6;
- M is selected from the group consisting of O, S, NH, NR 4 , NOH and NOR 4 ;
- R 2 is selected from the group consisting of H, Ci -C 10 alkyl, alkenyi, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C 4 -C 9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g.
- R 3 is selected from the group consisting of H, Ci -C 10 alkyl, alkenyi, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C -C 9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g.
- X and Y are the same or different and are independently selected from the group consisting of H, halo, C C 4 alkyl, N0 2 , OR 4 , SR 4 , C(0)R 5 , and NR 6 R 7 ;
- R a is C r C 4 alkyl
- R 6 and R 7 are the same or different and are independently selected from the group consisting of H, C ⁇ -C 6 alkyl, C -C 9 cycloalkyl, C 4 -C 9 heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroaryl alkyl.
- Halogen represents chlorine, fluorine, bromine or iodine.
- Alkyl as a group or part of a group refers to a straight or branched aliphatic hydrocarbon group, preferably a C-i-C- alkyl, more preferably C C ⁇ o alkyl, most preferably C C 6 unless otherwise noted.
- suitable straight and branched CrC 6 alkyl substituents include methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, t-butyl, hexyl, and the like.
- Alkylamino includes both monoalkylamino and dialkylamino, unless specified.
- “Monoalkylamino” means a -NH-Alkyl group
- “Dialkylamino” means a -N(alkyl) 2 group, in which the alkyl is as defined as above.
- the alkyl group is preferably a C C 6 alkyl group.
- Arylamino includes both mono-arylamino and di-arylamino unless specified.
- Mono- arylamino means a group of formula aryl NH-
- di-arylamino means a group of formula (aryl 2 ) N- where aryl is as defined herein.
- Examples of acyl include acetyl, benzoyl, phenylacetyl.
- Alkenyi as group or part of a group denotes an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched preferably having 2-14 carbon atoms, more preferably 2-12 carbon atoms, most preferably 2-6 carbon atoms, in the chain.
- the group may contain a plurality of double bonds in the normal chain and the orientation about each is independently E or Z.
- Exemplary alkenyi group include, but are not limited to, ethenyl and propenyl.
- Alkoxy refers to an -O-alkyl group in which alkyl is defined herein.
- the alkoxy is a C C 6 alkoxy. Examples include, but are not limited to, methoxy and ethoxy.
- alkenyloxy refers to an -O- alkenyi group in which alkenyi is as defined herein. Preferred alkenyloxy groups are C ⁇ -C 6 alkenyloxy groups.
- Alkynyloxy refers to an -O-alkynyl group in which alkynyl is as defined herein. Preferred alkynyloxy groups are C C 6 alkynyloxy groups.
- Alkoxycarbonyl refers to an -C(0)-0-alkyl group in which alkyl is as defined herein. The alkyl group is preferably a C C 6 alkyl group. Examples include, but not limited to, methoxycarbonyl and ethoxycarbonyl.
- Alkylsulfinyl means a -S(0)-alkyl group in which alkyl is as defined above.
- the alkyl group is preferably a CrC 6 alkyl group.
- Exemplary alkylsulfinyl groups include, but not limited to, methylsulfinyl and ethylsulfinyl.
- Alkylsulfonyl refers to a -S(0) 2 -alkyl group in which alkyl is as defined above.
- the alkyl group is preferably a C C 6 alkyl group. Examples include, but not limited to methylsulfonyl and ethylsulfonyl.
- Alkynyl as a group or part of a group means an aliphatic hydrocarbon group containing a carbon-carbon trip bond and which may be straight or branched preferably having from 2- 14 carbon atoms, more preferably 2-12 carbon atoms in the chain, preferably 2-6 carbon atoms in the chain.
- Exemplary structures include, but not limited to, ethynyl and propynyl.
- Alkylaminocarbonyl refers to an alkylamino-carbonyl group in which alkylamino is as defined above.
- Aminoacyl refers to the formula -C(0)-(CH 2 ) m -(CH)(NR 6 R 7 )-(CH 2 ) n -R 6 wherein R 6 and R 7 are as defined above, m and n are integers selected from 0 to 6.
- Aryl as a group or part of a group denotes (i) an optionally substituted monocyclic, or fused polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) preferably having from 5 to 12 atoms per ring.
- aryl groups include phenyl, naphthyl, and the like; (ii) an optionally substituted partially saturated bicyclic aromatic carbocyclic moiety in which a phenyl and a C 5-7 cycloalkyl or C 5 . 7 cycloalkenyl group are fused together to form a cyclic structure, such as tetrahydronaphthyl, indenyl or indanyl.
- the aryl group may be substituted by one or more substituent groups. When the aryl ring is divalent it has been referred to as "arylene" in this application.
- Arylalkenyl means an aryl-alkenyl- group in which the aryl and alkenyi are as previously described.
- Exemplary arylalkenyl groups include phenylallyl.
- Arylalkyl means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contains a C 1 . 5 alkyl moiety.
- Exemplary arylalkyl groups include benzyl, phenethyl and naphthelenemethyl.
- Cycloalkyl refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle preferably containing from 3 to 9 carbons per ring, such as cyclopropyl, cyclobutyi, cyclopentyl, cyclohexyl and the like, unless otherwise specified.
- alkyl and cycloalkyl substituents also applies to the alkyl portions of other substituents, such as without limitation, alkoxy, alkyl amines, alkyl ketones, arylalkyl, heteroarylalkyl, alkylsulfonyl and alkyl ester substituents and the like.
- Cycloalkylalkyl means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described.
- Exemplary monocycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cylcoheptylmethyl.
- Heterocycloalkyl refers to a ring containing from at least one heteroatom selected from nitrogen, sulfur, oxygen, preferably from 1 to 3 heteroatoms. Each ring is preferably from 3 to 4 membered, more preferably 4 to 7 membered.
- suitable heterocycloalkyl substituents include pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1 ,3-diazapane, 1 ,4-diazapane, 1 ,4- oxazepane, and 1 ,4-oxathiapane.
- Heterocycloalkenyl refers to a heterocycloalkyl as described above but containing at least one double bond.
- Heterocycloalkylalkyl refers to a heterocycloalkyl-alkyl group in which the heterocycloalkyl and alkyl moieties are as previously described.
- exemplary heterocycloalkylalkyl groups include (2-tetrahydrofuryl)methyl, (2- tetrahydrothiofuranyl)methyl.
- Heteroalkyl refers to a straight- or branched-chain alkyl group preferably having from 2 to 14 carbons atoms, more preferably 2 to 10 carbon atoms in the chain, wherein one or more of the carbon atoms have been replaced by a heteroatom selected from S, O, and N.
- exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl amines, alkyl sulfides, and the like.
- Cycloalkenyl means an optionally substituted non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and preferably having from 5-10 carbon atoms per ring.
- Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl. The cycloalkenyl group may be substituted by one or more substituent groups.
- Heteroaryl refers to a monocyclic, or fused polycyclic, aromatic heterocycle (ring structure preferably having a 5 to 10 member aromatic ring containing one or more heteroatoms selected from N, O and S).
- Typical heteroaryl substituents include furyl, thienyl, pyrrole, pyrazole, triazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, pyrazine, indole, benzimidazole, and the like.
- heteroaryl ring is divalent it has been referred to as "heteroarylene" in this application.
- Heteroarylalkyl means a heteroaryl-alkyl group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a lower alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.
- “Lower alkyl” as a group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having 1 to 6 carbon atoms in the chain, more preferably 1 to 4 carbons such as methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n- butyl, isobutyl or tertiary-butyl.
- “Sulfonyl” means a R-S0 2 - group in which the R is selected from aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, arylalkyl and heteroarylalkyl as described herein. G could be further substituted. Examples of sulfonyl include methanesulfonyl, benzenesulfonyl, 4- methylbenzenesulfonyl, naphthalene-2-sulfonyl, and the like.
- inventive compounds may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and /or diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the present invention. subject matter described and claimed.
- Formula I is intended to cover, where applicable, solvated as well as unsolvated forms of the compounds.
- each formula includes compounds having the indicated structure, including the hydrated as well as the non-hydrated forms.
- the HDAC inhibiting agents of the various embodiments include pharmaceutically acceptable salts, prodrugs, and active metabolites of such compounds, and pharmaceutically acceptable salts of such metabolites.
- “Pharmaceutically acceptable salts” refers to salts that retain the desired biological activity of the above-identified compounds, and include pharmaceutically acceptable acid addition salts and base addition salts.
- Suitable pharmaceutically acceptable acid addition salts of compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, sulfuric, and phosphoric acid.
- Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, fumaric, maleic, alkyl sulfonic, arylsulfonic.
- Suitable pharmaceutically acceptable base addition salts of compounds of Formula I include metallic salts made from lithium, sodium, potassium, magnesium, calcium, aluminium, and zinc, and organic salts made from organic bases such as choline, diethanolamine, morpholine.
- organic salts are: ammonium salts, quaternary salts such as tetramethylammonium salt; amino acid addition salts such as salts with glycine and arginine. Additional information on pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Co., Easton, PA 1995. In the case of agents that are solids, it is understood by those skilled in the art that the inventive compounds, agents and salts may exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulae.
- Prodrug means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of Formula I.
- metabolic means e.g. by hydrolysis, reduction or oxidation
- an ester prodrug of a compound of formula I containing a hydroxyl group may be convertible by hydrolysis in vivo to the parent molecule.
- esters of compounds of Formula (I) containing a hydroxyl group are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- ⁇ -hydroxynaphthoates, gestisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.
- an ester prodrug of a compound of formula I containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule. (Examples of ester prodrugs are those described by F. J.
- Possible HDAC inhibiting agents include those having an IC 50 value of 5 ⁇ M or less.
- Administration of compounds within Formula I to humans can be by any of the accepted modes for enteral administration such as oral or rectal, or by parenteral administration such as subcutaneous, intramuscular, intravenous and intradermal routes. Injection can be bolus or via constant or intermittent infusion.
- the active compound is typically included in a pharmaceutically acceptable carrier or diluent and in an amount sufficient to deliver to the patient a therapeutically effective dose.
- the inhibitor compound may be selectively toxic or more toxic to rapidly proliferating cells, e.g. cancerous tumors, than to normal cells.
- terapéuticaally effective amount is an amount sufficient to effect beneficial or desired clinical results.
- An effective amount can be administered in one or more administrations.
- An effective amount is typically sufficient to palliate, ameliorate, stabilize, reverse, slow or delay the progression of the disease state.
- a therapeutically effective amount can be readily determined by a skilled practitioner by the use of conventional techniques and by observing results obtained in analogous circumstances. In determining the effective amount a number of factors are considered including the species of the patient, its size, age, general health, the specific disease involved, the degree or severity of the disease, the response of the individual patient, the particular compound administered, the mode of administration, the bioavailability of the compound, the dose regimen selected, the use of other medication and other relevant circumstances.
- the compounds of the invention can be administered in any form or mode which makes the compound bioavailable.
- One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the condition to be treated, the stage of the condition to be treated and other relevant circumstances. We refer the reader to
- the compounds of the present invention can be administered alone or in the form of a pharmaceutical composition in combination with a pharmaceutically acceptable carrier, diluent or excipient.
- a pharmaceutically acceptable carrier diluent or excipient.
- the compounds of the invention while effective themselves, are typically formulated and administered in the form of their pharmaceutically acceptable salts as these forms are typically more stable, more easily crystallised and have increased solubility.
- compositions which are formulated depending on the desired mode of administration.
- the present invention provides a pharmaceutical composition including a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent or excipient.
- the compositions are prepared in manners well known in the art.
- kits comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- a pack or kit can be found a container having a unit dosage of the agent (s).
- the kits can include a composition comprising an effective agent either as concentrates (including lyophilized compositions), which can be diluted further prior to use or they can be provided at the concentration of use, where the vials may include one or more dosages.
- single dosages can be provided in sterile vials so that the physician can employ the vials directly, where the vials will have the desired amount and concentration of agent(s).
- Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- the compounds of the invention may be used or administered in combination with one or more additional drug (s) that include chemotherapeutic drugs or HDAC inhibitor drugs and/or procedures (e.g. surgery, radiotherapy) for the treatment of the disorder/diseases mentioned.
- additional drug s
- the components can be administered in the same formulation or in separate formulations. If administered in separate formulations the compounds of the invention may be administered sequentially or simultaneously with the other drug (s).
- the compounds of the invention may be used in a combination therapy. When this is done the compounds are typically administered in combination with each other. Thus one or more of the compounds of the invention may be administered either simultaneously (as a combined preparation) or sequentially in order to achieve a desired effect. This is especially desirable where the therapeutic profile of each compound is different such that the combined effect of the two drugs provides an improved therapeutic result.
- compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
- suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminium monostearate and gelatin.
- the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial- retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylceilulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and
- compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
- the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
- the active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate,
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
- compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Dosage forms for topical administration of a compound of this invention include powders, patches, sprays, ointments and inhalants.
- the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required.
- a preferred dosage will be a range from about 0.01 to 300 mg per kilogram of body weight per day.
- a more preferred dosage will be in the range from 0.1 to 100 mg per kilogram of body weight per day, more preferably from 0.2 to 80 mg per kilogram of body weight per day, even more preferably 0.2 to 50 mg per kilogram of body weight per day.
- a suitable dose can be administered in multiple sub-doses per day.
- the compounds of the embodiments disclosed inhibit histone deacetylases.
- the enzymatic activity of a histone deacetylase can be measured using known methodologies [Yoshida M. et al, J. Biol. Chem., 265, 17174 (1990), J. Taunton et al, Science 1996 272: 408].
- the histone deacetylase inhibitor interacts with and/or reduces the activity of more than one histone deacetylase in the cell, which can either be from the same class of histone deacetylase or different class of histone deacetylase.
- the histone deacetylase inhibitor interacts and/or reduces the activity of predominantly one histone deacetylase, for example HDAC-1 , HDAC-3 or HDAC-8 which belongs to Class I HDAC enzymes [De
- Certain preferred histone deacetylase inhibitors are those that interact with, and/or reduce the activity of a histone deacetylase which is involved in tumorigenesis, and these compounds may be useful for treating proliferative diseases.
- Examples of such cell proliferative diseases or conditions include cancer (include any metastases), psoriasis, and smooth muscle cell proliferative disorders such as restenosis.
- inventive compounds may be particularly useful for treating tumors such as breast cancer, colon cancer, lung cancer, ovarian cancer, prostate cancer, head and/or neck cancer, or renal, gastric, pancreatic cancer and brain cancer as well as hematologic malignancies such as lymphoma and leukemias.
- inventive compounds may be useful for treating a proliferative disease that is refractory to the treatment with other chemotherapeutics; and for treating hyperproliferative condition such as leukemias, psoriasis and restenosis.
- compounds in this invention can be used to treat pre-cancer conditions including myeloid dysplasia, endometrial dysplasia and cervical dysplasia.
- compounds of the various embodiments disclosed herein may be useful for treating neurodegenerative diseases, and inflammatory diseases and/or immune system disorders.
- the disorder is preferably selected from the group consisting of cancer, inflammatory diseases and/or immune system disorders (e.g. rheumatoid arthritis, systemic lupus erythematosus), angiofibroma, cardiovascular diseases, fibrotic diseases, diabetes, autoimmune diseases, chronic and acute neurodegenerative disease like Huntington's disease, Parkinson's disease, disruptions of nerval tissue and infectious diseases like fungal, bacterial and viral infections.
- the disorder is a proliferative disorder.
- histone deacetylase inhibitors of the invention have significant antiproliferative effects and promotes differentiation, for example, cell cycle arrest in the G1 or G2 phase, and induce apoptosis SYNTHESIS OF DEACETYLASE INHIBITORS
- the compounds of this invention may be prepared using the reaction routes and synthesis schemes as described below, employing the techniques available in the art using starting materials that are readily available.
- the preparation of particular embodiments is described in detail in the following examples, but the artisan will recognize that the chemical reactions described may be readily adapted to prepare a number of other agents of the various embodiments.
- the synthesis of non- exemplified compounds may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by changing to other suitable reagents known in the art, or by making routine modifications of reaction conditions.
- a list of suitable protecting groups in organic synthesis can be found in T.W. Greene and P. G. M. Wuts' Protective Groups in Organic Synthesis, 3rd Edtion, Wiley- InterScience, 1999.
- other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the various embodiments.
- Reagents useful for synthesizing compounds may be obtained or prepared according to techniques known in the art.
- THF Tetrahydrofuran
- DMF N, N- dimethyiformamide
- the reactions set forth below were performed under a positive pressure of nitrogen, argon or with a drying tube, at ambient temperature (unless otherwise stated), in anhydrous solvents, and the reaction flasks are fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven-dried and/or heat-dried. Analytical thin-layer chromatography was performed on glass-backed silica gel 60 F 254 plates (E Merck (0.25 mm)) and eluted with the appropriate solvent ratios (v/v). The reactions were assayed by TLC and terminated as judged by the consumption of starting material.
- the TLC plates were visualized by UV absorption or with a p-anisaldehyde spray reagent or a phosphomolybdic acid reagent (Aldrich Chemical, 20wt% in ethanol) which was activated with heat, or by staining in iodine chamber. Work-ups were typically done by doubling the reaction volume with the reaction solvent or extraction solvent and then washing with the indicated aqueous solutions using 25% by volume of the extraction volume (unless otherwise indicated). Product solutions were dried over anhydrous sodium sulfate prior to filtration, and evaporation of the solvents was under reduced pressure on a rotary evaporator and noted as solvents removed in vacuo. Flash column chromatography [Still et al, J. Org.
- Reverse-phase preparative HPLC was operated by using a C-
- High-throughput mass-dependent (reverse- phase HPLC) purification system was operated by using a C ⁇ 8 column (5 urn, 19x50 mm) at flow rate of 30 mL/min and a linear gradient from 5 to 95% of CH 3 CN + 0.05% TFA over 9 min.
- the fractions containing the desire product were lyophilized, or evaporated to dryness under vacuum to provide the dry compound, or evaporated to remove the volatile organic solvent then extracted with organic solvents (ethyl acetate or dichloromethane are commonly used, if necessary, the pH of the aqueous solution could also be adjusted in order to get free base, acid or the neutral compound).
- organic solvents ethyl acetate or dichloromethane are commonly used, if necessary, the pH of the aqueous solution could also be adjusted in order to get free base, acid or the neutral compound).
- NMR spectra were recorded on a Bruker AV400 instrument operating at 400 MHz, and 13 C-NMR spectra were recorded operating at 100 MHz. NMR spectra are obtained as CDCI 3 solutions (reported in ppm), using chloroform as the reference standard (7.26 ppm and 77.00 ppm), CD 3 OD (3.3 and 49.3 ppm), DMSO-d 6 (2.50 and 39.5 ppm), or an internal tetramethylsilane standard (0.00 ppm) when appropriate. Other NMR solvents were used as needed.
- R is a linking moiety or equal to -B-A-Z-L- as defined for Formula (2), R" is R less one CH 2 , R 11 is a C-i -C 6 alkyl or benzyl, R 21 is R 2 less one CH 2 and R 2 is defined as for Formula (I).
- the intermediate (2) in Scheme 1 could be prepared by (i) alkylation of amine (2a) with R 2 X (3a, X is halo, e.g., I " , Br “ , CI “ or a good leaving group), or (ii) reductive amination of amine (2a) with aldehyde (3b), or (iii) reductive amination of aldehyde (2b) with amine R 2 NH 2 (3c).
- the ester (6) is hydrolyzed to the acid (6a).
- the acid is subsequently converted to the hydroxamic acid (8) by either Method A or Method B.
- Method A (i) the acid is converted to acid chloride by treating it with CICOCOCI, or SOCI 2 , or other reagents under neutral conditions (such as Ph 3 P with CBr 4 , or 2,4,6- Trichloro-[1 ,3,5]triazine); or (ii) the acid is converted to an active ester by reacting it with isobutyl chloroformate; (iii) the acid chloride or active ester is reacted with hydroxylamine or the O-protected hydroxylamine [e.g., O-benzylhydroxylamine, 0-(2,4-dimethoxy- benzyl)-hydroxylamine, 0, ⁇ /-bis-(2,4-dimethoxy-benzyl)-hydroxylamine, 0-(tetrahydro- pyran-2-yl)-hydroxylamine, 0-(ferf-butyl-dimethyl-silyl)-hydroxylamine] to give the hydroxamic acid or the O-protected
- Method B Coupling the acid with hydroxylamine or O-protected hydroxylamine (R 12 ONH 2 ) with a coupling reagent, then followed by removing the protecting group by methods known in the literature. Synthesis of acylurea linked hydroxamic acid (9).
- Acylurea linked hydroxamic acid (9) could be synthesized by methods analogous to those used for synthesis of sulfonylurea linked hydroxamic acid (8).
- sulfonylurea linked hydroxamic acid (8) and acylurea linked hydroxamic acid (9) could also be synthesized by a synthetic route described in Scheme 4.
- O- protected hydroxamate starting material amine (2c) or aldehyde (2d) are used to make the O-protected hydroxamate intermediate (2P) which is subsequently converted to the corresponding sulfonylurea (8a) and acylurea (9a). After removal the protecting group, sulfonylurea (8) and acylurea (9) are obtained.
- R 13 is selected from R 11 or R 12 .
- the product (6b) could be converted to the hydroxamic acid (8b) by using the similar condition as described for (8) in Scheme 1 , 2 or 4.
- Scheme 5
- 8-Amino-octanoic acid (2.116 g, 13.29 mmol) and methanol (50 mL) were added. The mixture was stirred and cooled in a dry-ice /acetone bath under nitrogen. SOCI 2 (1.5 mL, 20.7 mmol) was added via syringe, then the dry-ice bath was removed and the mixture was stirred at room temperature for 2.5 h. The solution was evaporated and the residue was added diethyl ether. The solid was filtered and dried under vacuum. 8-Amino-octanoic acid methyl ester hydrochloride was obtained as white solid (2.772 g, 99.8%).
- 6-Amino-hexanoic acid methyl ester hydrochloride 0.555 g, 3.06 mmol
- NaBH(OAc) 3 0.782 g, 3, .69 mmol
- 3-Phenyl-propionaldehyde 0.47 mL, 3.21 mmol
- dichloromethane 10 mL
- triethylamine 0.43 mL, 3.09 mmol
- 6-Amino-hexanoic acid (13.1 g, 100 mmoL) was dissolved in 10% aqueous Na 2 CO 3 solution (300 mL), then dioxane (200 mL) was added to the above solution.
- Fmoc-Cl 26 g, 110 mmoL was added to the above mixture portion-wise, and the resultant reaction mixture was stirring for 12h.
- the mixture was extracted with ether (150 mL X 2), and the aqueous portion was acidified by 6N HCl.
- 6-(9H-Fluoren-9-ylmethoxycarbonylamino)-hexanoic acid 9.17 g, 25 mmoL
- 0-(2,4- dimethoxy-benzyl)-hydroxylamine 36 g, 26 mmoL
- DCM 250 mL
- DCC 6.18 g, 30 mmoL
- the resultant mixture was stirred for 3h at room temperature, then cooled to 0°C, filtered, and washed with DCM.
- the organic solution was evaporated to dryness to give the crude [5-(2,4-dimethoxy- benzyloxycarbamoyl)-pentyl]-carbamic acid 9/7-fluoren-9-ylmethyl ester.
- 6-(3-Benzoyl-thioureido)-hexanoic acid (2,4-dimethoxy-benzyloxy)-amide (crude fromSTEPI , 0.186 g equal to 0.27 mmoL) and Triethylsilane (0.05 mL) in DCM (1.7 mL) was added TFA (0.3 mL) at room temperature with stirring. After 20 min, the solution was evaporated to dryness and diluted with methanol and filtered. The filtrate was concentrated and the residue was purified by preparative HPLC. 6-(3-Benzoyl- thioureido)-hexanoic acid hydroxyamide was obtained as a white solid (0.027 g, 32% overall yield).
- Step 4 acylurea formation by reacting the above resin with benzoyl isocyanate.
- the crude products were purified by High throughput mass-dependent HPLC purification system.
- acyl isocyanates could be prepared according to the published literature methods.
- acetyl isocyanate could be synthesized by reacting Et 3 SnNCO with acetyl bromide [Chauzov, V. A.; Baukov, Yu. I. Zhurnal Obshchei Khimii (1972), 42(8), 1868-9], or by reacting Bu 3 SnNCO with acetyl chloride [Kodama, H. et al. Jpn.
- Recombinant GST-HDAC1 and GST-HDAC8 Protein expression and purification Human cDNA library was prepared using cultured SW620 cells. Amplification of human HDAC1 and HDAC8 coding region from this cDNA library was cloned separately into the baculovirus expression pDEST20 vector and pFASTBAC vector respectively (GATEWAY Cloning Technology, Invitrogen Pte Ltd). The pDEST20-HDAC1 and pFASTBAC-HTGST- HDAC8 constructs were confirmed by DNA sequencing. Recombinant baculovirus was prepared using the Bac-To-Bac method following the manufacturer's instruction (Invitrogen Pte Ltd). Baculovirus titer was determined by plaque assay to be about 10 8 PFU/ml.
- the GST-HDAC1 protein or GST-HDAC8 protein was eluted by elution buffer containing 50 mM Tris, pH ⁇ .0, 150mM NaCl, 1 % Triton X-100 and 10mM or 20mM reduced Glutathione.
- the purified GST-HDAC1 protein or purified GST-HDAC8 protein was dialyzed with HDAC storage buffer containing 10mM Tris, pH7.5, 100mM NaCl and 3mM MgCI 2 . 20% Glycerol was added to purified GST-HDAC1 protein or purified GST- HDAC8 before storage at -80°C.
- Flur de lys Developer was added and the reaction was incubated for 10 min. Briefly, deacetylation of the substrate sensitizes it to the developer, which then generates a fluorophore.
- the fluorophore is excited with 360 nm light and the emitted light (460 nm) is detected on a fluorometric plate reader (Tecan Ultra Microplate detection system, Tecan Group Ltd.).
- the analytical software, Prism 3.0® (GraphPad Software Inc) has been used to generate
- MB435 and MDA-MB231) were obtained from ATCC. Colo205 cells were cultivated in
- MDA-MB231 cells were cultivated in RPMI 1640 containing 2 mM L-glutamine, 5%FBS.
- MDA-MB435 cells were cultivated in DMEM containing 2 mM L-Glutamine, 5% FBS. Colo205 cells were seeded in 96-wells plate at 5000 cells per well respectively.
- MB231 cells were seeded in 96-wells plate at 6000 cells per well. The plates were incubated at 37°C, 5% CO 2 , for 24 h. Cells were treated with compounds at various concentrations for 96 h. Cell growth was then monitored using cyquant cell proliferation assay (Invitrogen Pte Ltd). Dose response curves were plotted to determine Gl 50 values for the compounds using XL-fit (ID Business Solution, Emeryville, CA).
- the cellular or growth inhibition activity results of representative compounds are shown in Table 4. These data indicate that compounds in this invention are highly active in inhibition of tumor cell growth. In addition, representative compounds have also demonstrated their ability to inhibit growth in other types of cancer cell lines including lung cancer cell lines (e.g. NCI-H522 and A549), prostate cancer cell line (e.g. PC3), leukemia cell line (e.g. HL-60), lymphoma cell line (e.g. Ramos) and pancreatic cancer cell line (MIAPaCA2) (data not shown).
- lung cancer cell lines e.g. NCI-H522 and A549
- prostate cancer cell line e.g. PC3
- leukemia cell line e.g. HL-60
- lymphoma cell line e.g. Ramos
- MIAPaCA2 pancreatic cancer cell line
- HDAC histone deacetylase
- the protein concentration was quantified using BCA method (Sigma Pte Ltd).
- the protein lysate was separated using 4-12% bis-tris SDS-PAGE gel (Invitrogen Pte Ltd) and was transferred onto PVDF membrane (BioRad Pte Ltd).
- the membrane was probed separately using primary antibody specific for acetylated H3, acetylated H4 or acetylated H2A (Upstate Pte Ltd).
- the detection antibody goat anti rabbit antibody conjugated with Horse radish peroxidase (HRP) was used according to the manufacturer instruction (Pierce Pte Ltd). After removing the detection antibody from the membrane, an enhanced chemiluminescent substrate for detection of HRP (Pierce Pte Ltd) was added onto the membrane.
- the membrane was exposed to an X-ray film (Kodak) for 1 sec - 20 mins.
- the X-ray film was developed using the X-ray film processor.
- the density of each band observed on the developed film could be analysed using UVP Bioimaging software (UVP, Inc, Upland, CA). The values were then normalized against the density of actin in the corresponding samples to obtain the expression of the protein.
- the results of histone deacetylase assay are shown in Table 5.
- the selective induction of apoptosis in proliferating cells such as tumor cells is one of the desirable approaches, and can be mediated by treatment with various anti-proliferative compounds
- Programmed cell death or apoptosis is the cellular response to stress factors such as DNA damage introduced during conventional anti-cancer treatment.
- Stress factors such as DNA damage introduced during conventional anti-cancer treatment.
- necrosis a non-coordinated form of cell death called necrosis.
- characteristic phenotypical cellular changes occur, which include the condensation of chromatin, the shrinkage of cells and finally the fragmentation of chromosomal DNA.
- One of the very early changes caused by apoptotic events occurs in the phospholipids bilayer of the plasma membrane.
- the phospholipid phosphatidylserine is translocated from the inner to the outer side of the plasma-membrane and, as a result, is exposed to the extracellular space.
- One way of detecting early apoptotic cells is to determine the amount of phosphatidyl-serine at the extracellular side of the plasma- membrane which is accomplished by the standard flow cytometric method of Annexin V staining.
- the phospholipids recognizing protein Annexin V binds with high affinity to these inverted and exposed phosphatidyl-serines.
- Ramos Burkitt -lymphoma cells This cell line is one of the gold standard cell lines commonly used as a tissue culture model for B cell lymphoma. Representative compounds as indicated below were added to 80,000 cells per 500 ⁇ l growth medium (RPMI1640 medium supplemented with 2 mM L-Glutamine, 10% heat-inactivated FBS, 1mM Na- Pyruvate and 10 mM HEPES) in 24 well format at various concentrations. Two days after the start of treatment, cells were collected and subjected to the Annexin V staining protocol following the instructions of the manufacturer (BD Biosciences).
- RPMI1640 medium supplemented with 2 mM L-Glutamine, 10% heat-inactivated FBS, 1mM Na- Pyruvate and 10 mM HEPES
- PI propidium iodide
- HL-60 cells which is an acute promyelocytic leukemia cell line (data not shown).
- compounds disclosed in this invention can be used to treat cancers including hematologic malignancies (e.g. lymphoma and leukemia).
- the efficacy of the compounds of the invention can then be determined using in vivo animal xenograft studies.
- the animal xenograft model is one of the most commonly used in vivo cancer models.
- mice Female athymic nude mice (Harlan), 12-14 weeks of age would be implanted subcutaneously in the flank with 5 x 10 6 cells of HCT116 or with 1 x 10 6 cells of Colo205 human colon carcinoma suspended in 50% Matrigel. When the tumor reaches the size 100 mm 3 , the xenograft nude mice would be paired-match into various treatment groups.
- the selected HDAC inhibitors would be dissolved in appropriate vehicles, such as 10%DMA/10% Cremophore/80%water and administered to xenograft nude mice intraperitonelly by daily for 14 days. The dosing volume will be 0.2-ml/20g mouse.
- Paclitaxol used as positive control, will be prepared for intravenous administration in 10%Ethanol/10%Cremophore/80%water.
- the dosing volume for Paclitaxol will be 0.015- ml/g mouse.
- Compounds in this invention that are tested would show significant reduction in tumor volume relative to controls treated with vehicle only.
- the activity of histone deacetylase when measured shall be reduced and results in accumulation of acetylated histone relative to vehicle treated control group. The result will therefore indicate that compounds in this invention are efficacious in treating a proliferative disorder such as cancer.
Abstract
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea/sulfonylurea containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase activities.
Description
ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES
FIELD OF THE INVENTION
The present invention relates to hydroxamate compounds that are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea or sulfonylurea containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase activities.
BACKGROUND OF THE INVENTION
Local chromatin architecture is generally recognized as an important factor in the regulation of gene expression. The architecture of chromatin, a protein-DNA complex, is strongly influenced by post-translational modifications of the histones which are the protein components. Reversible acetylation of histones is a key component in the regulation of gene expression by altering the accessibility of transcription factors to DNA. In general, increased levels of histone acetylation are associated with increased transcriptional activity, whereas decreased levels of acetylation are associated with repression of gene expression [Wade P.A. Hum. Mol. Genet. 10, 693-698 (2001), De Ruijter A.J.M. et al, Biochem. J., 370, 737-749 (2003)]. In normal cells, histone deacetylases (HDACs) and histone acetyltransferase together control the level of acetylation of histones to maintain a balance. Inhibition of HDACs results in the accumulation of acetylated histones, which results in a variety of cell type dependent cellular responses, such as apoptosis, necrosis, differentiation, cell survival, inhibition of proliferation and cytostasis.
Inhibitors of HDAC have been studied for their therapeutic effects on cancer cells. For example, suberoylanilide hydroxamic acid (SAHA) is a potent inducer of differentiation and/or apoptosis in murine erythroleukemia, bladder, and myeloma cell lines [Richon V.M. et al, Proc. Natl. Acad. Sci. USA, 93: 5705-5708 (1996), Richon V.M. et al, Proc. Natl. Acad. Sci. USA, 95: 3003-3007 (1998)]. SAHA has been shown to suppress the growth of prostate cancer cells in vitro and in vivo [Butler L.M. et al, Cancer Res. 60, 5165-5170 (2000)]. Other inhibitors of HDAC that have been widely studied for their anti- cancer activities are trichostatin A (TSA) and trapoxin B [Yoshida M. et al, J. Biol. Chem., 265, 17174 (1990), Kijima M. et al, J. Biol. Chem., 268, 22429 (1993)]. Trichostatin A is a reversible inhibitor of mammalian HDAC. Trapoxin B is a cyclic tetrapeptide, which is an irreversible inhibitor of mammalian HDAC. However, due to the in vivo instability of these
compounds they are less desirable as anti-cancer drugs. Recently, other small molecule
HDAC inhibitors have become available for clinical evaluation [US6,552,065]. Additional
HDAC inhibiting compounds have been reported in the literature [Bouchain G. et al, J.
Med. Chem., 46, 820-830 (2003)] and patents [WO 03/066579A2, WO 01/38322 A1]. The in vivo activity of such inhibitors can be directly monitored by their ability to increase the amount of acetylated histones in the biological sample. HDAC inhibitors have been reported to interfere with neurodegenerative processes, for instance, HDAC inhibitors arrest polyglutamine-dependent neurodegeneration [Nature, 413(6857): 739-43, 18
October, 2001]. In addition, HDAC inhibitors have also been known to inhibit production of cytokines such as TNF, IFN, IL-1 which are known to be implicated in inflammatory diseases and/or immune system disorders. [J. Biol. Chem. 1990; 265(18): 10230-10237;
Science, 1998; 281 : 1001-1005; Dinarello CA. and Moldawer L.L. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. A primer for clinicians. 2nd Edition,
Amergen Inc., 2000].
Nevertheless, there is still a need to provide further HDAC inhibitors that would be expected to have useful, improved pharmaceutical properties in the treatment of diseases such as cancer, neurodegenerative diseases and inflammatory and/or immune system disorders.
SUMMARY OF THE INVENTION
In one aspect the present invention provides compounds of the Formula (I)
Formula (I) wherein R is a linking moiety;
R1 is selected from the group consisting of H, d -C6 alkyl and acyl;
M is selected from the group consisting of O, S, NH, NR4, NOH and NOR4;
R2 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR4, CONHR4, NHCOR4,
NHCOOR4, NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted; or R2 together with the nitrogen to which it is attached and a portion of R form an optionally substituted heterocycloalky group;
R3 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR4, CONHR4, NHCOR4, NHCOOR4, NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted;
Q is selected from the group consisting of -S(O)2-, -C(=O)- and -C(=S)-; G is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; each R4 is independently selected from the group consisting of H, alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl,
heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl; each of which may be optionally substituted; or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment the present invention provides compounds having the Formula (2)
Formula (2) wherein R1 is selected from the group consisting of H, Ci -C6 alkyl and acyl;
L is a single bond or is a C C5 hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -0-, -S-, -S(O)- and -S(0)2- and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C C4 alkyl;
Z is selected from the group consisting of a single bond, N(R1), O, S, S(O) and S(O)2;
A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;
B is selected from the group consisting of a single bond, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, .optionally substituted alkylheteroarylene, optionally substituted C C3 alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene and optionally substituted -(CH2)m-C(0)-N(R4)- (CH2)n-, wherein n is an integer from 0 to 6, m is an integer from 0 to 6;
M is selected from the group consisting of O, S, NH, NR4, NOH and NOR4;
R2 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl,' arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR4, CONHR4, NHCOR4, NHCOOR4 NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted; or R2 together with the nitrogen to which it is attached and a portion of B form an optionally substituted heterocycloalky group;
R3 is independently selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR4, CONHR4, NHCOR4, NHCOOR4, NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted;
Q is selected from the group consisting of -S(0)2-, -C(=0)- and -C(=S)-;
G is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl; each R4 is independently selected from the group consisting of H, alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl,
heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl; each of which may be optionally substituted; or a pharmaceutically acceptable salt or prodrug thereof.
In a particularly preferred embodiment of the compounds of Formula (2) are compounds of Formula (2a)
Formula (2a) wherein R1 is selected from the group consisting of H, Cι -C6 alkyl and acyl L is a single bond or is a CrC5 hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -0-, -S-, -S(O)- and -S(0)2- and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C C4 alkyl;
Z is selected from the group consisting of a single bond, N(R1), O, S, S(O) and S(0)2;
A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;
B is selected from the group consisting of a single bond, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, optionally substituted alkylheteroarylene, optionally substituted d-C3 alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene and optionally substituted -(CH2)m-C(0)-N(R4)- (CH2)n-, wherein n is an integer from 0 to 6, m is an integer from 0 to 6;
M is selected from the group consisting of O,.S, NH, NR4, NOH and NOR4;
R2 is selected from the group consisting of H, Ci -C10 alkyl, alkenyi, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C4 -C9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, -C(0)OR4, -CONHR4, -NHCONHR4, C(=NOH)R4, and acyl;
R3 is selected from the group consisting of H, Ci -Cι0 alkyl, alkenyi, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C4 -C9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, -C(0)OR4, -CONHR4, -NHCONHR4, C(=NOH)R4, and acyl;
Q is selected from the group consisting of -S(0)2-, -CO- and -C(=S)-; G is selected from optionally substituted aryl, optionally substituted heteroaryl, alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl, wherein the substituents are independently selected from the group consisting of X, Y, R4, hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, -C(0)OR4, -C(O)OH, -SH, -CONHR4, - NHCONHR4, and C(=NOH)R4;
R4 is selected from the group consisting of C C alkyl, heteroalkyl, aryl, heteroaryl and acyl;
X and Y are the same or different and are independently selected from the group consisting of H, halo, C C4 alkyl, N02, OR4, SR4, C(0)R5, and NR6R7;
R5 is C C4 alkyl;
R6 and R7 are the same or different and are independently selected from the group consisting of H, C C6 alkyl, C4-C9 cycloalkyl, C4-C8 heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroaryl alkyl.
or a pharmaceutically acceptable salt or prodrug thereof.
Particularly preferred compounds of Formula (2) are those of Formula (2b) and (2c).
Formula (2b) or a pharmaceutically acceptable salt or prodrug thereof.
Formula (2c)
or a pharmaceutically acceptable salt or prodrug thereof.
Another preferred subset of compounds are those of Formula (2d) wherein R1 = R3 = H; R2, X, Y, Z, A, B, R3 and R4 are the same as for Formula (2).
Formula (2d)
or a pharmaceutically acceptable salt or prodrug thereof.
In further embodiments there is disclosed a compound of Formula (2e) wherein R1 = R3 =
H; R2, X, Y, Z, A, B, R3 and R4 are the same as for Formula (2).
Formula (2e)
or a pharmaceutically acceptable salt or prodrug thereof.
In further embodiments there is disclosed a compound of Formula (2f) wherein R2, X, Y, L, A, B, G, R3 and R4 are the same as for Formula (2).
Formula (2f)
or a pharmaceutically acceptable salt or prodrug thereof.
In further embodiments there is disclosed a compound of Formula (2g) wherein R2, X, Y, L, B, G and R4 are the same as for Formula (2).
Formula (2g)
or a pharmaceutically acceptable salt or prodrug thereof.
In a further embodiment there is disclosed a compound of Formula (2h)
Formula (2h) wherein n = integer from 1 to 8, Q = -C(O)- or -S02-, G and R2 are as for Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
In a further embodiment there is provided a compound of Formula (2i)
Formula (2i) wherein
Q = -C(O)- or-SO2-, and G and R2 are as for Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
In a further embodiment there is provided a compound of Formula (2j)
Formula (2j) wherein
Q = -C(0)- or-S02-, and
G and R2 are as for Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
There is also provided a compound of Formula (2k)
Formula (2k) wherein
Q = -C(0)- or-S02-, and
G and R2 are as for Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
There are also provided compounds of Formula (21)
wherein
Q = -C(0)- or-S02-, and G and R2 are as for Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
In a further embodiment there are provided compounds of Formula (2m)
Formula (2m) wherein
Q = -C(0)- or-S02-, and
G and R2 are as for Formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
In further embodiments there is disclosed a compound of Formula (2n) wherein B is a single bond or CH2, L is a single bond or selected from CH2, CH2CH2, -CH=CH-, -C-triple
bond-C-. B is attached to meta or para position of phenylene relative to L and G is selected from aryl, heteroaryl, alkyl and alkoxyalkyl.
Formula (2n) or a pharmaceutically acceptable salt or prodrug thereof.
In further embodiments there is disclosed a compound of Formula (2p) wherein n is an integer from 1 to 8; G is selected from aryl, heteroaryl, alkyl and heteroalkyl. R2 is selected from H, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, arylheteroalkyl, heteroarylalkyl, and heteroarylheteroalkyl.
Formula (2p)
or a pharmaceutically acceptable salt or prodrug thereof.
In further embodiments there is disclosed a compound of Formula (2q) wherein B is a single bond or CH2, L is a single bond or selected from CH2, CH2CH2, -CH=CH-, -C-triple bond-C-, R2 is selected from H, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, heteroalkyl, heteroarylalkyl, heteroarylheteroalkyl. X is selected from H, halo, C C4 alkyl, alkoxy, alkylamino; B is attached to meta or para position of phenylene relative to L.
Formula (2q)
or a pharmaceutically acceptable salt or prodrug thereof.
In further embodiments there is disclosed a compound of (2r) wherein n is an integer from 1 to 8, X is selected from H, halo, C C alkyl, alkoxy, alkylamino.
Formula (2r) or a pharmaceutically acceptable salt or prodrug thereof.
As with any group of structurally related compounds which possess a particular utility, certain groups are preferred for the compounds of the Formula (I), (2), (2a), (2b), (2c), (2d), (2e), (20, (2g), (2h), (2i), (2j), (2k), (21), (2m), (2n), (2p), (2q) and (2r) in their end use application.
In those embodiments in which it is present R1 is preferably H or C C4 alkyl, more preferably H or methyl, most preferably H.
M is preferably O or S, most preferably O.
Q is preferably S(0)2 or CO, most preferably CO.
G is preferably optionally substituted aryl, more preferably optionally substituted phenyl, most preferably 4-methyl phenyl or phenyl.
R2 is preferably selected from the group consisting of H, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted arylheteroalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylheteroalkyl, optionally substituted cycloalkylalkyl and optionally substituted heterocycloalkylalkyl.
In a particularly preferred embodiment R2 is selected from the group consisting of H, 2-
(1 H-indol-3-yl)-ethyl, 2-(2-methyl-1 H-indol-3-yl)-ethyl, pyridin-3-ylmethyl, 3-hydroxy- propyl, 2-pyridin-2-yl-ethyl, 2-pyridin-3-yl-ethyl, pyridin-3-ylmethyl, 2-pyridin-4-yl-ethyl, benzyl, 3-phenyl-propyl, 2-phenoxy-ethyl, morphoIin-4-yl, pyridin-2-yl, phenethyl, 2-(4- bromo-phenyl)-ethyl, 2-(4-fluoro-phenyl)-ethyl, 3-imidazol-1-yl-propyl, 2-(1 H-imidazol-4- yl)-ethyl, 1 H-Benzoimidazol-2-ylmethyl, 2-piperidin-1 -yl-ethyl, 2-pyrrolidin-1 -yl-ethyl, 2- cyclohex-1-enyl-ethyl, 2-ethyl-hexyl, 2-thiophen-2-yl-ethyl, 3,3-diphenyl-propyl, 2- biphenyl-4-yl-ethyl, -(4-phenoxy-phenyl, 2-(3-phenoxy-phenyl)-ethyl, 2-(2,3-dimethoxy- phenyl, 2-(2,4-dichloro-phenyl)-ethyl, cyclohexylmethyl, hexyl, isobutyl, 3-isopropoxy- propyl, 2-phenoxy-ethyl, 2-isopropoxy-ethyl, 3-methoxy-benzyl, 4-[1 ,2,3]thiadiazol-4-yl- benzyl, 2,4-dichloro-benzyl, 2-(2-methoxy-phenyl)-ethyl, 2-(3-fluoro-phenyl)-ethyl, 2-(2- fluoro-phenyl)-ethyl, 2,2-diphenyl-ethyl, 2-(4-methoxy-phenyl)-ethyl, 2-(3-chloro-phenyl)- ethyl, 4-phenyl-butyl, 3-phenyl-propyl, 3,3-diphenyl-propyl, 3-(4-methyl-piperazin-1-yl, 3- morpholin-4-yl-propyl, 3-(2-oxo-pyrrolidin-1-yl)-propyl, 3-pyrroIidin-1 -yl-propyl, tetrahydro- furan-2-ylmethyl, 1 ,5-dimethyl-hexyl, 2-diethylamino-ethyl and 2-dimethylamino-ethyl.
It is even more preferred that R2 is selected from the group consisting of H, 2-(1H-indol-3- yl)-ethyl, 2-(2-methyl-1H-indol-3-yl)-ethyl, pyridin-3-ylmethyl, 3-hydroxy-propyl, 2-pyridin- 2-yl-ethyl, 2-pyridin-3-yl-ethyl, pyridin-2-ylmethyl, pyridin-3-ylmethyl, 2-pyridin-4-yl-ethyl, benzyl, 3-phenyl-propyl, 2-phenoxy-ethyl, 2-morpholino ethyl, 2-phenyl ethyl, 2-(4-bromo- phenyl)-ethyl, 2-(4-fluoro-phenyl)-ethyl, 3-imidazol-1 -yl-propyl, 2-(1 H-imidazol-4-yl)-ethyl, 1H-Benzoimidazol-2-ylmethyl, 2-piperidin-1 -yl-ethyl and 2-pyrrolidin-1 -yl-ethyl.
In a most preferred embodiment R2 is selected from the group consisting of H, 2-(1 H- indol-3-yl)-ethyl, 2-(2-methyl-1 H-indol-3-yl)-ethyl, 2-phenyl ethyl, 2-piperidin-1 -yl-ethyl and 2-pyrrolidin-1 -yl-ethyl.
It is preferred that R3 is H.
It is preferred that L is selected from the group consisting of a single bond, -CH2-, -(CH2)2 - and -CH=CH-. Accordingly in one preferred embodiment L is a bond. In another preferred embodiment L is a group of formula -CH2-. In another preferred embodiment L is a group of formula -CH=CH-. The group of formula -CH=CH- is preferably in the "E" configuration.
Z is preferably a single bond.
A is preferably an optionally substituted arylene. In one preferred embodiment A is selected from the group consisting of 1 ,4-phenylene and 1 ,3-phenylene. It is particularly preferred that A is 1 ,4-phenylene.
It is preferred that B is selected from the group consisting of a single bond, methylene, ethylene, propylene, alkylarylene, and heteroalkylene. In one preferred embodiment B is methylene. In another preferred embodiment B is a bond. In another preferred embodiment B is ethylene. In yet another preferred embodiment B is propylene.
In one preferred embodiment the identities of B, A, Z and L are such that the group BAZL is a group of formula -(CH2)n- wherein n is an integer from 1 to 7.
In another preferred embodiment the identities of B, A, Z are such that the group BAZ is a group of formula -(CH2)- phenyl-
In a particularly preferred embodiment the identities of B, A, Z and L are such that the group BAZL is selected from the group consisting of
(CH2)7 -(CH2)6 (CH2)5 (CH2)4- -(CH2)3
is a single bond
In many of the formulae given herein the substituents are stated to be optionally substituted. Where substituents are present it is preferred that the optional substituents are selected from the group consisting of halogen, =O, =S, -CN, -N02, -CF3, -OCF3, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkenyl, heterocycloalkylalkenyl, arylalkenyl, heteroarylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, arylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycycloalkyl, alkoxyheterocycloalkyl, alkoxyaryl, alkoxyheteroaryl, alkoxycarbonyl, alkylaminocarbonyl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, phenoxy, benzyloxy, heteroaryloxy, arylalkyloxy, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, alkylsulfinyl, arylsulfinyl, aminosulfinylaminoalkyl, -COOH, -COR5, -C(0)OR5, CONHR5, NHCOR5, NHCOOR5, NHCONHR5, C(=NOH)R5 -SH, -SR5, -OR5 and acyl, or
wherein each R5 is independently selected from the group consisting of alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted;
In addition to compounds of the invention as described above the embodiments disclosed are also directed to pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of such compounds, and pharmaceutically acceptable salts of such metabolites. Such compounds, salts, prodrugs and metabolites are at times collectively referred to herein as "HDAC inhibiting agents" or "HDAC inhibitors". In certain embodiments the compounds disclosed are used to modify deacetylase activity, in some cases histone deacetylase activity and in some cases HDAC 8, or HDAC 1 activity.
The embodiments disclosed also relate to pharmaceutical compositions each comprising a therapeutically effective amount of a HDAC inhibiting agent of the embodiments described with a pharmaceutically acceptable carrier or diluent for treating cellular proliferative ailments. The term "effective amount" as used herein indicates an amount
necessary to administer to a host to achieve a therapeutic result, e.g., inhibition of proliferation of malignant cancer cells, benign tumor cells or other proliferative cells.
The invention also relates to pharmaceutical compositions including a compound of the invention with a pharmaceutically acceptable carrier, diluent or excipient.
In yet a further aspect the present invention provides a method of treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis including administration of a therapeutically effective amount of a compound of Formula (I).
The method preferably involves administration of a compound of Formula (2) more preferably a compound of Formula (2a) or (2b) or (2c), most preferably a compound of (2e) to (2r).
The disorder is preferably selected from the group consisting of but not limited to cancer (e.g. breast cancer, colon cancer, prostate cancer, pancreatic cancer, leukemias, lymphomas), inflammatory diseases/immune system disorders, angiofibroma, cardiovascular diseases (e.g. restenosis, arteriosclerosis), fibrotic diseases (e.g. liver fibrosis), diabetes, autoimmune diseases, chronic and acute neurodegenerative disease like disruptions of nerval tissue, Huntington's disease and infectious diseases like fungal, bacterial and viral infections. In another embodiment the disorder is a proliferative disorder. The proliferative disorder is preferably cancer. The cancer can include solid tumors or hematologic malignancies.
The invention also provides agents for the treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis including a compound of Formula (I) as disclosed herein. The agent is preferably an anti-cancer agent.
The agent preferably contains a compound of Formula (2) more preferably a compound of Formula (2a) or (2b) or (2c), most preferably a compound of (2e) to (2r).
The invention also relates to the use of compounds of Formula (I) in the preparation of a medicament for the treatment of a disorder caused by, associated with or accompanied
by disruptions of cell proliferation and/or angiogenesis. The disorder is preferably a proliferative disorder, most preferably a cancer.
The compounds of the present invention surprisingly show low toxicity, together with a potent anti-proliferative activity.
In yet a further embodiment the invention provides a method of treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase including administration of a therapeutically effective amount of a compound of Formula (I).
In yet a further embodiment the invention provides a method of treatment of a disorder, disease or condition that are mediated by deacetylase activity such as histone deacetylase including administration of a therapeutically effective amount of a compound of Formula (I).
The method preferably includes administration of a compound of Formula (2), more preferably a compound of Formula (2a) or (2b) or (2c), most preferably a compound of (2e) to (2r) as described herein.
The disorder is preferably selected from the group consisting of but not limited to Proliferative disorders (e.g. cancer); Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesis, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Progressive supranuclear palsy, Pick's disease, Intracerebral haemorrhage Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration, Rubeotic glaucoma, Interstitial keratitis, Diabetic retinopathy; Inflammatory diseases and/or Immune system disorders including Rheumatoid Arthritis (RA), Osteoarthritis, Juvenile chronic arthritis, Graft versus Host disease, Psoriasis, Asthma, ,Spondyloarthropathy, Crohn's Disease, inflammatory bowel disease, Colitis Ulcerosa, Alcoholic hepatitis, Diabetes, Sjoegrens's syndrome, Multiple Sclerosis, Ankylosing spondylitis, Membranous glomerulopathy, Discogenic pain, Systemic Lupus Erythematosus; Disease involving angiogenesis including cancer, psoriasis, rheumatoid arthritis; Psychological disorders including bipolar disease,
schizophrenia, depression and dementia; Cardiovascular Diseases including Heart failure, restenosis and arteriosclerosis; Fibrotic diseases including liver fibrosis, cystic fibrosis and angiofibroma; Infectious diseases including Fungal infections, such as
Candida Albicans, Bacterial infections, Viral infections, such as Herpes Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.
The invention also provides agents for the treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase including a compound of Formula (I) as disclosed herein. The agent is preferably an anti-cancer agent.
The invention also relates to the use of compounds of Formula (I) in the preparation of a medicament for the treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase.
In another embodiment the invention provides amethod of modifying deacetylase activity including contacting the deacetylase with a compound of Formula (I). The deacetylase activity is preferably histone deacetylase activity, even more preferably class I histone deacetylase activity. The histone deacetylase is preferably HDAC1 or HDAC8.
The invention also provides a method for inhibiting cell proliferation including administration of an effective amount of a compound according to Formula (I).
In yet an even further aspect the invention provides a method of treatment of a neurodegenerative disorder in a patient including administration of a therapeutically effective amount of a compound of Formula (I). The method preferably includes administration of a compound of Formula (2) more preferably a compound of Formula (2a) or (2b) or (2c), most preferably a compound of (2e) to (2r) as described herein. The neurodegenerative disorder is preferably Huntington's Disease.
The invention also provides agents for the treatment of neurodegenerative disorder including a compound of Formula (I) as disclosed herein. The agent is preferably anti- Huntington's disease agent.
The invention also relates to the use of compounds of Formula (I) in the preparation of a medicament for the treatment of a neurodegenerative disorder. The neurodegenerative disorder is preferably Huntington's Disease.
In yet an even further aspect the invention provides a method of treatment of an inflammatory disease and/or immune system disorder in a patient including administration of a therapeutically effective amount of a compound of Formula (I). The method preferably includes administration of a compound of Formula (2) more preferably a compound of Formula (2a) or (2b) or (2c), most preferably a compound of (2e) to (2r) as described herein. In one embodiment the inflammatory disease and/or immune system disorder is rheumatoid arthritis. In another embodiment the inflammatory disease and/or immune system disorder is Systemic Lupus Erythematosus.
The invention also provides agents for the treatment of inflammatory disease and/or immune system disorder including a compound of Formula (I) as disclosed herein.
The invention also relates to the use of compounds of Formula (I) in the preparation of a medicament for the treatment of inflammatory disease and/or immune system disorder. In one embodiment the inflammatory disease and/or immune system disorder is rheumatoid arthritis. In another embodiment the inflammatory disease and/or immune system disorder is Systemic Lupus Erythematosus.
In another embodiment the present invention provides the use of a compound of Formula (I) to modify deacetylase activity, preferably histone deacetylase activity, even more preferably HDACI or HDAC8.
The invention also provides the use of a compound of Formula (I) to treat cancer. In another embodiment, the cancer is selected from a group including but not limited to breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.
The present invention also provides the use of a compound of Formula (I) in the preparation of a medicament for the treatment of hematologic malignancies. The hematologic malignancy is preferably selected from the group consisting of B-cell lymphoma, T-cell lymphoma and leukemia.
The invention also provides a method for the treatment of a hematologic malignancy including administration of an effective amount of a compound of Formula (I).
The invention also provides an agent for the treatment of hematologic malignancy including a compound of Formula (I).
The invention also provides the use of a compound of Formula (I) in the preparation of a medicament for the treatment of solid tumors. The solid tumor is preferably selected from the group consisting of breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.
The invention also provides a method of treatment of a solid tumor including administration of an effective amount of a compound of Formula (I). The solid tumor is preferably selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer and brain cancer.
The invention also provides agents for the treatment of solid tumors including a compound of Formula (I).
In yet a further aspect the invention provides for the use of a compound of Formula (I) in the preparation of a medicament for the induction of cell death such as apoptosis of tumor cell.
The invention also provides a method of inhibiting tumor cell proliferation including the administration of a compound according to Formula (I).
The invention also provides a method of inhibiting the activity of histone deacetylase including contacting the histone deacetylase with an effective amount of a compound according to Formula (I).
The invention also provides the use of a compound of Formula (I) in the manufacture of medicaments for the induction of apoptosis of tumor cells.
In an even further embodiment the invention provides a method of inducing apoptosis in tumor cells including administration of an effective amount of a compound of Formula (I).
DETAILED DESCRIPTION OF THE INVENTION
There are disclosed hydroxamate compounds, for example acylurea/sulfhonylurea containing hydroxamic acid in one of the substituents, that may be inhibitors of deacetylases, including but not limited to inhibitors of histone deacetylases. The hydroxamate compounds may be suitable for prevention or treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis when used either alone or together with a pharmaceutically acceptable carrier, diluent or excipient. An example of such a disorder is cancer.
As used herein the term 'cancer' is a general term intended to encompass the vast number of conditions that are characterised by uncontrolled abnormal growth of cells.
It is anticipated that the compounds of the invention will be useful in treating various cancers including but not limited to bone cancers including Ewing's sarcoma, osteosarcoma, chondrosarcoma and the like, brain and CNS tumors including acoustic neuroma, neuroblastomas, glioma and other brain tumors, spinal cord tumors, breast cancers, colorectal cancers, colon cancer, advanced colorectal adenocarcinomas, endocrine cancers including adenocortical carcinoma, pancreatic cancer, pituitary cancer, thyroid cancer, parathyroid cancer, thymus cancer, multiple endocrine neoplasma, gastrointestinal cancers including stomach cancer, esophageal cancer, small intestine cancer, Liver cancer, extra hepatic bile duct cancer, gastrointestinal carcinoid tumor, gall bladder cancer, genitourinary cancers including testicular cancer, penile cancer, prostate cancer, gynaecological cancers including cervical cancer, ovarian cancer, vaginal cancer, uterus/endometrium cancer, vulva cancer, gestational trophoblastic cancer, fallopian tube cancer, uterine sarcoma, head and neck cancers including oral cavity cancer, lip cancer, salivary gland cancer, larynx cancer, hypopharynx cancer, orthopharynx cancer, nasal cancer, paranasal cancer, nasopharynx cancer, leukemias including childhood leukemia, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, acute promyelocytic leukemia, plasma cell leukemia, myelomas, haematological disorders including myelodysplastic syndromes, myeloproliferative disorders, aplastic anemia, Fanconi anemia, Waldenstroms Macroglobulinemia, lung cancers including small cell lung cancer, non-small cell lung cancer, lymphomas including Hodgkin's disease, non-Hodgkin's lymphoma, cutaneous T- cell lymphoma, peripheral T-cell lymphoma, AIDS related Lymphoma, B-cell lymphoma, Burkitt's lymphoma, eye cancers including retinoblastoma, intraocular melanoma, skin cancers including melanoma, non-melanoma skin cancer, merkel cell cancer, soft tissue
sarcomas such as childhood soft tissue sarcoma, adult soft tissue sarcoma, Kaposi's sarcoma, urinary system cancers including kidney cancer, Wilms tumor, bladder cancer, urethral cancer, and transitional cell cancer.
Preferred cancers that may be treated by the compounds of the present invention include but are not limited to breast cancer, colon cancer, pancreatic cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer and brain cancer.
Preferred cancers that may be treated by compounds of the present invention include but are not limited to B-cell lymphoma (e.g. Burkitt's lymphoma), leukemias (e.g. Acute promyelocytic leukemia), cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma.
Preferred cancers that may be treated by compounds of the present invention include but are not limited to solid tumors and hematologic malignancies.
The compounds may also be used in the treatment of a disorder involving, relating to, or associated with dysregulation of histone deacetylase (HDAC).
There are a number of disorders that have been implicated by or known to be mediated at least in part by HDAC activity, where HDAC activity is known to play a role in triggering disease onset, or whose symptoms are known or have been shown to be alleviated by HDAC inhibitors. Disorders of this type that would be expected to be amenable to treatment with the compounds of the invention include the following but not limited to: Proliferative disorders (e.g. cancer); Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesis, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Progressive supranuclear palsy, Pick's disease, intracerebreal haemorrphage, Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateralsclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration, Rubeotic glaucoma, Intersititial keratitis, Diabetic retinopathy; Inflammatory diseases and/or Immune system disorders including Rheumatoid Arthritis (RA), Osteoarthritis, Juvenile chronic arthritis, Graft versus
Host disease, Psoriasis, Asthma, .Spondyloarthropathy, Crohn's Disease , inflammatory bowel disease Colitis Ulcerosa, Alcoholic hepatitis, Diabetes , Sjoegrens's syndrome,
Multiple Sclerosis, Ankylosing spondylitis, Membranous glomerulopathy, Discogenic pain,
Systemic Lupus Erythematosus; Disease involving angiogenesis including cancer, psoriasis, rheumatoid arthritis; Psychological disorders including bipolar disease, schizophrenia, mainia, depression and dementia; Cardiovascular Diseases including heart failure, restenosis and arteriosclerosis; Fibrotic diseases including liver fibrosis, cystic fibrosis and angiofibroma; Infectious diseases including Fungal infections, such as
Candida Albicans, Bacterial infections, Viral infections, such as Herpes Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.
The hydroxamate compounds of the present invention have the following structure (I):
Formula (I) wherein R is a linking moiety;
R1 is selected from the group consisting of H, Ci -C6 alkyl and acyl; M is selected from the group consisting of O, S, NH, NR4, NOH and NOR4;
R2 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl; heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR4, CONHR4, NHCOR4,
NHCOOR4, NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted; or R2 together with the nitrogen to which it is attached and a portion of R form an optionally substituted heterocycloalky group;
R3 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR4, CONHR4, NHCOR4, NHCOOR4' NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted;
Q is selected from the group consisting of -S(0)2-, -C(=0)- and -C(=S)-;
G is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; each R4 is independently selected from the group consisting of H, alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted; or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment the compounds having the Formula (2)
Formula (2) wherein R1 is selected from the group consisting of H, C-i -C6 alkyl and acyl;
L is a single bond or is a C C5 hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -0-, -S-, -S(O)- and -S(0)2- and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C C alkyl;
Z is selected from the group consisting of a single bond, N(R1), O, S, S(O) and S(0)2; A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;
B is selected from the group consisting of a single bond, optionally substituted acylamino, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, optionally substituted alkylheteroarylene, optionally substituted Cι-C3 alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene and optionally substituted -(CH2)m-C(0)-N(R )-(CH2)n-, wherein n is an integer from 0 to 6, m is an integer from 0 to 6;
M is selected from the group consisting of O, S, NH, NR4, NOH and NOR4; R2 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl,
heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR4, CONHR4, NHCOR4, NHCOOR4 NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted; or R2 together with the nitrogen to which it is attached and a portion of B form an optionally substituted heterocycloalky group;
R3 is independently selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOH, COOR4, SH, CONHR4, NHCOR4, NHCOOR4, NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted;
Q is selected from the group consisting of -S(0)2-, -C(=0)- and -C(=S)-;
G is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl; each R4 is independently selected from the group consisting of H, alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted; or a pharmaceutically acceptable salt or prodrug thereof.
In another preferred embodiment of the compounds of Formula (2) are compounds of
Formula (2a)
Formula (2a) wherein R1 is selected from the group consisting of H, Ci -Cβ alkyl and acyl; L is a single bond or is a C C5 hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -O-, -S-, -S(O)- and -S(0)2- and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C1-C4 alkyl;
Z is selected from the group consisting of a single bond, N(R1), O, S, S(O) and S(O)2;
A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;
B is selected from the group consisting of a single bond, optionally substituted acyl amino, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, optionally substituted alkylheteroarylene, optionally substituted C C3 alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene and optionally substituted -(CH2)m-C(0)-N(R4)-(CH2)n-, wherein n is an integer from 0 to 6, m is an integer from 0 to 6;
M is selected from the group consisting of O, S, NH, NR4, NOH and NOR4;
R2 is selected from the group consisting of H, Ci -C10 alkyl, alkenyi, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C4 -C9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, -C(0)OR4, -CONHR4, -NHCONHR4, C(=NOH)R4, and acyl;
R3 is selected from the group consisting of H, Ci -C10 alkyl, alkenyi, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C -C9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, -C(0)OR4, -CONHR4, -NHCONHR4, C(=NOH)R4, and acyl; Q is selected from the group consisting of -S(0)2-, -CO- and -C(=S)-;
G is selected from optionally substituted aryl, optionally substituted heteroaryl, alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl, wherein the substituents are independently selected from the group consisting of X, Y, R4, hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, -C(0)OR4, -C(0)OH, -SH, -CONHR4, - NHCONHR4, and C(=NOH)R4; R4 is selected from the group consisting of CrC alkyl, heteroalkyl, aryl, heteroaryl and acyl;
X and Y are the same or different and are independently selected from the group consisting of H, halo, C C4 alkyl, N02, OR4, SR4, C(0)R5, and NR6R7;
Ra is CrC4 alkyl;
R6 and R7 are the same or different and are independently selected from the group consisting of H, Cι-C6 alkyl, C -C9 cycloalkyl, C4-C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroaryl alkyl.
or a pharmaceutically acceptable salt or prodrug thereof.
Particularly preferred embodiments within the scope of these formulae are as described previously.
In particular embodiments the compound is selected from the group consisting of the following compounds in the table below
8-[3-(4-methylbenzenesuIfonyl)-ureido])- octanoic acid hydroxyamide,
7-[3-(4-methylbenzenesulfonyl)-ureido])- heptanoic acid hydroxyamide,
6-[3-(4-methylbenzenesulfonyI)-ureido])- hexanoic acid hydroxyamide,
6-[3-(benzenesulfonyl)-ureido])-hexanoic acid hydroxyamide,
N-Hydroxy-4-[3-(4- methylbenzenesulfonyl)ureido]methyl- benzamide,
N-Hydroxy-2-{4-[3-(4- methylbenzenesulfonyl)ureido]-phenyl}- acetamide,
N-Hydroxy-2-{3-[3-(4- methylbenzenesulfonyl)ureido]-phenyl}- acetamide,
N-Hydroxy-3-{4-[3-(4- methylbenzenesulfonyl)ureido]-phenyl}- acrylamide,
N-Hydroxy-3-{3-[3-(4- methylbenzenesulfonyl)ureido]-phenyl}- acrylamide,
6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide,
7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide,
8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide,
6-[3-Benzoyl-1-(3-phenyl-propyl)-ureido]- hexanoic acid hydroxyamide,
4-(3-Benzoyl-ureidomethyl)-N-hydroxy- benzamide,
2-[4-(3-Benzoyl-ureido)-phenyl]-N-hydroxy- acetamide,
2-[3-(3-Benzoyl-ureido)-phenyl]-N-hydroxy- acetamide,
3-[4-(3-Benzoyl-ureido)-phenyl]-N-hydroxy- acrylamide,
3-(4-{3-Benzoyl-1 -[2-(1 H-indol-3-yl)-ethyl]- ureidomethyl}-phenyl)-N-hydroxy- acrylamide,
3-[4-(3-Benzoyl-1-pyridin-3-ylmethyl- ureidomethyl)-phenyl]-N-hydroxy- acrylamide,
3-{4-[3-Benzoyl-1-(3-hydroxy-propyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
4-{3-Benzoyl-1 -[2-(1 H-indol-3-yl)-ethyl]- ureidomethyl}-N-hydroxy-benzamide,
4-(3-Benzoyl-ureido)-N-hydroxy- butyramide,
4-(3-Benzoyl-1-benzyl-ureidomethyl)-N- hydroxy-benzamide,
4-[3-Benzoyl-1-(2-pyhdin-2-yl-ethyl)- ureidomethyl]-N-hydroxy-benzamide,
4-[3-Benzoyl-1-(3-hydroxy-propyl)- ureidomethyl]-N-hydroxy-benzamide,
3-[4-(3-Benzoyl-1-benzyl-ureidomethyl)- phenyl]-N-hydroxy-acrylamide,
3-{4-[3-Benzoyl-1-(3-phenyl-propyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-{4-[3-Benzoyl-1-(2-phenoxy-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
4-[3-Benzoyl-1-(3-phenyl-propyl)- ureidomethyl]-N-hydroxy-benzamide,
4-(3-Benzoyl-1-pyridin-3-ylmethyl- ureidomethyl)-N-hydroxy-benzamide,
(S)-6-[2-(3-Benzoyl-ureido)-3-(1 H-indol-3- yl)-propionylamino]-hexanoic acid hydroxyamide,
4-(4-BenzoylaminocarbonyI-piperazin-1- ylmethyl)-N-hydroxy-benzamide,
7-(3-Benzoyl-1-pyridin-2-ylmethyl-ureido)- heptanoic acid hydroxyamide,
6-(3-Benzoyl-1-pyridin-2-ylmethyl-ureido)- hexanoic acid hydroxyamide,
3-{4-[3-Benzoyl-1-(2-morpholin-4-yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
7-(3-Benzoyl-1-benzyl-ureido)-heptanoic acid hydroxyamide,
6-(3-Benzoyl-1-benzyl-ureido)-hexanoic acid hydroxyamide,
3-{4-[3-Benzoyl-1-(2-pyridin-2-yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-[4-(3-Benzoyl-1 -phenethyl- ureidomethyl)-phenyl]-N-hydroxy- acrylamide,
3-(4-{3-Benzoyl-1-[2-(4-bromo-phenyl)- ethyl]-ureidomethyl}-phenyl)-N-hydroxy- acrylamide,
3-(4-{3-Benzoyl-1-[2-(4-fluoro-phenyl)- ethyl]-ureidomethyl}-phenyl)-N-hydroxy- acrylamide,
N-{4-[4-(2-Hydroxycarbamoyl-vinyl)- benzyl]-piperazine-1-carbonyl}-benzamide,
3-{4-[3-Benzoyl-1 -(3-imidazol-1 -yl-propyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-(4-{3-Benzoyl-1-[2-(1 H-imidazol-4-yl)- ethyl]-ureidomethyl}-phenyl)-N-hydroxy- acrylamide,
6-(3-Benzoyl-thioureido)-hexanoic acid hydroxyamide,
3-{4-[1 -(1 H-Benzoimidazol-2-ylmethyl)-3- benzoyl-ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-{4-[3-Benzoyl-1-(2-pyridin-3-yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-{4-[3-Benzoyl-1-(2-pyridin-4-yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-{4-[3-Benzoyi-1 -(2-piperidin-1 -yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-{4-[3-Benzoyl-1 -(2-pyrrolidin-1 -yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
As used herein, the term unsubstituted means that there is no substituent or that the only substituents are hydrogen.
The term "optionally substituted" as used throughout the specification denotes that the group may or may not be further substituted or fused (so as to form a condensed polycyclic system), with one or more substituent groups. Preferably the substituent groups are one or more groups independently selected from the group consisting of halogen, =0, =S, -CN, -NO2, -CF3, -OCF3, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkenyl, heterocycloalkylalkenyl, arylalkenyl, heteroarylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, arylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycycloalkyl, alkoxyheterocycloalkyl, alkoxyaryl, alkoxyheteroaryl, alkoxycarbonyl, alkylaminocarbonyl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, phenoxy, benzyloxy, heteroaryloxy, arylalkyloxy, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, alkylsulfinyl, arylsulfinyl, aminosulfinylaminoalkyl, -COOH, -COR5, -C(0)OR5, CONHR5, NHCOR5, NHCOOR5, NHCONHR5, C(=NOH)R5,-SH, -SR5, -OR5 and acyl.
"Halogen" represents chlorine, fluorine, bromine or iodine.
"Alkyl" as a group or part of a group refers to a straight or branched aliphatic hydrocarbon group, preferably a C-i-C- alkyl, more preferably C Cιo alkyl, most preferably C C6 unless otherwise noted. Examples of suitable straight and branched CrC6 alkyl substituents include methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, t-butyl, hexyl, and the like.
"Alkylamino" includes both monoalkylamino and dialkylamino, unless specified. "Monoalkylamino" means a -NH-Alkyl group, "Dialkylamino" means a -N(alkyl)2 group, in which the alkyl is as defined as above. The alkyl group is preferably a C C6 alkyl group.
"Arylamino" includes both mono-arylamino and di-arylamino unless specified. Mono- arylamino means a group of formula aryl NH-, di-arylamino means a group of formula (aryl2) N- where aryl is as defined herein.
"Acyl" means a R-C(=0)- or G-C(=S)- group in which R is selected from aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, arylalkyl and heteroarylalkyl as described herein. G could be further substituted. Examples of acyl include acetyl, benzoyl, phenylacetyl.
"Alkenyi" as group or part of a group denotes an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched preferably having 2-14 carbon atoms, more preferably 2-12 carbon atoms, most preferably 2-6 carbon atoms, in the chain. The group may contain a plurality of double bonds in the normal chain and the orientation about each is independently E or Z. Exemplary alkenyi group include, but are not limited to, ethenyl and propenyl.
"Alkoxy" refers to an -O-alkyl group in which alkyl is defined herein. Preferably the alkoxy is a C C6 alkoxy. Examples include, but are not limited to, methoxy and ethoxy.
"Alkenyloxy" refers to an -O- alkenyi group in which alkenyi is as defined herein. Preferred alkenyloxy groups are Cι-C6 alkenyloxy groups.
"Alkynyloxy" refers to an -O-alkynyl group in which alkynyl is as defined herein. Preferred alkynyloxy groups are C C6 alkynyloxy groups.
"Alkoxycarbonyl" refers to an -C(0)-0-alkyl group in which alkyl is as defined herein. The alkyl group is preferably a C C6 alkyl group. Examples include, but not limited to, methoxycarbonyl and ethoxycarbonyl.
"Akylsulfinyl" means a -S(0)-alkyl group in which alkyl is as defined above. The alkyl group is preferably a CrC6 alkyl group. Exemplary alkylsulfinyl groups include, but not limited to, methylsulfinyl and ethylsulfinyl.
"Alkylsulfonyl" refers to a -S(0)2-alkyl group in which alkyl is as defined above. The alkyl group is preferably a C C6 alkyl group. Examples include, but not limited to methylsulfonyl and ethylsulfonyl.
"Alkynyl as a group or part of a group means an aliphatic hydrocarbon group containing a carbon-carbon trip bond and which may be straight or branched preferably having from 2- 14 carbon atoms, more preferably 2-12 carbon atoms in the chain, preferably 2-6 carbon atoms in the chain. Exemplary structures include, but not limited to, ethynyl and propynyl.
"Alkylaminocarbonyl" refers to an alkylamino-carbonyl group in which alkylamino is as defined above.
"Aminoacyl" refers to the formula -C(0)-(CH2)m-(CH)(NR6R7)-(CH2)n-R6 wherein R6 and R7 are as defined above, m and n are integers selected from 0 to 6.
"Aryl" as a group or part of a group denotes (i) an optionally substituted monocyclic, or fused polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) preferably having from 5 to 12 atoms per ring. Examples of aryl groups include phenyl, naphthyl, and the like; (ii) an optionally substituted partially saturated bicyclic aromatic carbocyclic moiety in which a phenyl and a C5-7 cycloalkyl or C5.7 cycloalkenyl group are fused together to form a cyclic structure, such as tetrahydronaphthyl, indenyl or indanyl. The aryl group may be substituted by one or more substituent groups. When the aryl ring is divalent it has been referred to as "arylene" in this application.
"Arylalkenyl" means an aryl-alkenyl- group in which the aryl and alkenyi are as previously described. Exemplary arylalkenyl groups include phenylallyl.
"Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contains a C1.5 alkyl moiety. Exemplary arylalkyl groups include benzyl, phenethyl and naphthelenemethyl.
"Cycloalkyl" refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle preferably containing from 3 to 9 carbons per ring, such as cyclopropyl, cyclobutyi, cyclopentyl, cyclohexyl and the like, unless otherwise specified.
The above discussion of alkyl and cycloalkyl substituents also applies to the alkyl portions of other substituents, such as without limitation, alkoxy, alkyl amines, alkyl ketones, arylalkyl, heteroarylalkyl, alkylsulfonyl and alkyl ester substituents and the like.
"Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cylcoheptylmethyl.
"Heterocycloalkyl" refers to a ring containing from at least one heteroatom selected from nitrogen, sulfur, oxygen, preferably from 1 to 3 heteroatoms. Each ring is preferably from 3 to 4 membered, more preferably 4 to 7 membered. Examples of suitable heterocycloalkyl substituents include pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1 ,3-diazapane, 1 ,4-diazapane, 1 ,4- oxazepane, and 1 ,4-oxathiapane.
"Heterocycloalkenyl" refers to a heterocycloalkyl as described above but containing at least one double bond.
"Heterocycloalkylalkyl" refers to a heterocycloalkyl-alkyl group in which the heterocycloalkyl and alkyl moieties are as previously described. Exemplary heterocycloalkylalkyl groups include (2-tetrahydrofuryl)methyl, (2- tetrahydrothiofuranyl)methyl.
"Heteroalkyl" refers to a straight- or branched-chain alkyl group preferably having from 2 to 14 carbons atoms, more preferably 2 to 10 carbon atoms in the chain, wherein one or more of the carbon atoms have been replaced by a heteroatom selected from S, O, and N. Exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl amines, alkyl sulfides, and the like.
"Cycloalkenyl" means an optionally substituted non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and preferably having from 5-10 carbon atoms per ring. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl. The cycloalkenyl group may be substituted by one or more substituent groups.
"Heteroaryl" refers to a monocyclic, or fused polycyclic, aromatic heterocycle (ring structure preferably having a 5 to 10 member aromatic ring containing one or more heteroatoms selected from N, O and S). Typical heteroaryl substituents include furyl, thienyl, pyrrole, pyrazole, triazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, pyrazine, indole, benzimidazole, and the like. When the heteroaryl ring is divalent it has been referred to as "heteroarylene" in this application.
"Heteroarylalkyl" means a heteroaryl-alkyl group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a lower alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.
"Lower alkyl" as a group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having 1 to 6 carbon atoms in the chain, more preferably 1 to 4 carbons such as methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n- butyl, isobutyl or tertiary-butyl.
"Sulfonyl" means a R-S02- group in which the R is selected from aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, arylalkyl and heteroarylalkyl as described herein. G could be further substituted. Examples of sulfonyl include methanesulfonyl, benzenesulfonyl, 4- methylbenzenesulfonyl, naphthalene-2-sulfonyl, and the like.
It is understood that included in the family of compounds of Formula I as well as in Formulae 2 to 2k are isomeric forms including diastereoisomers, enantiomers, tautomers, and geometrical isomers in "E" or "Z" configurational isomer or a mixture of E and Z isomers. It is also understood that some isomeric forms such as diastereomers, enantiomers, and geometrical isomers can be separated by physical and/or chemical methods and by those skilled in the art.
Some of the inventive compounds may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and /or diastereomers. All such single stereoisomers, racemates
and mixtures thereof are intended to be within the scope of the present invention. subject matter described and claimed.
Additionally, Formula I is intended to cover, where applicable, solvated as well as unsolvated forms of the compounds. Thus, each formula includes compounds having the indicated structure, including the hydrated as well as the non-hydrated forms.
In addition to compounds of the Formula I, the HDAC inhibiting agents of the various embodiments include pharmaceutically acceptable salts, prodrugs, and active metabolites of such compounds, and pharmaceutically acceptable salts of such metabolites.
The term "Pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the above-identified compounds, and include pharmaceutically acceptable acid addition salts and base addition salts. Suitable pharmaceutically acceptable acid addition salts of compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, sulfuric, and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, fumaric, maleic, alkyl sulfonic, arylsulfonic. Suitable pharmaceutically acceptable base addition salts of compounds of Formula I include metallic salts made from lithium, sodium, potassium, magnesium, calcium, aluminium, and zinc, and organic salts made from organic bases such as choline, diethanolamine, morpholine. Other examples of organic salts are: ammonium salts, quaternary salts such as tetramethylammonium salt; amino acid addition salts such as salts with glycine and arginine. Additional information on pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Co., Easton, PA 1995. In the case of agents that are solids, it is understood by those skilled in the art that the inventive compounds, agents and salts may exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulae.
"Prodrug" means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of Formula I. For example an ester prodrug of a compound of formula I containing a hydroxyl group may be convertible by hydrolysis in vivo to the parent molecule. Suitable esters of compounds of Formula (I) containing a hydroxyl group, are for example acetates, citrates, lactates, tartrates,
malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-β-hydroxynaphthoates, gestisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates. As another example an ester prodrug of a compound of formula I containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule. (Examples of ester prodrugs are those described by F. J.
Leinweber, Drug Metab. Res., 18:379, 1987).
Possible HDAC inhibiting agents include those having an IC50 value of 5 μM or less.
Administration of compounds within Formula I to humans can be by any of the accepted modes for enteral administration such as oral or rectal, or by parenteral administration such as subcutaneous, intramuscular, intravenous and intradermal routes. Injection can be bolus or via constant or intermittent infusion. The active compound is typically included in a pharmaceutically acceptable carrier or diluent and in an amount sufficient to deliver to the patient a therapeutically effective dose. In various embodiments the inhibitor compound may be selectively toxic or more toxic to rapidly proliferating cells, e.g. cancerous tumors, than to normal cells.
The term "therapeutically effective amount" or "effective amount" is an amount sufficient to effect beneficial or desired clinical results. An effective amount can be administered in one or more administrations. An effective amount is typically sufficient to palliate, ameliorate, stabilize, reverse, slow or delay the progression of the disease state. A therapeutically effective amount can be readily determined by a skilled practitioner by the use of conventional techniques and by observing results obtained in analogous circumstances. In determining the effective amount a number of factors are considered including the species of the patient, its size, age, general health, the specific disease involved, the degree or severity of the disease, the response of the individual patient, the particular compound administered, the mode of administration, the bioavailability of the compound, the dose regimen selected, the use of other medication and other relevant circumstances.
In using the compounds of the invention they can be administered in any form or mode which makes the compound bioavailable. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the condition to be treated, the stage
of the condition to be treated and other relevant circumstances. We refer the reader to
Remingtons Pharmaceutical Sciences, 19th edition, Mack Publishing Co. (1995) for further information.
The compounds of the present invention can be administered alone or in the form of a pharmaceutical composition in combination with a pharmaceutically acceptable carrier, diluent or excipient. The compounds of the invention, while effective themselves, are typically formulated and administered in the form of their pharmaceutically acceptable salts as these forms are typically more stable, more easily crystallised and have increased solubility.
The compounds are, however, typically used in the form of pharmaceutical compositions which are formulated depending on the desired mode of administration. As such in a further embodiment the present invention provides a pharmaceutical composition including a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent or excipient. The compositions are prepared in manners well known in the art.
The invention in other embodiments provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. In such a pack or kit can be found a container having a unit dosage of the agent (s). The kits can include a composition comprising an effective agent either as concentrates (including lyophilized compositions), which can be diluted further prior to use or they can be provided at the concentration of use, where the vials may include one or more dosages. Conveniently, in the kits, single dosages can be provided in sterile vials so that the physician can employ the vials directly, where the vials will have the desired amount and concentration of agent(s). Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
The compounds of the invention may be used or administered in combination with one or more additional drug (s) that include chemotherapeutic drugs or HDAC inhibitor drugs and/or procedures (e.g. surgery, radiotherapy) for the treatment of the disorder/diseases mentioned. The components can be administered in the same formulation or in separate
formulations. If administered in separate formulations the compounds of the invention may be administered sequentially or simultaneously with the other drug (s).
In addition to being able to be administered in combination with one or more additional drugs that include chemotherapeutic drugs or HDAC inhibitor drugs the compounds of the invention may be used in a combination therapy. When this is done the compounds are typically administered in combination with each other. Thus one or more of the compounds of the invention may be administered either simultaneously (as a combined preparation) or sequentially in order to achieve a desired effect. This is especially desirable where the therapeutic profile of each compound is different such that the combined effect of the two drugs provides an improved therapeutic result.
Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminium monostearate and gelatin.
If desired, and fpr more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
The injectable formulations can be sterilized, for example, by filtration through a bacterial- retaining filter, or by incorporating sterilizing agents in the form of sterile solid
compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylceilulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Dosage forms for topical administration of a compound of this invention include powders, patches, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required.
A preferred dosage will be a range from about 0.01 to 300 mg per kilogram of body weight per day. A more preferred dosage will be in the range from 0.1 to 100 mg per kilogram of body weight per day, more preferably from 0.2 to 80 mg per kilogram of body weight per day, even more preferably 0.2 to 50 mg per kilogram of body weight per day. A suitable dose can be administered in multiple sub-doses per day.
As discussed above, the compounds of the embodiments disclosed inhibit histone deacetylases. The enzymatic activity of a histone deacetylase can be measured using
known methodologies [Yoshida M. et al, J. Biol. Chem., 265, 17174 (1990), J. Taunton et al, Science 1996 272: 408]. In certain embodiments, the histone deacetylase inhibitor interacts with and/or reduces the activity of more than one histone deacetylase in the cell, which can either be from the same class of histone deacetylase or different class of histone deacetylase. In some other embodiments, the histone deacetylase inhibitor interacts and/or reduces the activity of predominantly one histone deacetylase, for example HDAC-1 , HDAC-3 or HDAC-8 which belongs to Class I HDAC enzymes [De
Ruijter A.J.M. et al, Biochem. J., 370, 737-749 (2003)]. Certain preferred histone deacetylase inhibitors are those that interact with, and/or reduce the activity of a histone deacetylase which is involved in tumorigenesis, and these compounds may be useful for treating proliferative diseases. Examples of such cell proliferative diseases or conditions include cancer (include any metastases), psoriasis, and smooth muscle cell proliferative disorders such as restenosis. The inventive compounds may be particularly useful for treating tumors such as breast cancer, colon cancer, lung cancer, ovarian cancer, prostate cancer, head and/or neck cancer, or renal, gastric, pancreatic cancer and brain cancer as well as hematologic malignancies such as lymphoma and leukemias. In addition, the inventive compounds may be useful for treating a proliferative disease that is refractory to the treatment with other chemotherapeutics; and for treating hyperproliferative condition such as leukemias, psoriasis and restenosis. In other embodiments, compounds in this invention can be used to treat pre-cancer conditions including myeloid dysplasia, endometrial dysplasia and cervical dysplasia.
Additionally compounds of the various embodiments disclosed herein may be useful for treating neurodegenerative diseases, and inflammatory diseases and/or immune system disorders.
The disorder is preferably selected from the group consisting of cancer, inflammatory diseases and/or immune system disorders (e.g. rheumatoid arthritis, systemic lupus erythematosus), angiofibroma, cardiovascular diseases, fibrotic diseases, diabetes, autoimmune diseases, chronic and acute neurodegenerative disease like Huntington's disease, Parkinson's disease, disruptions of nerval tissue and infectious diseases like fungal, bacterial and viral infections. In another embodiment the disorder is a proliferative disorder.
The histone deacetylase inhibitors of the invention have significant antiproliferative effects and promotes differentiation, for example, cell cycle arrest in the G1 or G2 phase, and induce apoptosis
SYNTHESIS OF DEACETYLASE INHIBITORS
The compounds of this invention may be prepared using the reaction routes and synthesis schemes as described below, employing the techniques available in the art using starting materials that are readily available. The preparation of particular embodiments is described in detail in the following examples, but the artisan will recognize that the chemical reactions described may be readily adapted to prepare a number of other agents of the various embodiments. For example, the synthesis of non- exemplified compounds may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by changing to other suitable reagents known in the art, or by making routine modifications of reaction conditions. A list of suitable protecting groups in organic synthesis can be found in T.W. Greene and P. G. M. Wuts' Protective Groups in Organic Synthesis, 3rd Edtion, Wiley- InterScience, 1999. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the various embodiments.
Reagents useful for synthesizing compounds may be obtained or prepared according to techniques known in the art.
In the examples described below, unless otherwise indicated, all temperatures in the following description are in degrees Celsius and all parts and percentages are by weight, unless indicated otherwise.
Various starting materials and other reagents were purchased from commercial suppliers, such as Aldrich Chemical Company or Lancaster Synthesis Ltd., and used without further purification, unless otherwise indicated. Tetrahydrofuran (THF) and N, N- dimethyiformamide (DMF) were purchased from Aldrich in SureSeal bottles and used as received. All solvents were purified by using standard methods in the art, unless otherwise indicated.
The reactions set forth below were performed under a positive pressure of nitrogen, argon or with a drying tube, at ambient temperature (unless otherwise stated), in anhydrous solvents, and the reaction flasks are fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven-dried and/or heat-dried. Analytical thin-layer chromatography was performed on glass-backed silica gel 60 F 254 plates (E Merck (0.25 mm)) and eluted with the appropriate solvent ratios
(v/v). The reactions were assayed by TLC and terminated as judged by the consumption of starting material.
The TLC plates were visualized by UV absorption or with a p-anisaldehyde spray reagent or a phosphomolybdic acid reagent (Aldrich Chemical, 20wt% in ethanol) which was activated with heat, or by staining in iodine chamber. Work-ups were typically done by doubling the reaction volume with the reaction solvent or extraction solvent and then washing with the indicated aqueous solutions using 25% by volume of the extraction volume (unless otherwise indicated). Product solutions were dried over anhydrous sodium sulfate prior to filtration, and evaporation of the solvents was under reduced pressure on a rotary evaporator and noted as solvents removed in vacuo. Flash column chromatography [Still et al, J. Org. Chem., 43, 2923 (1978)] was conducted using E Merck-grade flash silica gel (47-61 mm) and a silica gekcrude material ratio of about 20:1 to 50:1 , unless otherwise stated. Hydrogenolysis was done at the pressure indicated or at ambient pressure.
Reverse-phase preparative HPLC (RPHPLC) was operated by using a C-|8 column (5 urn, 21.2x150 mm) at flow rate of 20 mL/min and a linear gradient from 5 to 95% of CH3CN + 0.1 % TFA (trifluoroacetic acid) over 18 min. High-throughput mass-dependent (reverse- phase HPLC) purification system (HTP) was operated by using a Cι8 column (5 urn, 19x50 mm) at flow rate of 30 mL/min and a linear gradient from 5 to 95% of CH3CN + 0.05% TFA over 9 min. The fractions containing the desire product were lyophilized, or evaporated to dryness under vacuum to provide the dry compound, or evaporated to remove the volatile organic solvent then extracted with organic solvents (ethyl acetate or dichloromethane are commonly used, if necessary, the pH of the aqueous solution could also be adjusted in order to get free base, acid or the neutral compound).
1H NMR spectra were recorded on a Bruker AV400 instrument operating at 400 MHz, and 13C-NMR spectra were recorded operating at 100 MHz. NMR spectra are obtained as CDCI3 solutions (reported in ppm), using chloroform as the reference standard (7.26 ppm and 77.00 ppm), CD3OD (3.3 and 49.3 ppm), DMSO-d6 (2.50 and 39.5 ppm), or an internal tetramethylsilane standard (0.00 ppm) when appropriate. Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, m = multiplet, b or br = broadened, dd = doublet of doublets, dt = doublet of triplets, tt = triplet of triplets. Coupling constants, when given, are reported in Hertz.
Mass spectra were obtained using LC-MS either in ESI or APC1. All melting points are uncorrected.
All final products had greater than 90% purity (by HPLC at wavelengths of 220 nm and
254 nm).
The following examples are intended to illustrate the embodiments disclosed and are not to be construed as being limitations thereto. Additional compounds, other than those described below, may be prepared using the following described reaction scheme or appropriate variations or modifications thereof.
SYNTHESIS
Scheme 1 illustrates the procedure used for preparing compounds of Formula (I), wherein R1 = R3 =H, M = S(0)2 or C=0.
Formula (I)
In Scheme 1, R is a linking moiety or equal to -B-A-Z-L- as defined for Formula (2), R" is R less one CH2, R11 is a C-i -C6 alkyl or benzyl, R21 is R2 less one CH2 and R2 is defined as for Formula (I).
Scheme 1.
NH2OH HCI, NaOMe/MeOH
The intermediate (2) in Scheme 1 could be prepared by (i) alkylation of amine (2a) with R2X (3a, X is halo, e.g., I", Br", CI" or a good leaving group), or (ii) reductive amination of amine (2a) with aldehyde (3b), or (iii) reductive amination of aldehyde (2b) with amine R2NH2 (3c).
Synthesis of sulfonylurea linked hydroxamic acid (8). Scheme 1. Amine (2) or Amine (2a, for R2 = H) is reacted with sulfonylisocyanate (4) to give sulfonylurea (6) which is subsequently converted to hydroxamic acid (8) by amination of the ester with hydroxylamine.
Sulfonylurea linked hydroxamic acid (8) could also be synthesized by a synthetic route as described in Scheme 2. R12 is a protecting group; examples are benzyl, 2,4-dimethoxy- benzyl, tetrahydro-pyran-2-yl and ferf-Butyl-dimethyl-silyl.
Scheme 2.
chloride
The ester (6) is hydrolyzed to the acid (6a). The acid is subsequently converted to the hydroxamic acid (8) by either Method A or Method B.
Method A. (i) the acid is converted to acid chloride by treating it with CICOCOCI, or SOCI2, or other reagents under neutral conditions (such as Ph3P with CBr4, or 2,4,6- Trichloro-[1 ,3,5]triazine); or (ii) the acid is converted to an active ester by reacting it with isobutyl chloroformate; (iii) the acid chloride or active ester is reacted with hydroxylamine or the O-protected hydroxylamine [e.g., O-benzylhydroxylamine, 0-(2,4-dimethoxy- benzyl)-hydroxylamine, 0,Λ/-bis-(2,4-dimethoxy-benzyl)-hydroxylamine, 0-(tetrahydro- pyran-2-yl)-hydroxylamine, 0-(ferf-butyl-dimethyl-silyl)-hydroxylamine] to give the hydroxamic acid or the O-protected hydroxamic acid in which the protecting group is subsequently removed by methods known in the literature such as hydrogenolysis to remove the benzyl group or acidic cleavage to cleave the acid labile protecting groups.
Method B. Coupling the acid with hydroxylamine or O-protected hydroxylamine (R12ONH2) with a coupling reagent, then followed by removing the protecting group by methods known in the literature.
Synthesis of acylurea linked hydroxamic acid (9).
Acylurea linked hydroxamic acid (9) could be synthesized by methods analogous to those used for synthesis of sulfonylurea linked hydroxamic acid (8).
Scheme 1. Amine (2) or Amine (2a, for R2 = H) is reacted with acylisocyanate (5) to give acylurea (7) which is subsequently converted to hydroxamic acid (9) by amination of the ester with hydroxylamine.
Acylurea linked hydroxamic acid (9) could also be synthesized by method described in Scheme 3.
chloride
Furthermore, sulfonylurea linked hydroxamic acid (8) and acylurea linked hydroxamic acid (9) could also be synthesized by a synthetic route described in Scheme 4. O- protected hydroxamate starting material amine (2c) or aldehyde (2d) are used to make the O-protected hydroxamate intermediate (2P) which is subsequently converted to the corresponding sulfonylurea (8a) and acylurea (9a). After removal the protecting group, sulfonylurea (8) and acylurea (9) are obtained.
Scheme 4
deprotection of R 12
Scheme 5 illustrates the procedure used for preparing compounds of Formula (I), wherein R1 = H, M = S(0)2. R13 is selected from R11 or R12.
Due to acidity of the sulfonylurea (6), the R3 group could be introduced by alkylation of 6 with R3X (X = l", Br" or CI") or by reacting with R3OH under Mitsunobu reaction condition. The product (6b) could be converted to the hydroxamic acid (8b) by using the similar condition as described for (8) in Scheme 1 , 2 or 4.
Scheme 5.
The following preparation and examples are given to enable those skilled in the art to more clearly understand and to practice the subject matter hereof. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
INTERMEDIATE 1
Preparation of 6-[3-(Benzenesulfonyl)ureido]-hexanoic acid methyl ester
To a mixture of 6-Amino-hexanoic acid methyl ester hydrochloride (0. 10 g, 0.5 mmol), triethylamine (0.12 g, 1.2 mmol, 0.17 mL) and DMAP (0.06 g, 0.05 mmol) in the presence of CH2CI2 (5 mL) was added phenyl sulfonyl isocyanate (0.12 g, 0.6 mmol). The reaction mixture was stirred at room temperature for 4 days. The reaction mixture was diluted with water (10 mL) and extracted with CH2CI2 (3 x 10 mL). The combined organic extracts were dried over MgS0 , filtered and the solvent was removed in vacuo. The crude residue was chromatographed (silica) with 1-10% MeOH in CH2CI2 to give 6-[3- (Benzenesulfonyl)ureido]-hexanoic acid methyl ester (0.1 g, 0.3 mmol, 58%) as a colorless oil which solidified on standing.
1H NMR (CDCI3) .57.95-7.89 (2H, m), 7.66-7.53 (3H, m), 3.67 (3H, s), 3.22 (2H, q, J = 6.9 Hz), 2.29 (2H, t, J = 7.4 Hz), 1.62 (2 H, m, J = 7.4 Hz), 1.50 (2 H, m, J - 7.4 Hz) and 1.31- 1.27 (2H, m).
INTERMEDIATE 2
Preparation of 4-[3-(toluene-4-sulfonyl)ureidomethyl-benzoic acid methyl ester
Proceeding as described in Intermediate 1 above but using appropriate starting materials. Yield: 67%. Light yellow solid; LC-MS (ESI, positive mode) m/z 363 ([M+H]+). 1H NMR (DMSO-de) δ 10.78 (bs, 1H), 7.85 (d, 2H, J = 8.2 Hz), 7.78 (d, 2H, J = 8.2 Hz), 7.40 (d, 2H, J = 8.0 Hz), 7.23 (d, 2H, J = 8.1 Hz), 4.22 (d, 2H, J = 5.9 Hz), 3.84 (s, 3H), 2.40 (s, 3H).
INTERMEDIATE 3
Preparation of 6-(3-Benzoyl-ureido)-hexanoic acid methyl ester
To a mixture of 6-Amino-hexanoic acid methyl ester hydrochloride (0.05 g, 0.27 mmol), triethylamine (0.069 g, 0.6 mmol, 0.096 mL) and DMAP (0.03 g, 0.027 mmol) in the presence of CH2CI2 (2 mL) was added benzoyl isocyanate (0.048 g, 0.3 mmol). The reaction mixture was stirred at room temperature for 4 days. The reaction mixture was diluted with water (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried over MgSO4, filtered and the solvent was removed in vacuo. The crude residue was chromatographed with 1 - 10% MeOH in CH2Cl2 to give 6-(3-Benzoyl- ureido)-hexanoic acid methyl ester (0.087 g, 0.2 mmol, quantitative yield) as a colorless oil which solidified on standing. 1H NMR (CDCI3) δ 8.66 (br s, 2H), 7.89-7.87 (m, 2H), 7.62-7.48 (m, 3H), 3.67 (s, 3H), 3.39 (q, 2H, J = 7.0 Hz), 2.33 (t, 2H, J = 7.4 Hz), 1.70-1.60 (m, 4H) and 1.45-1.40 (m, 2 H).
Large scale To a mixture of 6-Amino-hexanoic acid methyl ester hydrochloride (0.363 g, 2.00 mmol), triethylamine (0.558 mL, 4.00 mmol) and DMAP (0.024 g, 0.20 mmol) in the presence of CH2CI2 (10 mL) was added benzoyl isocyanate (0.276 mL, 2.20 mmol). The reaction mixture was stirred at room temperature for 6 h. The reaction mixture was added brine and extracted with 10% methanol in dichloromethane. The extract was dried and concentrated and purified by reverse-phase preparative HPLC to give 6-(3-Benzoyl- ureido)-hexanoic acid methyl ester (0.459 g, 79%).
INTERMEDIATE 4
Preparation of 6-(3-Benzoyl-ureido)-hexanoic acid
To a solution of 6-(3-Benzoyl-ureido)-hexanoic acid methyl ester (0.043 g, 0.14 mmol) in dry MeOH (2 mL) was added NH2OH.HCI (0.015 g, 0.2 mmol) followed by NaOMe (0.08 mL, 5.38M, 0.4 mmol). The reaction mixture was stirred at room temperature under nitrogen for 2 hours, and then was diluted with acetonitrile and the solvent was removed in vacuo. The crude residue was purified by mass induced HTP. No hydroxamic acid was obtained but the corresponding 6-(3-Benzoyl-ureido)-hexanoic acid was obtained as a white fluffy solid.
1H NMR (DMSO-cf6) δ 10.6 (1 H, s), 8.60 (1 H, bs), 7.92-7.90 (2H, m), 7.58-7.55 (1 H, m), 7.47-7.43 (2H, m), 3.20-3.15 (2 H, m), 2.16 (2 H, t, J = 7.3 Hz), 1.52-1.42 (4 H, m) and 1.30-1.24 (2H, m).
INTERMEDIATE 5
Preparation of 4-(3-Benzoyl-ureidomethyl)-benzoic acid methyl ester
To a solution of 4-Aminomethyl-benzoic acid methyl ester hydrochloride (0.425 g, 2.1 1 mmol), triethylamine (0.60 mL, 0.4.31 mmol) and DMAP (0.020 g, 0.16 mmol) in CH2CI2 (10 mL) was added benzoyl isocyanate (Sigma-Aldrich, 90% pure, 0.413 g, 0.2.53 mmol). The reaction mixture was stirred at room temperature for 2.5 h and was evaporated to dryness. The white residue was added water, filtered and the solid was washed with water (x4) and dried. 4-(3-Benzoyl-ureidomethyl)-benzoic acid methyl ester was obtained as white solid (0.586 g, 89%). HPLC purity at 254nm: 99.7%; LC-MS (ESI, positive mode) m/z 313 ([M+H]+);
1H NMR (DMSO-cfe) 59.12 (1H, t, J = 5.4 Hz), 8.68 (1H, s), 8.04 (2H, dt, J = 8.4, 1.8 Hz), 7.89 (2H, dt, J = 8.2, 1.6 Hz), 7.62 (1 H, tt, J = 7.4, 1.8 Hz), 7.50 (2H, t, J = 8.0 Hz), 7.44 (2H, d, J = 8.4 Hz), 4.64 (2H, d, J = 6.0 Hz), 3.93 (3H, s).
INTERMEDIATE 6
Preparation of 3-(4-{3-Benzoyl-1-[2-(1 H-indol-3-yl)-ethyl]-ureidomethyl}-phenyl)-acrylic acid methyl ester
To a solution of 3-(4-{[2-(1H-lndol-3-yl)-ethylamino]-methyl}-phenyl)-acrylic acid methyl ester (0.100 g, 0.300 mmol), triethylamine (0.063 mL, 0.45 mmol) and DMAP (0.004 g, 0.03 mmol) in CH2CI2 (3 mL) was added benzoyl isocyanate (90% pure, 0.045 mL, 0.36 mmol). The reaction mixture was stirred at room temperature for 22 h and was extracted with ethyl acetate. The extract was dried (MgS04) and concentrated. The residue was purified by HTP. 3-(4-{3-Benzoyl-1-[2-(1H-indol-3-yl)-ethyl]-ureidomethyl}-phenyl)-acrylic acid methyl ester was obtained as pale yellow solid (0.072 g, 50%). LC-MS (ESI, positive mode) m/z 482 ([M+H]+);
1H NMR (DMSO-c6) δ 10.82 (1 H, s), 10.25 (1 H, bs), 7.83 (2H, d, J = 8.1 Hz, PhH), 7.74 (1 H, d, J = 16.0 Hz), 7.61 (1 H,t, J = 7.3 Hz), 7.50 (2H, t, J = 7.5 Hz), 7.45 (2H, br d like), 7.38-7.35 (1 H, br m), 7.31 (1 H, d, J = 8.1 Hz), 7.10 (1 H, bs like), 7.02 (1 H, t, J = 7.2 Hz), 6.90-6.70 (1 H, very broad s), 6.66 (1 H, d, J = 16.0 Hz), 4.69 (2H, s), 3.73 (3H, s), 3.52 (2H, t, J = 7.7 Hz), 2.97 (2H, t, J = 7.5 Hz); 13C NMR (DMSO-cfe) δ 166.7, 166.4, 154.1(br), 144.2, 140.3, 136.1 , 133.2, 133.0, 132.2, 128.5, 128.4, 127.9, 127.8, 126.9, 122.9, 120.9, 118.2, 118.0, 117.6, 111.4, 110.7, 51.4, 49.5*, 49.3*, 24.4* (*: very broad and weak peaks, identified by 1H-13C HSQC).
INTERMEDIATE 7 Preparation of 8-Amino-octanoic acid methyl ester hydrochloride
To a 100 mL round-bottomed flask, 8-Amino-octanoic acid (2.116 g, 13.29 mmol) and methanol (50 mL) were added. The mixture was stirred and cooled in a dry-ice /acetone bath under nitrogen. SOCI2 (1.5 mL, 20.7 mmol) was added via syringe, then the dry-ice bath was removed and the mixture was stirred at room temperature for 2.5 h. The solution was evaporated and the residue was added diethyl ether. The solid was filtered and dried under vacuum. 8-Amino-octanoic acid methyl ester hydrochloride was obtained as white solid (2.772 g, 99.8%). LC-MS (ESI, positive mode) m/z 376 ([M-CI]+). 1H NMR (DMSO-cfe) δ 8.24 (3H, s, NH3 +), 3.67 (3H, s, OCH3), 3.00 (2H, m), 2.30 (2H, t, J = 7.5
Hz), 1.78 (2H, penta, J = 7.3 Hz), 1.61 (2H, penta, J = 7.2 Hz), 1.41 (2H, m), 1.39-1.32
(4H, m); 13C NMR (DMSO-cfe) δ 174.1 , 51.4, 39.9, 33.9, 28.6, 27.5, 26.3, 24.7.
INTERMEDIATE 8 Preparation of 8-[3-(4-methylbenzenesulfonyl)ureido]octanoic acid methyl ester
To a mixture of 8-Amino-octanoic acid methyl ester hydrochloride (0.601 g, 2.865 mmol), triethylamine (1.0 mL, 7.18 mmol) and DMAP (0.0313 g, 0.256 mmol) in CH2CI2 (20 mL) was added p-toluene sulfonylisocyanate (0.63 mL, 4.12 mmol). The reaction mixture was stirred at room temperature for 19.5 h. The reaction mixture was diluted with 1 N HCl and extracted with CH2CI2 (100 mL x1 , 50 mL x 2). The combined organic extracts were dried over MgS04, filtered and the solvent was removed in vacuo. The crude residue was chromatographed (silica) with 2-10% MeOH in CH2CI2 to give 8-[3-(4- methylbenzenesulfonyl)ureido]octanoic acid methyl ester (0.730 g, 69%) as a white solid. LC-MS (ESI, positive mode) m/z 371 ([M+Hf).
1H NMR (CDCI3) δ 8.80 (1 H, bs), 7.78 (2H, d, J = 8.3 Hz), 7.31 (2H, d, J = 8.1 Hz), 6.52 (1 H, t, J = 5.2 Hz), 3.67 (3H, s, OCH3), 3.19 (2H, q, J = 6.6 Hz), 2.44 (3H, s, Ar-CH3), 2.30 (2H, t, J = 7.5 Hz), 1.63-.1.58 (2H, m), 1.48-1.42 (2H, m), 1.31-1.22 (6H, m); 13C NMR (DMSO-cfe) δ 174.3, 151.9, 144.6, 136.8, 129.6, 127.0, 51.5, 40.2,34.0, 29.4, 28.9, 28.8, 26.6, 24.8, 21.6
INTERMEDIATE 9
Preparation of 8-[3-methyl-3-(4-methylbenzenesulfonyl)ureido]octanoic acid methyl ester
To a mixture of 8-[3-(4-methylbenzenesulfonyl)ureido]octanoic acid methyl ester (0.161 g, 0.435 mmol), K2CO3 (0.572 g, 4.14 mmol) and acetonitrile (4 mL) was added Mel (0.270 mL, 4.35 mmol). The reaction mixture was stirred at room temperature under nitrogen for 17 h. The reaction mixture was diluted with 1 N HCl and extracted with ethyl acetate (Na2S203 was added to the aqueous layer to reduce the l2). The combined organic extracts were dried over MgS0 , filtered and the solvent was removed in vacuo. 1H NMR of the crude residue (0.166 g) showed that the molar ratio of 8-[3-(4- methylbenzenesulfonyl)ureido]octanoic acid methyl ester to degraded product 4,N,N- Trimethyl-benzenesulfonamide was 3:1.
LC-MS (ESI, positive mode) m/z 385 ([M+H]+).
1H NMR (CDCI3) δ 7.70 (2H, d, J = 8.3 Hz), 7.34 (2H, d, J = 8.5 Hz), 3.66 (3H, s, OCH3),
3.24 (2H, q, J = 5.7 Hz), 3.12 (3H, s, NCH3), 2.43 (3H, s, Ar-CH3), 2.31 (2H, t, J = 7.5 Hz),
1.65-1.60 (2H, m), 1.55-1.51 (2H, m), 1.33-1.26 (6H, m).
INTERMEDIATE 10
Preparation of 8-(3-Benzoyl-ureido)-octanoic acid methyl ester
To a solution of 8-Amino-octanoic acid methyl ester hydrochloride (0.423 g, 2.02 mmol), triethylamine (0.56 mL, 4.02 mmol) and DMAP (0.022 g, 0.18 mmol) in CH2CI2 (10 mL) was added benzoyl isocyanate (90% pure, 0.370 g, 2.26 mmol). The reaction mixture was stirred at room temperature for 2 h and was added silica gel and filtered through silica and washed with ethyl acetate. The filtrate was evaporated to dryness to give colorless oil (0.691 g, 106%), which was solidified at room temperature under vacuum. LC-MS (ESI, positive mode) m/z 321 ([M+H]+).
1H NMR (CDCI3) δ 10.52 (1H, s), 8.92 (1H, t, J = 5.6 Hz), 8.09 (2H, d, J = 7.2 Hz), 7.56 (1 H, t like), 7.45 (2H, t, J = 7.7 Hz), 3.64 (3H, s, OCH3), 3.35 (2H, q, J = 6.0 Hz), 2.29 (2H, t, J = 7.5 Hz), 1.63-1.56 (4H, m), 1.39-1.32 (6H, m); 13C NMR (CDCI3) δ 173.6, 168.1 , 154.6, 132.3, 132.0, 128.0, 127.7, 50.9, 39.3, 33.5, 29.0, 28.5, 28.4, 26.3, 24.3.
INTERMEDIATE 11
Preparation of 7-Amino-heptanoic acid methyl ester hydrochloride
Proceeding as described in Intermediate 7 above but using appropriate starting materials (7-Amino-heptanoic acid), the titled compound was prepared as white solid (0.490 g, 100%).
INTERMEDIATE D
Preparation of 7-(3-Benzoyl-ureido)-heptanoic acid methyl ester
Proceeding as described in Intermediate 10 above but using appropriate starting materials (7-Amino-heptanoic acid methyl ester hydrochloride), the crude titled compound
was obtained as oil which was solidified under vacuum and could be used for next step of reaction without further purification. LC-MS (ESI, positive mode) m/z 307 ([M+H]+).
1H NMR (CDCI3) δ 10.30 (1 H, s), 8.90 (1 H, t, J = 5.4 Hz), 8.05 (2H, d, J = 7.5 Hz), 7.57
(1H, t, J = 7.4 Hz), 7.47 (2H, d, J = 7.6 Hz), 3.65 (3H, s, OCH3), 3.35 (2H, q, J = 6.6 Hz),
2.30 (2H, t, J = 7.5 Hz), 1.68-1.56 (4H, m), 1.45-1.35 (4H, m); 13C NMR (CDCI3) δ 173.6,
168.1 , 154.5, 132.4, 132.0, 128.1 , 127.6, 51.0, 39.3, 33.5, 28.9, 28.3, 26.1 , 24.3.
INTERMEDIATE 13
Preparation of a salt of 6-(3-Phenyl-propylamino)-hexanoic acid methyl ester.
To a 100 mL flask, 6-Amino-hexanoic acid methyl ester hydrochloride (0.555 g, 3.06 mmol), NaBH(OAc)3 (0.782 g, 3, .69 mmol), 3-Phenyl-propionaldehyde (0.47 mL, 3.21 mmol), dichloromethane (10 mL) and triethylamine (0.43 mL, 3.09 mmol) were added. The above mixture was sonicated for 1 min then stirred at room temperature overnight. The reaction mixture was added aqueous Na2C03 and extracted with dichloromethane (x 2). The extract was dried and purified by reverse-phase preparative HPLC to give the titled compound as an oil (0.202 g, 30% calculated as TFA salt). LC-MS (ESI, positive mode) m/z 264 ([M+H]+). 1H NMR (CDCI3) δ 11.82 (1 H, s), 8.62 (2H, s, -NH2 +-), 7.26 (2H, t, J = 7.3 Hz), 7.18 (1 H, t, J = 7.3 Hz), 7.11 (2H, d, J = 7.0 Hz), 3.64 (3H, s, OCH3), 2.94 and 2.92 (each of 2H, overlapped, identified by COSY), 2.63 (2H, t, J = 7.5 Hz), 2.26 (2H, t, J = 7.3 Hz), 2.00 (2H, penta, J = 7.6 Hz), 1.65 (2H, penta, J = 7.5 Hz), 1.55 (2H, penta, J = 7.7 Hz), 1.33 (2H, m); 13C NMR (CDCI3) δ 173.6, 139.2, 128.2, 127.7, 126.0, 51.1 , 47.3, 47.1 , 32.9, 32.0, 26.9, 25.2, 25.0, 23.4.
INTERMEDIATE 14
Preparation of 6-[3-Benzoyl-1-(3-phenyl-propyl)-ureido]-hexanoic acid methyl ester
Proceeding as described in Intermediate 10 above but using appropriate starting materials (a salt of 6-(3-Phenyl-propylamino)-hexanoic acid methyl ester with 2 TFA), the crude titled compound was purified by reverse-phase preparative HPLC and flash
chromatography (silica, 5% Methanol in dichloromethane) to give the pure compound as gum (0.063 g, 43%). LC-MS (ESI, positive mode) m/z 411 ([M+H]+).
1H NMR (CDCI3) δ 8.20 (1H, bs), 7.78 (2H, bs), 7.54 (1 H, t, J = 7.4 Hz), 7.43 (2H, t, J =
7.6 Hz), 7.24 (2H, d, J = 7.2 Hz), 7.18-7.13 (3H, m), 3.65 (3H, s), 3.36 [4H, m or 3.38 (2H, m) and 3.36 (2H, m)], 2.64 (2H, t, J = 7.4 Hz), 2.30 (2H, t, J = 7.4 Hz), 1.96 (2H, penta, J
= 7.4 Hz), 1.66-1.56 (4H, m), 1.31 (2H, m); 13C NMR (CDCI3) δ 173.5, 165.8 (br), 153.4
(br), 140.7 (br), 132.7, 132.1 , 128.1 , 128.0, 127.9, 127.3, 125.6, 51.0, 46.9 (br, 2 x CH2N),
33.4, 32.4, 28.9, 27.1 (br), 25.8, 24.1.
INTERMEDIATE 15
Preparation of 4-{[2-(1 H-lndol-3-yl)-ethylamino]-methyl}-benzoic acid methyl ester.
To a 250 mL flask, tryptamine hydrochloride (0.582 g, 2.96 mmol), 4-Formyl-benzoic acid methyl ester (0.488 g, 2.97 mmol), dichloromethane (25 mL), methanol (10 mL) and triethylamine (0.50 mL, 3.59 mmol) were added and the mixture was stirred at room temperature for 4 h, then evaporated to dryness. The residue was dissolved in dichloromethane (25 mL), added NaBH(OAc)3 (0.805 g, 3.80 mmol) and stirred at room temperature overnight. The mixture was added aqueous NaHCO3, extracted with dichloromethane (x 3) and dried (MgSO ). The residue was purified by reverse-phase preparative HPLC and the desire fractions were combined and evaporated to remove the organic solvent. The resultant solution was neutralized with aqueous NaHC03 and extracted with dichloromethane (x 3), dried (MgS04) to give the titled compound as a gum (0.437 g, 48%). LC-MS (ESI, positive mode) m/z 309 ([M+H]+). 1H NMR (CDCI3) δ 8.24 (1H, s), 7.95 (2H, d, J = 8.3 Hz), 7.59 (1 H, d, J = 7.9 Hz), 7.32 (3H, overlapped by CHx2 and CH, d, J = 8.2 Hz), 7.18 (1H, td, J = 7.5, 1.1 Hz), 7.10 (1H, td, J = 7.5, 1.0 Hz), 6.98 (1H, d, J = 2.3 Hz), 3.89 (3H, s), 3.84 (2H, s), 2.99-2.95 (4H, m); 13C NMR (CDCI3) δ 166.7, 145.4, 136.0, 129.2, 128.3, 127.5, 127.0, 121.6 (two CH overlapped), 118.8, 118.4, 113.3, 110.8, 53.0 (CH2N), 51.6 (OCH3), 48.9, 25.3.
INTERMEDIATE 16
Preparation of 4-{[(Pyridin-3-ylmethyl)-amino]-methyl}-benzoic acid methyl ester.
Proceeding as described in INTERMEDIATE 15 above but using appropriate starting materials 3-(aminomethyl)pyridine and 1 equivalent of acetic acid (neither triethylamine nor methanol was added). After workup, the crude extract was used for further step of reaction without further purification.
LC-MS (ESI, positive mode) m/z 257 ([M+H]+).
INTERMEDIATE 17
Preparation of 4-(Benzylamino-methyl)-benzoic acid methyl ester.
Proceeding as described in INTERMEDIATE 16 above but using appropriate starting material benzylamine. After workup, the crude extract was used for further step of reaction without further purification. LC-MS (ESI, positive mode) m/z 256 ([M+H]+).
INTERMEDIATE 18
Preparation of 4-[(3-Hydroxy-propylamino)-methyl]-benzoic acid methyl ester.
Proceeding as described in INTERMEDIATE 16 above but using appropriate starting material 3-Amino-propan-1-ol. After workup, the crude extract was used for further step of reaction without further purification.
LC-MS (ESI, positive mode) m/z 224 ([M+Hf).
INTERMEDIATE 19
Preparation of 4-[(2-Pyridin-2-yl-ethylamino)-methyl]-benzoic acid methyl ester.
Proceeding as described in INTERMEDIATE 16 above but using appropriate starting material 2-Pyridin-2-yl-ethylamine. After workup, the crude extract was used for further step of reaction without further purification. LC-MS (ESI, positive mode) m/z 271 ([M+H]+).
INTERMEDIATE 20
Preparation of 4-(Phenethylamino-methyl)-benzoic acid methyl ester.
Proceeding as described in INTERMEDIATE 16 above but using appropriate starting materials phenethylamine. After workup, the crude extract was used for further step of reaction without further purification. LC-MS (ESI, positive mode) m/z 270 ([M+H]+).
INTERMEDIATE 21 Preparation of 3-(4-{[(Pyridin-3-y!methyl)-aminoj-methyl}-phenyl)-acrylic acid methyl ester.
Proceeding as described in INTERMEDIATE 16 above but using appropriate starting materials 3-(4-Formyl-phenyl)-acrylic acid methyl ester, 3-(aminomethyl)pyridine. After workup, the crude extract was used for further step of reaction without further purification. LC-MS (ESI, positive mode) m/z 283 ([M+H]+).
INTERMEDIATE 22
Preparation of 3-{4-[(2-Pyridin-2-yl-ethylamino)-methyl]-phenyl}-acrylic acid methyl ester.
Proceeding as described in INTERMEDIATE 16 above but using appropriate starting materials 3-(4-Formyl-phenyl)-acrylic acid methyl ester and 2-Pyridin-2-yl-ethylamine. After workup, the crude extract was used for further step of reaction without further purification. LC-MS (ESI, positive mode) m/z 297 ([M+H]+).
INTERMEDIATE 23
Preparation of 3-{4-[(3-Hydroxy-propylamino)-methyl]-phenyl}-acrylic acid methyl ester.
Proceeding as described in INTERMEDIATE 16 above but using appropriate starting materials. 3-(4-Formyl-phenyl)-acrylic acid methyl ester and 3-Amino-propan-1-ol. After workup, the crude extract was used for further step of reaction without further purification.
LC-MS (ESI, positive mode) m/z 250 ([M+H]+).
INTERMEDIATE 24
Preparation of 3-{4-[3-Benzoyl-1-(3-hydroxy-propyl)-ureidomethyl]-phenyl}-acrylic acid methyl ester.
Proceeding as described in INTERMEDIATE 6 above but using appropriate starting materials. LC-MS (ESI, positive mode) m/z 397 ([M+H]+).
INTERMEDIATE 25
Preparation of 3-{4-[3-Benzoyl-1-(2-pyridin-2-yi-ethyl)-ureidomethyl]-phenyl}-acrylic acid methyl ester.
Proceeding as described in INTERMEDIATE 6 above but using appropriate starting materials. LC-MS (ESI, positive mode) m/z 444 ([M+H]+).
INTERMEDIATE 26
Preparation of 3-[4-(3-Benzoyl-1-pyridin-3-ylmethyl-ureidomethyl)-phenyl]-acrylic acid methyl ester.
Proceeding as described in INTERMEDIATE 6 above but using appropriate starting materials. Yield: 67%. LC-MS (ESI, positive mode) m/z 430 ([M+HJ+).
1H NMR (CDCI3) δ 9.68 (1 H, bs), 8.49 (1 H,d, J = 3.3 Hz), 8.44 (1 H, s), 7.86 (2H, d, J = 7.5
Hz), 7.69 (1 H, m), 7.66 (1H, d, J = 16.0 Hz), 7.50 (1 H, J = 7.3 Hz), 7.47 (2H, d, J = 8.2
Hz), 7.38 (2H, t, J = 7.7 Hz), 7.27-7.23 (3H, m), 6.42 (1H, d, J = 16.0 Hz), 4.57 (2H, s),
4.56 (2H, s), 3.79 (3H, s); 13C NMR (CDCI3) 5 166.8, 166.6, 155.3, 148.7, 148.5, 143.6,
137.8, 133.5, 132.3, 132.2, 123.3, 117.6, 51.2, 50.5, 47.6.
INTERMEDIATE 27
Preparation of 4-{3-Benzoyl-1-[2-(1 H-indol-3-yI)-ethyl]-ureidomethyl}-benzoic acid methyl ester.
Proceeding as described in INTERMEDIATE 6 above but using appropriate starting materials. Yield 65%. LC-MS (ESI, positive mode) m/z 456 ([M+H]+).
1H NMR (CDCI3) 5 9.08 (1 H, bs), 7.96 (2H, d, J = 8.2 Hz), 7.45-7.05 [10H, including 7.43 (2H, d, J = 7.6 Hz), 7.17 (2H, bs), 7.11 (1 H, t, J =7.6 Hz)], 6.98 (1H, t, J = 7.4 Hz), 6.91 (1 H, bs), 4.65 (2H, s), 3.87 (3H, s), 3.57 (2H, br t like, J = 5.8 Hz), 2.98 (2H, br t, J = 5.4 Hz); 13C NMR (CDCI3) δ 169.3, 166.0, 153.9, 141.7, 136.1 , 132.3, 131.9, 129.6, 129.0, 128.0, 127.3, 127.0, 126.2, 123.0, 121.7, 1191.1 , 117.6, 111.4, 110.7, 51.7, 49.3 (identified by HSQC), 48.2, 23.2.
INTERMEDIATE 28
Preparation of 4-[3-Benzoyl-1-(3-hydroxy-propyl)-ureidomethyl]-benzoic acid methyl ester.
Proceeding as described in INTERMEDIATE 6 above but using appropriate starting materials. LC-MS (ESI, positive mode) m/z 371 ([M+H]+).
INTERMEDIATE 29
Preparation of 4-[3-Benzoyl-1-(2-pyridin-2-yi-ethyl)-ureidomethyI]-benzoic acid methyl ester.
Proceeding as described in INTERMEDIATE 6 above but using appropriate starting materials. LC-MS (ESI, positive mode) m/z 418 ([M+Hf).
INTERMEDIATE 30
Preparation of 4-(3-Benzoyl-1-pyridin-3-ylmethyl-ureidomethyl)-benzoic acid methyl ester.
Proceeding as described in INTERMEDIATE 6 above but using appropriate starting materials. LC-MS (ESI, positive mode) m/z 404 ([M+H]+).
INTERMEDIATE 31
Preparation of 4-(3-Benzoyl-ureido)-butyric acid ethyl ester.
Proceeding as described in INTERMEDIATE 6 above but using appropriate starting materials. LC-MS (ESI, positive mode) m/z 279 ([M+H]+).
1H NMR (CDCI3) δ 10.38 (1H, s), 8.96 (1H, t, J = 5.6 Hz, 8.06 (2H, t, J = 7.5 Hz), 7.58
(1 H, t, J = 7.4 Hz), 7.48 (2H, t, J = 7.6 Hz), 4.12 (2H, q, J = 7.1 Hz), 3.42 (2H, td, J = 6.7 and 6.3 Hz), 2.40 (2H, t, J = 7.4 Hz), 1.95 (2H, penta, J = 7.2 Hz); 13C NMR (CDCI3) δ
172.5, 168.1 , 154.7, 132.5, 131.9, 128.1, 127.6, 59.9, 38.7, 31.1 , 24.5, 13.7.
INTERMEDIATE 32
Preparation of 4-Piperazin-1-ylmethyl-benzoic acid methyl ester (2*TFA salt)
To a solution of 4-Formyl-benzoic acid methyl ester (0.167 g, 1.02 mmoL) and piperazine (0.557 g, 6.47 mmoL) in mixed solvent of MeOH (5 mL) and DCM (5 mL), was added NaBH3CN (0.111 g, 1.76 mmoL) and followed by acetic acid (0.75 mL, 13.1 mmoL). After being stirred at room temperature for 1 h, the reaction mixture was basified with aqueous Na2C03 and extracted with DCM (x2). After workup, the residue was purified by preparative reverse-phase HPLC and the title compound was obtained as 2*TFA salt (0.195 g, 42%). HPLC purity (254 nm) = 98%; LC-MS (ESI, positive mode) m/z 235 ([M+H]+).
1H NMR (CD3OD) δ 8.01 (d, 2H, J = 8.3 Hz), 7.58 (d, 2H, J = 8.3 Hz), 4.39 (s, 2H), 3.84 (s, 3H, OCH3), 3.52-3.47 (m, 8H); 13C NMR (CD3OD) δ 167.7, 135.3, 132.4, 131.2, 61.1 , 52.9, 49.5, 42.2.
INTERMEDIATE 33
Preparation of 3-(4-Piperazin-1-ylmethyl-phenviy-acrylic acid methyl ester
Proceeding as described in INTERMEDIATE 32 above but using appropriate starting material (3-(4-Formyl-phenyl)-acrylic acid methyl ester). LC-MS (ESI, positive mode) m/z 261 ([M+H]+).
INTERMEDIATE 34
Preparation of 0-(2.4-Dimethoxy-benzylVhvdroxylamine
This compound was made according to the procedure described in the publication
(Barlaam B., et al. Tetrahedron Lett. 39: 7865-7868 (1998)).
INTERMEDIATE 35
Preparation of 6-Amino-hexanoic acid (2,4-dimethoxy-benzyloxy)-amide
Scheme 6.
6-Amino-hexanoic acid (13.1 g, 100 mmoL) was dissolved in 10% aqueous Na2CO3 solution (300 mL), then dioxane (200 mL) was added to the above solution. Fmoc-Cl (26 g, 110 mmoL) was added to the above mixture portion-wise, and the resultant reaction mixture was stirring for 12h. The mixture was extracted with ether (150 mL X 2), and the aqueous portion was acidified by 6N HCl. The mixture was filtered, and the solid was washed with water and dried to give 6-(9/7-Fluoren-9-ylmethoxycarbonylamino)-hexanoic acid as a white solid (31 g, 81 %).
6-(9H-Fluoren-9-ylmethoxycarbonylamino)-hexanoic acid (9.17 g, 25 mmoL) and 0-(2,4- dimethoxy-benzyl)-hydroxylamine (36 g, 26 mmoL) were dissolved in DCM (250 mL), then DCC (6.18 g, 30 mmoL) was added ortion-wise. The resultant mixture was stirred for 3h at room temperature, then cooled to 0°C, filtered, and washed with DCM. The organic solution was evaporated to dryness to give the crude [5-(2,4-dimethoxy- benzyloxycarbamoyl)-pentyl]-carbamic acid 9/7-fluoren-9-ylmethyl ester.
The crude ester was reacted with piperidine (5 mL) in MeOH (150 mL) at room temperature for12 h. The solution was evaporated and the residue was purified by flash chromatography (silica, EtOAc: MeOH = 5 : 1). 6-Amino-hexanoic acid (2,4-dimethoxy- benzyloxy)-amide was obtained as a white solid (4.15 g, 56%).
INTERMEDIATE 36
Preparation of 7-Amino-heptanoic acid (2,4-dimethoxy-benzyloxy)-amide
Proceeding as described in INTERMEDIATE 35 above but using appropriate starting materials.
INTERMEDIATE 37
Preparation of 8-Amino-octanoic acid (2.4-dimethoxy-benzyloxy)-amide
Proceeding as described in INTERMEDIATE 35 above but using appropriate starting materials.
EXAMPLE 1
Preparation of 6-[3-(toluene-4-sulfonyI)ureido]-hexanoic acid hydroxyamide
To a solution of 6-[3-(toluene-4-sulfonyl)ureido]-hexanoic acid methyl ester (0.035 g, 0.1 mmol) in dry MeOH (2 mL) was added NH2OH.HCI (0.021 g, 0.3 mmol) followed by NaOMe (0.11 mL, 5.38M, 0.6 mmol). The reaction mixture was stirred at room temperature under nitrogen for 2 hours. The formation of the hydroxamic acid was followed by LCMS. Upon consumption of the starting material, the reaction mixture was diluted with acetonitrile and the solvent was removed in vacuo. The crude residue was purified by mass induced HPLC purification system to give 6-[3-(toluene-4- sulfonyl)ureido]-hexanoic acid hydroxyamide as a pale yellow/whitish solid. 1H NMR (DMSO-cfe) d 10.37 (1 H, bs), 10.13 (1 H, s), 8.46 (1 H, s), 7.60 (2H, d, J = 8.3 Hz, aromatic CH), 7.23 (2H, d, J = 8.0 Hz, CH), 6.27 (1 H, t, J = 5.2 Hz), 2.92 (2H, q, J = 6.1 Hz), 2.39 (3H,s), 1.89 (2H, t, J = 7.5 Hz), 1.43 (2H, penta, J = 7.5 Hz), 1.31 (2H, penta, J = 7.4 Hz), 1.17-1.09 (2H, m).
EXAMPLE 2
Preparation of Λ/-Hydroxy-{3-[4-[3-(toluene-4-sulfonyl)ureido]-phenyl}-acrylamide
Proceeding as described in EXAMPLE 1 above but using appropriate starting materials Yield: 5% from the corresponding methyl ester. White solid. HPLC purity at 254nm: 93%; LC-MS (ESI, positive mode) m/z 376 ([M+Hf).
EXAMPLE 3
Preparation of N-Hydroxy-3-{3-[3-(4-methylbenzenesulfonyl)ureido]-phenyl}-acrylamide
Proceeding as described in EXAMPLE 1 above but using appropriate starting materials. Yield: 64%. White solid. HPLC purity at 254nm: 95%. LC-MS (ESI, positive mode) m/z 376 ([M+Hf). 1H NMR (DMSO-cfe) δ 7.70 (d, 2H, J = 6.0 Hz), 7.36 (d, 2H, J = 8.1 Hz), 7.30 (d, 1 H, J - 15.8 Hz), 7.25 (s, 1 H), 7.11 (t, 1 H, J = 7.7 Hz), 6.80 (d, 1H, J = 8.2 Hz), 6.68 (d, 1 H, J = 7.6 Hz), 6.33 (d, 1 H, J = 15.8 Hz), 2.37 (s, 3H, -CH3).
EXAMPLE 4
Preparation of 4-[3-(toluene-4-sulfonyl)ureidomethyl-Λ/-hydroxy-benzamide
Proceeding as described in EXAMPLE 1 above but using appropriate starting materials. Yield: 58%. White solid. HPLC purity at 254nm: 100%. LC-MS (ESI, positive mode) m/z 364 ([M+Hf); 1H NMR (DMSO-cfe) δ 11.14 (s, 1 H), 10.74 (s, 1 H), 8.98 (d, 1 H, J = 1.7 Hz), 7.79 (d, 2H, J = 8.3), 7.65 (d, 2H, J = 8.3 Hz), 7.41 (d, 2H, J = 8.0 Hz), 7.18 (d, 2H, J = 8.2 Hz), 7.05 (t, 1 H, J = 5.8 Hz), 4.19 (d, 2H, J = 5.9), 2.47 (s, 3H).
EXAMPLE 5
Preparation of Λ/-Hydroxy-2-{4-[3-(toluene-4-sulfonyl)ureido]-phenyl}-acetamide
Proceeding as described in EXAMPLE 1 above but using appropriate starting materials. Yield: 99%. White solid. HPLC purity at 254nm: 99%. LC-MS (ESI, positive mode) m/z 364 ([M+Hf);
1H NMR (DMSO-cfe) δ 10.47 (s, 1 H), 8.64 (s, 1 H), 7.73 (d, 2H, J = 8.2 Hz), 7.32 (d, 2H, J = 8.1 Hz), 7.13 (d, 2H, J = 8.5 Hz), 7.02 (d, 2H, J = 8.3 Hz), 3.08 (s, 2H), 2.29 (s, 2H); 13C NMR (DMSO-cfe) δ 167.0, 149.2, 141.9, 137.1 , 130.8, 129.4, 129.2, 127.4, 125.6, 118.8, 38.6, 21.0.
EXAMPLE 6
Preparation of 4-(3-Benzoyl-ureidomethyl)-Λ/-hydroxy-benzamide
To a solution of 4-(3-Benzoyl-ureidomethyl)-benzoic acid methyl ester (0.030 g, 0.096 mmol) in dry MeOH (0.5 mL) was added NH2OH.HCI (0.020 g, 0.288 mmol) followed by 30% NaOMe solution (5.38 M, 0.106 mL, 0.576 mmol). The reaction mixture was stirred at room temperature under nitrogen for 22 hours then quenched by addition of concentrated hydrochloric acid. The mixture was subjected to RPHPLC for purification. 4-(3-Benzoyl-ureidomethyl)-Λ/-hydroxy-benzamide was obtained as white solid (yield 47%).
HPLC purity at 254nm: 99.7%, tR = 4.55 min. LC-MS (ESI, positive mode) m/z 314 ([M+Hf); 1H NMR (DMSO-cfe) 5 11.11 (s, 1 H), 10.71 (s, 1 H), 9.04-9.07 (tr, 1H, J = 6.0 Hz), 8.92 (br s, 1 H), 7.89-7.91 (d, 2H, J = 8.4 Hz), 7.65-7.67 (d, 2H, J = 8.3 Hz), 7.54-7.58 (m, 1 H), 7.42-7.48 (m, 2H), 7.32-7.34 (d, 2H, J = 8.3 Hz), 4.42-4.43 (d, 2H, J = 6.0 Hz), 2.47 (s, 3H); 13C NMR (DMSO-cfe) δ 167.5, 153.0, 141.8, 132.0, 131.8, 130.7, 128.4, 127.8, 127.7, 127.4, 126.3, 41.8. Anal. Calculated for C16Hι5N304: C, 61.34; H, 4.83; N, 13.41. Found: C, 61.31 ; H, 4.79; N, 13.38.
EXAMPLE 7
Preparation of 2-[3-(3-Benzoyl-ureido)-phenyl]-Λ/-hydroxy-acetamide
Prepared from the corresponding methyl ester. Yield: 7%. White solid. HPLC purity at 254nm: 99%; LC-MS (ESI, positive mode) m/z 314 ([M+Hf);
1H NMR (DMSO-cfe) δ 1 1.02 (s, 1 H), 10.84 (s, 1 H), 10.66 (s, 1 H), 8.83 (s, 1H), 8.01- 8.038.02 (d, 2H, J = 8.5 Hz), 7.64-7.667.65 (m, 1 H), 7.53-7.57 (m, 2H), 7.49-7.517.50 (dd, 1 H, J = 8.1 Hz), 7.44 (s, 1 H), 7.27-7.30 (tr, 1 H, J = 7.8 Hz), 7.00-7.027.01 (d, 1 H, J = 7.8 Hz), 3.29 (s, 2H).
EXAMPLE 8
Preparation of 2-[4-(3-Benzoyl-ureido)-phenyl]-Λ/-hydroxy-acetamide
Prepared from the corresponding methyl ester. Yield: 2%. White solid. HPLC purity at 254nm: 98%; LC-MS (ESI, positive mode) m/z 314 ([M+Hf).
EXAMPLE 9
Preparation of 3-{4-[3-Benzoyl-1 -(3-hydroxy-propyl)-ureidomethyl]-phenyl}-N-hydroxy- acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC.
HPLC purity at 254nm: 97%; LC-MS (ESI, positive mode) m/z 398 ([M+Hf).
1H NMR (DMSO-cfe) δ 10.69 (1 H, s), 10.27 (1 H, s), 8.97 (s, 1 H), 7.76 (br d, 2H, J = 6.4 Hz), 7.54 (t, 1 H, J = 7.3 Hz), 7.49 (d, 2H, J = 8.4 Hz), 7.42 (t, 2H, J = 7.6 Hz), 7.38 (d, 1 H, J = 15.9 Hz), 7.31 (br d like, 2H), 6.39 (d, 1 H, J = 15.8 Hz), 4.80 (br s, 1 H), 4.51 (s, 2H), 3.25 and 3.32 (each 2H, overlapped with solvent peak), 1.61 (m, 2H).
EXAMPLE 10
Preparation of 6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide
Method A: To a solution of 6-(3-Benzoyl-ureido)-hexanoic acid (0.0033 g, 0.01 mmol) in DMF (1 mL) was added Py-BOP (0.07 g, 0.013 mmol) and N,N-diisopropylethylamine (0.013 mL, 0.07 mmol). The reaction mixture was stirred for 5 minutes and the NH2OH.HCI (0.02 g, 0.02 mmol) was added. The reaction mixture was stirred overnight at room temperature under nitrogen. The crude reaction mixture was purified by mass induced HPLC to give 6-(3- Benzoyl-ureido)-hexanoic acid hydroxyamide as an off white solid.
Method B:
To a solution of 6-(3-Benzoyl-ureido)-hexanoic acid methyl ester (0.300 g, 1.03 mmol) in dry MeOH (2.0 mL) was added NH2OH.HCI (0.555 g, 8.00 mmol) followed by 30% NaOMe in MeOH (2.23 mL, 5.38M, 12.0 mmol). The reaction mixture was stirred at room temperature under nitrogen for 1 h then was added trifluoroacetic acid (0.3 mL) in an ice- bath. The solution was extracted with 10% MeOH in dichloromethane. The extract was dried and concentrated. The residue was purified by reverse-phase preparative HPLC to give 6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide (0.175 g, 59%) as white solid. HPLC purity at 254 nm: 99.7%, tR = 5.15 min. LC-MS (ESI, positive mode) m/z 293 ([M+Hf).
1H NMR (DMSO-cfe) δ 10.63 (1 H, s), 10.34 (1 H, s), 8.70-8.60 (1 H, bs), 8.65 (1 H, t, J = 5.7 Hz), 7.95 (2H, dt, J = 7.2, 1.6 Hz), 7.62 (1H, tt, J = 7.4, 1.2 Hz), 7.50 (2H, t, J = 7.9 Hz), 3.22 (2H, q, J = 6.6 Hz, CH2N), 1.96 (2H, t, J = 7.4 Hz, CH2CO), 1.56-1.46 (4H, m), .130- 1.24 (2H, m); 13C NMR (DMSO-cfe) 5 169.1 (CONHOH), 168.2 (PhCO), 153.4 (NHCONH), 132.7 (CH), 132.6 (Cq), 128.4 (CH x 2), 128.0 (CH x 2), 38.9 (CH2N), 32.2 (CH2CO), 28.9, 25.9, 24.8. Anal. Calculated for C H19N304: C, 57.33; H, 6.53; N, 14.33. Found: C, 57.06; H, 6.32; N, 13.88.
EXAMPLE 11
Preparation of 3-(4-{3-Benzoyl-1-[2-(1 H-indol-3-yl)-ethyl]-ureidomethyl}-phenyl)-N- hydroxy-acrylamide
To a cooled solution of 3-(4-{3-Benzoyi-1-[2-(1 H-indol-3-yl)-ethyl]-ureidomethyl}-phenyl)- acrylic acid methyl ester (crude , 2.86 g, 5.93 mmoL) and hydroxylamine hydrochloride (4.14 g, 59.5 mmol) in dry MeOH (40 mL) was added NaOMe in MeOH (4.37 M, 16.9 mL, 73.9 mmol) via syringe. The reaction mixture was stirred at room temperature under nitrogen for 1 h then was added dry ice powder, followed by addition of water and neutralized with 6N HCl to pH 6-7. The resultant mixture was concentrated to remove the organic solvent and the residue was filtered and washed with water. The residue was purified by preparative reverse-phase HPLC to give 3-(4-{3-Benzoyl-1-[2-(1 H-indol-3-yl)- ethyl]-ureidomethyl}-phenyl)-N-hydroxy-acrylamide (0.85 g, 30%) as pale yellow or white solid. LC-MS (ESI, positive mode) m/z 483 ([M+Hf). HPLC purity (254 nm) = 97%. 1H NMR (DMSO-cfe) δ 10.80 (s, 1 H), 10.77 (s, 1H), 10.28 (s, 1 H), 9.05 (br s, 1 H), 7.82 (d, 2H, J = 7.4 Hz), 7.60 (t, 1 H, J = 7.3 Hz), 7.57 (d, 2H, J = 8.3 Hz), 7.50 (t or d, 2H, J = 7.7 Hz), 7.46 (d, 1 H, J = 14.2 Hz), 7.46 -7.34 (br m, 3H), 7.10 (br s, 1 H), 7.02 (t, 1H, J = 7.4 Hz), 6.9-6.7 (very br s, 1 H), 6.47 (d, 1 H, J = 15.8 Hz), 4.67 (s, 2H), 3.52 (dt or br t-like, 2H, J = 6.7 Hz), 2.96 (br t-like, 2H, J = 7.6 Hz); 13C NMR (DMSO-cfe) 5 166.5, 162.8, 154.1 , 139.0, 138.0 (CH=), 136.1 , 133.8, 133.2, 132.2, 128.4, 127.92, 127.88, 127.6, 126.9, 122.9, 120.9, 118.8, 118.2, 118.0, 111.4, 110.7, 49.4*, 49.2*, 24.5* (* these peaks are weak and broad, identified by 1H-13C HSQC). Anal. Calculated for C28H26N404: C, 69.70; H, 5.43; N, 11.61. Found: C, 69.43; H, 5.45; N, 11.62.
EXAMPLE 12
Preparation of 8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide.
To a solution of 8-(3-Benzoyl-ureido)-octanoic acid methyl ester (0.275 g, equal to 0.811 mmol) and NH2OH.HCI (0.562 g, 8.09 mmol) was added dry MeOH (5 mL) and followed by NaOMe in MeOH (2.30 mL, 4.37 M, 10.0 mmol). The reaction mixture was stirred at
room temperature under nitrogen for 50 min then was neutralized with trifluoroacetic acid
(0.80 mL). The mixture was purified by reverse-phase preparative HPLC (Cιs, 5 urn,
21.2x150 mm, 20 mL/min, 5 to 95% of CH3CN + 0.05% TFA over 18 min), to give 8-(3-
Benzoyl-ureido)-octanoic acid hydroxyamide as white powder (0.115 g, 44%). LC-MS (ESI, positive mode) m/z 322 ([M+Hf).
1H NMR (DMSO-cfe) δ 10.64 (1 H, s), 10.34 (1 H, s), 8.70-8.60 (1 H, bs), 8.66 (1 H, t, J = 5.1
Hz), 7.96 (2H, d, J = 7.5 Hz), 7.62 (1H, t, J = 7.0 Hz), 7.50 (2H, t, J = 7.3 Hz), 3.23 (2H, q,
J = 6.1 Hz, CH2N), 1.95 (2H, t, J = 7.2 Hz, CH2CO), 1.50-1.48 (4H, m), 1.29-1.22 (6H, m);
13C NMR (DMSO-cfe) δ 169.1 (CONHOH), 168.2 (PhCO), 153.5 (NHCONH), 132.7 (CH), 132.6 (Cq), 128.4 (CH x 2), 128.1 (CH x 2), 39.0 (CH2N), 32.2 (CH2CO), 29.1 , 28.5, 28.4,
26.3, 25.0.
EXAMPLE 13
Preparation of 7-(3-BenzoyI-ureido)-heptanoic acid hydroxyamide.
Proceeding as described in Example 12 above but using appropriate starting materials (7- (3-Benzoyl-ureido)-heptanoic acid methyl ester), and the reaction mixture was neutralized by TFA and evaporated to dryness. The residue was washed with water and the titled compound was obtained as white solid (0.175 g, 67% in two steps). LC-MS (ESI, positive mode) m/z 308 ([M+Hf). HPLC purity at 254 nm: 98.7%
1H NMR (DMSO-cfe) 5 10.64 (1 H, s), 10.35 (1H, s), 8.70-8.60 (1 H, bs), 8.64 (1 H, t, J = 5.6 Hz), 7.96 (2H, d, J = 7.4 Hz), 7.62 (1 H, t, J = 7.4 Hz), 7.50 (2H, t, J = 7.7 Hz), 3.22 (2H, q, J = 6.5 Hz, CH2N), 1.95 (2H, t, J = 7.3 Hz, CH2CO), 1.55-1.40 (4H, m), 1.35-1.20 (4H, m); 13C NMR (DMSO-cfe) δ 169.1 (CONHOH), 168.2 (PhCO), 153.4, 132.7, 132.6 (Cq), 128.4 (CH x 2), 128.1 (CH x 2), 39.0, 32.2, 29.1, 28.2, 26.1, 25.0.
EXAMPLE 14
8-[3-(4-methylbenzenesulfonyl)-ureido])-octanoic acid hydroxyamide:
Proceeding as described in EXAMPLE 1 above but using appropriate starting materials.
LC-MS (ESI, positive mode) m/z 372 ([M+Hf). HPLC purity at 254 nm: 100%.
EXAMPLE 15
7-[3-(4-methylbenzenesulfonyl)-ureido])-heptanoic acid hydroxyamide:
Proceeding as described in EXAMPLE 1 above but using appropriate starting materials. LC-MS (ESI, positive mode) m/z 358 ([M+Hf). HPLC purity at 254 nm: 100%.
EXAMPLE 16
6-[3-(benzenesulfonyl)-ureido])-hexanoic acid hydroxyamide
Proceeding as described in EXAMPLE 1 above but using appropriate starting materials. LC-MS (ESI, positive mode) m/z 330 ([M+Hf). HPLC purity at 254 nm: 100%.
EXAMPLE 17
Preparation of 6-[3-Benzoyl-1-(3-phenyl-propyl)-ureido]-hexanoic acid hydroxyamide.
Proceeding as described in Example 12 above but using appropriate starting materials 6- [3-Benzoyl-1-(3-phenyl-propyl)-ureido]-hexanoic acid methyl ester, and the reaction mixture was neutralized by TFA and was purified by reverse-phase HPLC to give the titled compound as a gum (15 mg, 32%). LC-MS (ESI, positive mode) m/z 412 ([M+Hf). HPLC purity at 254 nm: 98.1 % 1H NMR (DMSO-cfe) δ 10.34 (1 H, s), 10.08 (1H, s), 7.81 (2H, d, J = 7.1 Hz), 7.59 (1 H, t, J = 7.4 Hz), 7.49 (2H, t, J = 7.5 Hz), 7.30-7.10 (5H, m), 3.40-3.20 (4H, m), 2.57 (2H, m), 1.93 (2H, t or penta like, J = 7.0 Hz), 1.85 (2H, penta, J = 7.2 Hz), 1.60-1.40 (4H, m), 1.30-1.10 (2H, m); 13C NMR (DMSO-cfe) δ 169.0, 166.1 , 153.5, 133.4, 132.0, 128.4,
128.2, 128.1, 127.8, 125.7, 48.0*, 46.4*, 32.22, 32.17, 29.9*, 27.9*, 25.8, 24.8 (*: very weak and broad peaks identified by 1H-13C HSQC).
EXAMPLE 18 Preparation of 6-(3-Benzoyl-thioureido)-hexanoic acid hydroxyamide. Scheme 7.
STEP 1 Preparation of 6-(3-BenzoyI-thioureido)-hexanoic acid (2,4-dimethoxy-benzyloxy)-amide. To a solution of 6-Amino-hexanoic acid (2,4-dimethoxy-benzyloxy)-amide (0.160 mg, 0.54 mmol) in Dichloromethane (DCM, 4 mL) was added triethylamine (0.11 mL, 0.79 mmol) and Benzoyl isothiocyanate (0.11 mL, 0.82 mmol). The reaction was stirred at room temperature overnight and worked up. The residue (0.369 g) was used without further purification. LC-MS: m/z = 460 (M+H).
STEP 2
Preparation of 6-(3-Benzoyl-thioureido)-hexanoic acid hydroxyamide.
To a solution of 6-(3-Benzoyl-thioureido)-hexanoic acid (2,4-dimethoxy-benzyloxy)-amide (crude fromSTEPI , 0.186 g equal to 0.27 mmoL) and Triethylsilane (0.05 mL) in DCM (1.7 mL) was added TFA (0.3 mL) at room temperature with stirring. After 20 min, the solution was evaporated to dryness and diluted with methanol and filtered. The filtrate was concentrated and the residue was purified by preparative HPLC. 6-(3-Benzoyl- thioureido)-hexanoic acid hydroxyamide was obtained as a white solid (0.027 g, 32% overall yield). LC-MS (ESI, positive mode) m/z = 310 (M+H). HPLC (254 nm) purity 95.4%. 1H NMR (DMSO-cfe) δ 11.24 (s, 1 H), 10.87 (s, 1 H), 10.36 (s, 1 H), 8.9-8.4 (very broad, 0.6 H), 7.92 (d, 2H, J = 7.4 Hz), 7.63 (t, 1H, J = 7.4 Hz), 7.51 (t, 2H, J = 7.7 Hz), 3.60 (dt or q-like, 2H, J = 6.7 and 6.0 Hz), 1.97 (t, 2H, J = 7.3 Hz), 1.54 (penta, 2H, J = 6.0 Hz), 1.54 (penta, 2H, J = 7.4 Hz), 1.32 (m, 2H); 13C NMR (DMSO-cfe) δ 179.9, 169.0, 168.0, 132.9, 132.2 (Cq), 128.45, 128.38, 44.6, 32.1 , 27.3, 26.0, 24.8.
EXAMPLE 19
Preparation of 6-(3-Benzoyl-1-pyridin-2-ylmethyl-ureido)-hexanoic acid hydroxyamide
Scheme 8
STEP1
Preparation of 6-[(Pyridin-2-ylmethyl)-amino1-hexanoic acid (2.4-dimethoxy-benzyloxy)- amide
By using analogous method described in INTERMEDIATE 13, 6-Amino-hexanoic acid (2,4-dimethoxy-benzyloxy)-amide and pyridine-2-carbaldehyde was converted to 6- [(Pyridin-2-ylmethyl)-amino]-hexanoic acid (2,4-dimethoxy-benzyloxy)-amide.
STEP2
Preparation of 6-(3-Benzoyl-1-pyridin-2-ylmethyl-ureido)-hexanoic acid (2,4-dimethoxy- benzyloxy)-amide By using analogous method described in INTERMEDIATE 14, 6-[(Pyridin-2-ylmethy!)- aminofhexanoic acid (2,4-dimethoxy-benzyloxy)-amide was converted to the title compound.
STEP3 Preparation of 6-(3-Benzoyl-1-pyridin-2-ylmethyl-ureido)-hexanoic acid hydroxyamide
By using analogous method described in Example 18, Step 2, 6-(3-Benzoyl-1-pyridin-2- ylmethyl-ureido)-hexanoic acid (2,4-dimethoxy-benzyloxy)-amide was deprotected by 15% TFA in DCM and provided 6-(3-Benzoyl-1-pyridin-2-ylmethyl-ureido)-hexanoic acid hydroxyamide as a TFA salt after preparative HPLC purification. HPLC purity at 254nm: 100%; LC-MS (ESI, positive mode) m/z 385.43 ([M+Hf); 1H NMR (CD3OD) δ 8.63-7.80 (br, m, Ar-H), 7.58-7.44 (m, Ar-H), 4.71-4.54 (d, 2H, N-CH2-py), 3.44-3.40 (t, 2H, N-CH2), 2.02-1.98 (t, 2H, 0=C-CH2), 1.61-1.50, 1.27-1.21 (m, 8H, CH2); 3C NMR (CD3OD) δ 170.8, 167.0, 154.4 (C=0), 148.7, 136.8 (Ar-C), 132.0, 127.9, 127.7, 127.5, 127.2, 127.1, 126.7, 12.4, 123.1, 122.1 (Ar-CH), 49.8, 31.6, 31.3, 26.6, 25.1, 24.8, 24.3, 24.0 (CH2).
EXAMPLE 20
Preparation of 7-(3-Benzoyl-1-pyridin-2-ylmethyl-ureido)-heptanoic acid hydroxyamide
Proceeding as described in EXAMPLE 19 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC and obtained as TFA salt. HPLC purity at 254nm: 100%; LC-MS (ESI, positive mode) m/z 399 ([M+Hf); 1H NMR (CD3OD) δ 8.58-7.75 (br, m), 7.58-7.34 (m, Ar-H), 3.40-3.36 (t, 2H), 1.97-1.93 (t, 2H), 1.52-1.19 (br, m, 8H); 13C NMR (CD3OD) δ 131.9, 127.9, 127.1 , 31.6, 27.6, 25.2, 24.5.
EXAMPLE 21
Preparation of 7-(3-Benzoyl-1-benzyl-ureido)-heptanoic acid hydroxyamide Proceeding as described in EXAMPLE 19 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC.
HPLC purity at 254nm: 95%; LC-MS (ESI, positive mode) m/z 398 ([M+Hf); 1H NMR (CD3OD) δ 7.69-7.17 (br, m, Ar-H), 4.56 (s, 2H), 3.31-3.26 (t, 2H), 1.97-1.93 (t, 2H), 1.51- 1.21 (m, 8H); 13C NMR (CD3OD) δ 170.9, 167.2, 154.2, 136.3, 132.7, 131.7, 128.9, 128.4, 127.8, 127.7, 127.2, 127.0, 126.7, 31.6, 27.7, 27.4, 26.4, 25.3, 24.5, 24.2.
EXAMPLE 22
Preparation of 6-(3-Benzoyl-1-benzyl-ureido)-hexanoic acid hydroxyamide
Proceeding as described in EXAMPLE 19 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC.
HPLC purity at 254nm: 96%; LC-MS (ESI, positive mode) m/z 384 ([M+Hf); 1H NMR (CD3OD) δ 7.68-7.16 (br, m, Ar-H), 4.52 (s, 2H), 3.31-3.27 (t, 2H), 1.98-1.95 (t, 2H), 1.55- 1.22 (m, 7H, CH2); 13C NMR (CD3OD) δ 136.3, 132.7 (Ar-C), 127.8, 127.7, 127.0, 126.7, 31.6, 25.2, 24.3 (CH2).
EXAMPLE 23
Preparation of 3-f4-(3-Benzoyl-1 -phenethyl-ureidomethvO-phenvπ-N-hvdroxy-acrylamide Scheme 9
STEP 1
Preparation of 3-f4-(Phenethylamino-methvπ-phenyll-acrylic acid methyl ester. To a solution of 3-(4-Formyl-phenyi)-acrylic acid methyl ester (4.16 g, 5.17 mmol) in DCM (150 mL) was added phenethylamine (4.05 g, 33.4 mmol) and the solution was stirred at room temperature for 1 hour. NaBH(OAc)3 (9.15 g, 38.9 mmol) was added to the above solution in portions and followed by acetic acid (2 mL, 34.9 mmol) an dth emixture was stirred at room temperature overnight. The mixture was basified by adding aqueous NaHCO3 and extracted with EtOAc (x3). After workup, the residue was purified by flash chromatography (silica, EtOAc:DCM:MeOH = 100:95:5) and provided 3-[4- (Phenethylamino-methyl)-phenyl]-acrylic acid methyl ester as white solid (5.47 g, 86%). LC-MS (ESI, positive mode) m/z =296 (M+H)
STEP 2
Preparation of 3-f4-(3-Benzoyl-1-phenethyl-ureidomethyl)-phenvn-acrylic acid methyl ester.
To a mixture of 3-[4-(PhenethyIamino-methyl)-phenyl]-acrylic acid methyl ester (3.01 g,
10.2 mmoL) and benzoylisocyante (2.43 g, 90% pure, 14.8 mmoL) was added DCM (30 mL) and followed by Et3N (1.8 mL, 12.9 mmoL). The solution was stirred at room temperature overnight and evaporated to dryness. The crude solid product can be used for next step of reaction without further purification. LC-MS (ESI, positive mode) m/z =
443 (M+H).
STEP 3
Preparation of 3-[4-(3-Benzoyl-1 -phenethyl-ureidomethyl)-phenyll-N-hvdroxy-acrylamide. To a cooled solution of 3-[4-(3-Benzoyl-1-phenethyl-ureidomethyl)-phenyl]-acrylic acid methyl ester (crude from STEP 2, 10.2 mmoL) and hydroxylamine hydrochloride (7.08 g, 102 mmoL) in MeOH (60 mL) was slowly added sodium methoxide solution in MeOH (4.37 M, 30 mL, 131 mmoL) via a syringe. The resultant mixture was then stirred at room temperature for about 2 h (monitoring the progress by LC-MS) and quenched by adding dry-ice powder. The cold mixture was added de-ionized water and pH was adjusted to 3-4 by adding of 4N HCl. The solution was evaporated to remove all the organic solvent and the residue was washed with water (x3). The crude product was purified by preparative reverse phase HPLC and provided 3-[4-(3-Benzoyl-1-phenethyl- ureidomethyl)-phenyl]-N-hydroxy-acrylamide as white powder/solid (0.945 g, 21 % from STEP 2). HPLC (254 nm) purity 97%. LC-MS (ESI, positive mode) m/z = 444 (M+H). 1H NMR (DMSO-dβ) δ 10.76 (s, 1 H), 10.27 (s, 1H), 9.04 (br s, 1 H), 7.81 (d, 2H, j = 7.3 Hz), 7.60 (t, 1 H, J = 7.3 Hz), 7.56 (d, 2H, J = 8.0 Hz), 7.50 (d or t, 2H, J = 7.2 Hz), 7.44 (d, 1 H, J = 16.4 Hz), 7.39 (br d, 2H), 7.26 (t, 2H, J = 7.2 Hz), 7.21-7.10 (m, 3H), 6.46 (1 H, d, J = 15.8 Hz), 4.60 (s, 2H), 3.48 (t, 2H, J = 7.7 Hz), 2.84 (t, 2H, J = 7.6 Hz); 13C NMR (DMSO- /6) δ 166.6, 162.8, 154.0, 139.0, 138.7, 138.0, 133.8, 133.4, 132.2, 128.6, 128.42, 128.40, 127.90, 127.88, 127.6, 126.3, 118.9, 49.7*, 49.5*, 34.2* (* these peaks are weak and broad, identified by 1H "13C HSQC). Anal. Calculated for C26H25N304: C, 70.41 , H, 5.68, N, 9.47. Found: C, 69.95, H, 5.97, N, 9.41.
EXAMPLE 24
Preparation of 3-{4-f3-Benzoyl-1 -(2-morpholin-4-yl-ethyl)-ureidomethvπ-phenyl)-N- hydroxy-acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC as TFA salt. LC-MS (ESI, positive mode) m/z 453 ([M+Hf); 1H NMR (CD3OD) δ 7.71-7.25 (br, m, Ar- H), 6.40-6.36 (d, 1H, J = 16Hz), 4.64 (s, 2H), 3.82-3.71 (br, m, 5H), 3.32-3.25 (br, t, 2H); 13C NMR (CD3OD) 5 167.7, 164.1 , 155.1 , 137.1 , 134.2 (Ar-C), 138.8, 132.2, 132.1, 127.8, 127.5, 127.2, 117.0, 63.1 , 54.2, 51.9, 41.2.
EXAMPLE 25
Preparation of 3-(4-(3-Benzoyl-1 -r2-(4-bromo-phenyl)-ethvH-ureidomethyl)-phenvD-/V- hvdroxy-acrylamide.
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. HPLC purity at 254nm: 96%; LC-MS (ESI, positive mode) m/z 524 ([M+Hf); 1H NMR (CD3OD) δ 7.67-7.01 (br, m, Ar-H), 6.41-6.37 (d, 1 H, J = 16Hz), 4.56 (s, 2H), 3.54-3.50 (br, t, 2H), 2.81-2.77 (br, t, 2H); 13C NMR (CD3OD) δ 169.1, 141.0, 140.0, 134.5, 133.7, 138.3, 132.7, 131.9, 131.7, 131.5, 129.6, 129.4, 129.1 , 128.9, 121.3 (CH=CH), 34.6.
EXAMPLE 26
Preparation of 3-(4-f3-Benzoyl-1 -r2-(4-f luoro-phenylVethvπ-ureidonriethylV-phenvD-Λ/- hvdroxy-acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. HPLC purity at 254nm: 91%; LC-MS (ESI, positive mode) m/z 462 ([M+Hf); 1H NMR (CD3OD) δ 7.68-7.66 (br, m, Ar-H), 6.41-6.37 (d, 1 H, J = 16Hz), 4.56 (s, 2H), 3.52-3.26 (br t, 2H), 2.82-2.79 (br t, 2H); 13C NMR (CD3OD) 5 167.2, 162.4, 159.9, 138.2, 134.0, 132.6, 116.6, 139.1 , 131.8, 129.7, 129.6, 114.4, 114.2, 116.6, 32.4.
EXAMPLE 27
Preparation of 3-(4-f3-Benzoyl-1 -(3-imidazol-1 -yl-propyl)-ureidomethyll-phenyl>-N- hydroxy-acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC as TFA salt. HPLC purity at 254nm: 98%; LC-MS (ESI, positive mode) m/z 448 ([M+Hf); 1H NMR (CD3OD) 5 8.83 (s, 1 H, NH), 7.70-7.26 (b, m, Ar-H), 6.40-6.36 (d, 1 H, J = 16Hz), 4.24 (br s, 2H), 3.40-3.37 (brt, 2H), 2.17-2.10 (br, t, 2H); 13C NMR (CD3OD) δ 138.9, 132.0, 136.2, 127.8, 127.3, 127.1 , 121.2, 119.2, 116.9, 45.9, 27.15.
EXAMPLE 28
Preparation of 3-(4-{3-Benzoyl-1-r2-(1 H-imidazol-4-yl)-ethyll-ureidomethyl)-phenvπ-N- hydroxy-acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC as TFA salt. HPLC purity at 254nm: 100%; LC-MS (ESI, positive mode) m/z 434 ([M+Hf); 1H NMR (CD3OD) δ 8.67 (s, 1H, NH), 7.72-7.24 (b, m, Ar-H), 6.44-6.40 (d, 1H, J = 16Hz), 4.57 (br, s, 2H), 3.71-3.68 (br, t, 2H), 3.02-2.99 (br, t, 2H); 13C NMR (CD3OD) 5 167.3, 164.3, 154.4, 137.9, 133.9, 132.3, 130.2, 139.0, 132.3, 131.9, 127.8, 127.3, 127.1, 116.8, 116.1 (CH=CH), 45.9, 22.0.
EXAMPLE 29 Preparation of 3-(4-H-(1 H-Benzoimidazol-2-ylmethyl)-3-benzoyl-ureidomethvπ-phenyl)-N- hvdroxy-acrylamide.
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. LC-MS (ESI, positive mode) m/z 470 ([M+Hf); 1H NMR (CD3OD) δ 7.80-7.31 (br, m, Ar- H), 6.41-6.37 (d, 1 H, J = 16Hz), 4.81 (s, 2H), 4.70 (s, 2H); 3C NMR (CD3OD) δ 166.9, 154.1 , 134.0, 133.5, 137.8, 132.4, 128.4, 128.1, 127.7, 124.2, 119.0, 114.5.
EXAMPLE 30
Preparation of 4-(4-Benzoylaminocarbonyl-piperazin-1 -ylmethvD-N-hydroxy-benzamide
Proceeding as described in EXAMPLE 23 (STEP 2 and 3) above but using appropriate starting material (INTERMEDAITE 32). The crude titled compound was purified by reverse-phase preparative HPLC and obtained as TFA salt. LC-MS (ESI, positive mode) m/z 383 ([M+Hf). 1H NMR (CD3ODJ δ 7.83 (d, 2H, J = 7.2 Hz), 7.63 (d, 2H, J = 7.7 Hz), 7.56 (t, 1 H, J = 7.5 Hz), 7.53 (d, 1 H, J = 15.7 Hz), 7.51 (d, 2H, J = 6.4 Hz), 7.45 (t, 2H, J = 7.5 Hz), 4.38 (s, 2H), 4.0-3.2 (very br m, 8H).
EXAMPLE 31
Preparation of N-(4-[4-(2-Hvdroxycarbamoyl-vinyl)-benzvπ-piperazine-1-carbonyl)- benzamide
Proceeding as described in EXAMPLE 23 (STEP 2 and 3) above but using appropriate starting material (INTERMEDAITE 33). The crude titled compound was purified by reverse-phase preparative HPLC and obtained as freebase after basification (23% from two steps). LC-MS (ESI, positive mode) m/z 408 ([M+Hf). HPLC purity (254 nm) = 94%. 1H NMR (CD3ODj 5 7.83 (d, 2H, J = 7.3 Hz), 7.80 (d, 2H, J = 8.3 Hz), 7.58 (d, 2H, J = 8.1 Hz), 7.55 (t, 1 H, J = 7.4 Hz), 7.44 (t, 2H, J = 7.6 Hz)., 4.42 (s, 2H), 4.3-3.3 (very br m, 8H).
EXAMPLE 32
Preparation of 6-f2-(3-Benzoyl-ureido 3-(1 H-indol-3-vπ-propionylaminol-hexanoic acid hydroxyamide.
Scheme 10
STEP 1
Preparation of (S)-6-[2-(9H-Fluoren-9-ylmethoxycarbonyIamino)-3-(1 H-indol-3-yl)- propionylamino]-hexanoic acid methyl ester. To a solution of Fmoc-L-Tryptophan (0.422 g, 0.99 mmol) and HOBt hydrate (0.171 g, 1.13 mmol) in Dichloromethane (DCM, 10 mL) was added diisopropyl-carbodiimide (DIG, 0.170 mL, 1.09 mmoL). After being stirred at room temperature for 1 h, 6-Amino-hexanoic acid methyl ester hydrochloride salt (0.201 g, 1.11 mmoL) was dded to the above solution and followed by diisopropylethylamine (0.210 mL, 1.21 mmoL). The reaction mixture was stirred overnight, worked up and purified by flash chromatography (silica, 50% to 100% of EtOAc in hexanes). LC-MS (ESI, positive mode) m/z = 554 (M+H).
STEP 2
Preparation of 6-[2-Amino-3-(1 H-indol-3-yl)-propionylamino]-hexanoic acid methyl ester. To a solution of (S)-6-[2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-(1 H-indoI-3-yl)- propionylamino]-hexanoic acid methyl ester (crude, 0.433 g, equal to 0.61 mmoL) in DCM (4 mL) was added piperidine (1 mL). After being stirred at room temperature for 30 min, the solution was evaporated to dryness and the residue was washed with hexanes (x4) and worked up to give the title compound (0.219 g). LC-MS (ESI, positive mode) m/z = 332 (M+H).
Proceeding as described in EXAMPLE 23 (STEP 2 and 3) above but using appropriate starting material (6-[2-Amino-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid methyl ester). The crude titled compound was purified by reverse-phase preparative HPLC. LCMS (ESI, positive mode) m/z 480 ([M+Hf). HPLC purity (254 nm) = 94%.
1H NMR (CD3OD) 5 7.79 (d or dd, 2H, J = 7.2, 1.3 Hz), 7.53 (d, 1H, J = 5.4 Hz), 7.51 (t,
1 H, J = 7.5 Hz), 7.40 (t, 2H, J = 7.7 Hz), 7.23 (d, 1 H, J = 8.1 Hz), 7.09 (s, 1 H), 6.98 (td,
1 H, J = 7.0, 0.9 Hz), 6.90 (td, 1 H, J = 7.4, 0.7 Hz), 4.51 (t, 1 H, J = 6.7 Hz), 3.18 (2H, overlapped by HDO), 3.03 and 2.91 (m, each 1H), 1.93 (t, 2H, J = 7.4 Hz), 1.42 (penta,
2H, J= 7.5 Hz), 1.20 (penta, 2H, J = 7.5 Hz), 1.04 (m, 2H).
EXAMPLE 33
Preparation of 3-r4-(3-Benzoyl-1 -pyridin-3-ylmethyl-ureidomethyl)-phenvπ-N-hvdroxy- acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. HPLC purity at 254nm: 99%; LC-MS (ESI, positive mode) m/z 431 ([M+Hf); 1H NMR (DMSO-cfe) 5 10.70 (br s, 1 H), 10.40 (s, 1 H), 8.52* (d like, 2H, including 1H (d, J = 4.0 Hz) and 1H (s)), 7.87 (br, 1 H), 7.74 (d, 2H, J = 7.3 Hz), 7.51 (t, 1H, J = 7.4 Hz), 7.49 (overlapped, 1 H), 7.48*(d, 2H, J = 8.0 Hz), 7.42 (t, 2H, J = 7.8 Hz), 7.38 (d, 1 H, J = 16.7 Hz), 7.26* (d, 2H, J = 7.3 Hz), 6.39 (d, 1H, J = 15.8 Hz), 4.56 (s, 2H), 4.54 (s, 2H); 13C NMR (DMSO-cfe) 5 166.6, 162.5*, 154.5, 146.4*(br, CHx2), 138.3, 137.8, 137.5*, 134.0, 133.1 , 132.3, 128.4, 127.9* (CHx2x2), 124.4, 119.0, 51.9*, 48.3* (* these peaks are identified by 1H-13C HSQC and HMBC).
EXAMPLE 34
Preparation of 4-(3-Benzoyl-ureido)-N-hvdroxy-butyramide,
Proceeding as described in EXAMPLE 10 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. HPLC purity at 254nm: 98%; LC-MS (ESI, positive mode) m/z 266 ([M+Hf); 1H NMR (DMSO-cfe) δ 10.60 (s, 1 H), 10.34 (s, 1H), 8.62 (br, 1 H), 8.61 (t, 1H, J = 5.7 Hz), 7.89 (d, 2H, J = 7.4 Hz), 7.55 (t, 1 H, J = 7.4 Hz), 7.44 (t, 2H, J = 7.7 Hz), 3.16 (q-like, 2H, J = 6.4 Hz), 1.94 (t, 2H, J = 7.5 Hz), 1.66 (penta, 2H, J = 7.3 Hz); 13C NMR (DMSO-cfe) δ 168.6, 168.1 , 153.5, 132.7, 132.6, 128.5, 128.1 , 38.7, 29.8, 25.5.
EXAMPLE 35
Preparation of 3-(4-r3-Benzoyl-1 -(3-phenyl-propyD-ureidomethvπ-phenyl)-N-hvdroxy- acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. LC-MS (ESI, positive mode) m/z 458 ([M+Hf); 1H NMR (CD3ODJ δ 7.65 (d, 2H, J = 7.3 Hz), 7.49 (1H, t, J = 7.4 Hz), 7.47 (1H, d, J = 15.6 Hz), 7.44 (d, 2H,j = 7.7 Hz), 7.37 (t, 2H, J = 7.7 Hz), 7.27 (br d, 2H), 7.14 (t-like, 1 H), 7.05 (m, 2H), 7.02 (m, 2H), 6.37 (d, 1 H, J =15.8 Hz), 4.58 (s, 2H), 3.28 (m, 2H), 3.15 (s-like, 2H), 1.83 (penta, 2H, J = 7.4 Hz).
EXAMPLE 36
Preparation of 3-{4-f3-Benzoyl-1 -(2-phenoxy-ethvD-ureidomethyll-phenyl)-N-hvdroxy- acrylamide
Proceed oing aιs described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. LC-MS (ESI, positive mode) m/z 460 ([M+Hf); 1H NMR (CD3ODJ δ 7.74 (br s, 2H), 7.50 (t, 1H, J = 7.3 Hz), 7.45 (d, 1H, J = 15.3 Hz), 7.43 (d, 2H, J = 7.3 Hz), 7.37 (t, 2H, J = 7.6 Hz), 7.32 (d, 2H, J = 7.7 Hz), 7.14 (td, 2H, J = 7.4, 1.2, Hz), 6.85 (t, 1H, J = 7.4 Hz), 6.75 (d, 2H, J = 7.4 Hz), 6.35 (d, 1H, J = 15.8 Hz), 4.69 (s, 2H), 4.08 (t, 2H, J = 4.8 Hz), 3.75 (t, 2H, J = 4.9 Hz).
EXAMPLE 37
Preparation of 4-f3-Benzoyl-1 -(3-phenyl-propyl)-ureidomethyll-N-hvdroxy-benzamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. LC-MS (ESI, positive mode) m/z 432 ([M+Hf); 1H NMR (CD3ODJ δ 7.65 (d, 2H, J = 7.6 Hz), 7.63 (d, 2H, J = 8.3 Hz), 7.50 (t, J = 7.3 Hz), 7.38 (t, 2H, J = 7.7 Hz), 7.33 (br d, 2H, J = 6.6 Hz), 7.10-6.88 (m, 5H), 4.62 (s, 2H), 3.27 (m, 2H), 2.50 (t-like, 2H, J = 6.9 Hz), 1.84 (penta, 2H, J = 7.5 Hz).
EXAMPLE 38
Preparation of 4-(3-Benzoyl-1 -pyridin-3-ylmethyl-ureidomethyl)-N-hvdroxy-benzamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. HPLC purity at 254nm: 98%; LC-MS (ESI, positive mode) m/z 405 ([M+Hf); 1H NMR (CD3ODJ δ 8.73 (s, 1 H), 8.64 (d, 1 H, J = 5.4 Hz), 8.38 (br d, 1 H, J = 6.9 Hz), 7.85 (t, 1 H, J 6.8 Hz), 7.76 (d, 2H, J = 8.5 Hz), 7.67 (d, 2H, J = 8.3 Hz), 7.55 (tt, 1 H, J = 7.7 Hz), 7.43 (t, 2H, j = 7.7 Hz), 7.34 (d, 2H, J = 8.2 Hz), 4.79 (s, 2H), 4.73 (s, 2H).
EXAMPLE 39
Preparation of 4-(3-Benzoyl-1 -benzyl-ureidomethvD-N-hvdroxy-benzamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC.
HPLC purity at 254nm: 97%; LC-MS (ESI, positive mode) m/z 404 ([M+Hf); 1H NMR
(CDsODJ 7.638 (d, 2h, J =7.0 Hz), 7.636 (d, 2h, J = 8.4 Hz), 7.48 (tt, 1 H, j = 7.4, 1.2 Hz),
7.36 (t, 2H, J = 7.7 Hz), 7.31 (br d-like, 2H), 7.28-7.17 (m, 5H), 4.58 (s, 2H), 4.53 (s, 2H).
EXAMPLE 40
Preparation of 4-[3-Benzoyl-1 -(2-pyridin-2-yl-ethylVureidomethvπ-N-hvdroxy-benzamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. LC-MS (ESI, positive mode) m/z 419 ([M+Hf); 1H NMR (CD3ODJ δ 8.54 (br s, 1H), 8.28 (br s, 1 H), 7.80-7.60 (m, 6H), 7.48 (t, 1 H, J = 7.4 Hz), 7.37 (t, 2H, J = 8.0 Hz), 7.30 (d, 2H, J = 7.6 Hz), 4.62 (s, 2H), 3.82 (t, J = 6.5 Hz), 3.25 (t, 2H, J = 6.4 Hz).
EXAMPLE 41 Preparation of 4-f3-Benzoyl-1-(3-hvdroxy-propyl)-ureidomethvn-N-hydroxy-benzamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. HPLC purity at 254nm: 97%; LC-MS (ESI, positive mode) m/z 372 ([M+Hf); 1H NMR (CD3OD δ 7.78 (br m, 2H), 7.65 (d, 2H, J = 8.3 Hz), 7.49 (t, 1 H, J = 7.4 Hz), 7.41-7.36 (m, 4H), 4.59 (s, 2H), 3.52 (t, 2H, J = 5.8 Hz), 3.48 (t, 2H, J = 6.5 Hz), 1.72 (t, 2H, J = 6.0 Hz).
EXAMPLE 42
Preparation of 3-f4-(3-Benzoyl-1-benzyl-ureidomethvπ-phenvn-N-hvdroxy-acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. HPLC purity at 254nm: 96%; LC-MS (ESI, positive mode) m/z 430 ([M+Hf); 1H NMR (CD3ODJ δ 7.67 (dd, 2H, J = 8.5, 1.3 Hz), 7.55-7.46 (m, 4H), 7.39 (t, 2H, J = 7.4 Hz), 7.32-7.22 (m, 7H), 6.37 (d, 1H, J = 15.7 Hz), 4.58 (s, 2H), 4.57 (s, 2H).
EXAMPLE 43
Preparation of 3-(4-f3-Benzoyl-1 -(2-pyridin-2-yl-ethyl)-ureidomethvπ-phenyl)-N-hvdroxy- acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. HPLC purity at 254nm: 96%; LC-MS (ESI, positive mode) m/z 558 ([M+Hf); 1H NMR (CD3ODJ δ 8.56 (1 H, s), 8.32 (br s, 1 H), 7.83 (br s, 1 H), 7.76 (br s, 1 H), 7.66 (d, 2H, J = 6.6 Hz), 7.51-7.45 (m, 4H), 7.37 (t, 2H, J = 7.5 Hz), 7.25 (d, 2H, J = 7.4 Hz), 6.39 (d, 1H, J = 14.7 Hz), 4.58 (s, 2H), 3.82 (t, 2H, J = 8.4 Hz), 3.26 (t, 2H, J 6.3 Hz).
EXAMPLE 44
Preparation of 3-(4-f3-Benzoyl-1-(2-pyridin-3-yl-ethyl)-ureidomethvπ-phenyl|-N-hvdroxy- acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. LC-MS (ESI, positive mode) m/z 445 ([M+Hf); 1H NMR (CD3ODJ 58.67-8.39, 7.27 (br m, py-H), 7.84-7.35 (br, m, Ar-H), 6.40-6.36 (d, 1 H, J = 16Hz), 4.58 (s, 2H), 3.73-3.69 (t, 2H), 3.10-3.07 (t, 2H); 13C NMR (CD3OD) δ 167.1 , 164.2, 154.4, 137.9, 133.9, 132.3 (Ar-C), 141.8, 138.9, 131.9, 127.8, 127.3, 127.2, 127.0, 126.0, 116.9, 29.8.
EXAMPLE 45 Preparation of 3-(4-f3-Benzoyl-1 -(2-pyridin-4-yl-ethyl)-ureidomethyll-phenyl)-N-hydroxy- acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC.
HPLC purity at 254nm: 100%; LC-MS (ESI, positive mode) m/z 445 ([M+Hf); 1H NMR (CD3ODJ δ 8.66-8.53 and 7.28-7.27 (br m), 7.86-7.35 (br m), 6.41-6.37 (d, 1 H, J = 16Hz), 4.61 (s, 2H), 3.77-3.74 (t, 2H), 3.16-3.15 (t, 2H); 13C NMR (CD3OD) 5 167.1 , 164.2, 160.3, 154.4, 138.9, 137.8, 133.9, 132.3, 140.5, 131.9,127.8, 127.3, 127.3, 127.2, 127.1, 116.9, 33.3.
EXAMPLE 46
Preparation of 3-(4-f3-Benzoyl-1 -(2-piperidin-1 -yl-ethvD-ureidomethvπ-phenylV-N-hvdroxy- acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. HPLC purity at 254nm: 100%; LC-MS (ESI, positive mode) m/z 451 ([M+Hf); 1H NMR (CD30Dj δ 7.70-7.32 (m, 11 H), 6.43 (d, 1 H, J =16 Hz), 4.61 (t, 2H), 3.77(t, 2H), 3.56-3.53 (br, 2H), 2.94 (br, 2H), 1.90-1.47 (br, 6H); 13C NMR (CD3OD) δ 167.4, 164.1, 137.2, 134.2, 132.1 , 138.8, 132.2, 127.8, 127.5, 127.2, 117.0, 53.7, 53.1 , 51.0, 41.6, 22.3, 20.6.
EXAMPLE 47
Preparation of 3-{4-[3-Benzoyl-1-(2-pyrrolidin-1-yl-ethyl)-ureidomethyll-phenyl)-N- hvdroxy-acrylamide
Proceeding as described in EXAMPLE 23 above but using appropriate starting materials the crude titled compound was purified by reverse-phase preparative HPLC. HPLC purity at 254nm: 97%; LC-MS (ESI, positive mode) m/z 437 ([M+Hf); 1H NMR (CD3OD) δ 7.70 (d, 2H, J = 7.5 Hz), 7.52 (t, 1 H, J = 7.4 Hz), 7.51 (d, 2H, J = 7.8 Hz), 7.48 (d, 1 H, J = 18.3 Hz), 7.39 (t, 2H, J = 7.6 Hz), 7.30 (d, 2H, J = 7.9 Hz), 6.40 (d, 1 H, J = 15.8 Hz), 4.66 (s, 2H), 3.72 (t, 2H, J = 6.3 Hz), 3.67 (br m, 2H), 3.34 (t, 2H, J = 6.2 Hz) N- CH2), 3.05 (br m, 2H), 2.07 (br m, 2H), 1.96 (br m, 2H).
Solid-phase synthesis of acylurea containing hydroxamates.
The following protocol was used for synthesis of acylurea on solid-phase.
Step 1.
The 0-(2,4-Dimethoxy-benzyl)-hydroxylamine was attached to the aldehyde of SASRIN
(Super Acid Sensitive Resin, Katritzky, A.R. 38: 7849-7850 (1997)) by reductive amination to give the protected acid labile hydroxylamine resin.
Step 2.
3-(4-Formyl-phenyl)-acryIic acid was attached to the resin by treating with PyBroP
(Bromo-tris-pyrrolidino-phosphonium hexaflurophosphate) and N,N-diisopropylethylamine
(DIEA). Step 3.
Reductive amination with selected variety of amines.
Step 4. acylurea formation by reacting the above resin with benzoyl isocyanate.
Steo5. TFA cleavage and subsequent workup.
Step 6.
The crude products were purified by High throughput mass-dependent HPLC purification system.
Scheme 11
er formed)
Table 1. Examples made by solid-phase synthesis
By methods analogous to those disclosed above and by varying the starting materials used in the synthesis, a wide variety of compounds of Formula (I) could be prepared, including, but not limited to, those in Table 2. Non-commercial available acyl isocyanates could be prepared according to the published literature methods. For example, acetyl isocyanate could be synthesized by reacting Et3SnNCO with acetyl bromide [Chauzov, V. A.; Baukov, Yu. I. Zhurnal Obshchei Khimii (1972), 42(8), 1868-9], or by reacting Bu3SnNCO with acetyl chloride [Kodama, H. et al. Jpn. Tokkyo Koho (1972) JP47009568]. Acyl isocyanate R'CONCO [R' = C1-4 alkyl, (substituted) Ph, naphthyl] could be made by reaction of R'COX (X = halo) with NaOCN [Caubere, P. et al. Eur. Pat. Appl. (1989), EP 334720 A1]
105
BIOLOGICAL TESTING AND ENZYME ASSAYS
Recombinant GST-HDAC1 and GST-HDAC8 Protein expression and purification Human cDNA library was prepared using cultured SW620 cells. Amplification of human HDAC1 and HDAC8 coding region from this cDNA library was cloned separately into the baculovirus expression pDEST20 vector and pFASTBAC vector respectively (GATEWAY Cloning Technology, Invitrogen Pte Ltd). The pDEST20-HDAC1 and pFASTBAC-HTGST- HDAC8 constructs were confirmed by DNA sequencing. Recombinant baculovirus was prepared using the Bac-To-Bac method following the manufacturer's instruction (Invitrogen Pte Ltd). Baculovirus titer was determined by plaque assay to be about 108 PFU/ml.
Expression of GST-HDAC1 or HTGST-HDAC8 was done by infecting SF9 cells (Invitrogen Pte Ltd) with pDEST20-HDAC1 or pFASTBAC-GST-HDAC8 baculovirus at MOI=1 for 48 h. Soluble cell lysate was incubated with pre-equilibrated Glutathione Sepharose 4B beads (Amersham) at 4°C for 2 h. The beads were washed with PBS buffer for 3 times. The GST-HDAC1 protein or GST-HDAC8 protein was eluted by elution buffer containing 50 mM Tris, pHδ.0, 150mM NaCl, 1 % Triton X-100 and 10mM or 20mM reduced Glutathione. The purified GST-HDAC1 protein or purified GST-HDAC8 protein was dialyzed with HDAC storage buffer containing 10mM Tris, pH7.5, 100mM NaCl and 3mM MgCI2. 20% Glycerol was added to purified GST-HDAC1 protein or purified GST- HDAC8 before storage at -80°C.
In vitro HDAC assay for determination of ICfin values The assay has been carried out in 96 well format and the BIOMOL fluorescent-based HDAC activity assay has been applied. The reaction composed of assay buffer, containing 25 mM Tris pH 7.5, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCI2, 1 mg/ml BSA, tested compounds, 500 nM HDAC8 enzyme or 600 nM HDAC1 enzyme, 200 μM Flurde lys p53 peptide substrate for HDAC8 enzyme or 500 μM Flurde lys generic substrate for HDAC1 enzyme and subsequently was incubated at room temperature for 2 h. Flur de lys Developer was added and the reaction was incubated for 10 min. Briefly, deacetylation of the substrate sensitizes it to the developer, which then generates a fluorophore. The fluorophore is excited with 360 nm light and the emitted light (460 nm) is detected on a fluorometric plate reader (Tecan Ultra Microplate detection system, Tecan Group Ltd.).
The analytical software, Prism 3.0® (GraphPad Software Inc) has been used to generate
IC50 from a series of data.
The HDAC enzyme inhibition results of representative compounds are shown in Table 3.
Table 3. HDAC enzyme inhibition activities of representative examples
Cell-based proliferation assay for determination of GIso values
Human colon cancer cell lines (Colo205) and human breast cancer cell lines (MDA-
MB435 and MDA-MB231) were obtained from ATCC. Colo205 cells were cultivated in
RPMI 1640 containing 2 mM L-Glutamine, 5% FBS, 1.0 mM Na Pyruvate. MDA-MB231 cells were cultivated in RPMI 1640 containing 2 mM L-glutamine, 5%FBS. MDA-MB435 cells were cultivated in DMEM containing 2 mM L-Glutamine, 5% FBS. Colo205 cells were seeded in 96-wells plate at 5000 cells per well respectively. MDA-MB435 and MDA-
MB231 cells were seeded in 96-wells plate at 6000 cells per well. The plates were incubated at 37°C, 5% CO2, for 24 h. Cells were treated with compounds at various concentrations for 96 h. Cell growth was then monitored using cyquant cell proliferation assay (Invitrogen Pte Ltd). Dose response curves were plotted to determine Gl50 values for the compounds using XL-fit (ID Business Solution, Emeryville, CA).
The cellular or growth inhibition activity results of representative compounds are shown in Table 4. These data indicate that compounds in this invention are highly active in inhibition of tumor cell growth. In addition, representative compounds have also demonstrated their ability to inhibit growth in other types of cancer cell lines including lung cancer cell lines (e.g. NCI-H522 and A549), prostate cancer cell line (e.g. PC3), leukemia cell line (e.g. HL-60), lymphoma cell line (e.g. Ramos) and pancreatic cancer cell line (MIAPaCA2) (data not shown).
Table 4. Cellular activities of representative examples
Histone H3. H4, H2A and H2B acetylation assay
A hallmark of histone deacetylase (HDAC) inhibition is the increase in the acetylation level of histones. Histone acetylation, including H3, H4, H2A and H2B can be detected by immuno-blotting (western-blot). Colo205 cells, approximately 1.5 x10δ cells/ 10 cm dish, were seeded in the previously described medium, cultivated for 24 h and subsequently treated with HDAC inhibitory agents at 0.1 , 1 , 5 and 10 μM final concentration. After 24 h, cells were harvested and lysed according to the instruction from Sigma Mammalian Cell
Lysis Kit. The protein concentration was quantified using BCA method (Sigma Pte Ltd).
The protein lysate was separated using 4-12% bis-tris SDS-PAGE gel (Invitrogen Pte Ltd) and was transferred onto PVDF membrane (BioRad Pte Ltd). The membrane was probed separately using primary antibody specific for acetylated H3, acetylated H4 or acetylated H2A (Upstate Pte Ltd). The detection antibody, goat anti rabbit antibody conjugated with Horse radish peroxidase (HRP) was used according to the manufacturer instruction (Pierce Pte Ltd). After removing the detection antibody from the membrane, an enhanced chemiluminescent substrate for detection of HRP (Pierce Pte Ltd) was added onto the membrane. After removing the substrate, the membrane was exposed to an X-ray film (Kodak) for 1 sec - 20 mins. The X-ray film was developed using the X-ray film processor. The density of each band observed on the developed film could be analysed using UVP Bioimaging software (UVP, Inc, Upland, CA). The values were then normalized against the density of actin in the corresponding samples to obtain the expression of the protein. The results of histone deacetylase assay are shown in Table 5.
Table 5. Effects of representative examples on accumulation of acetylated histone.
"Active" means accumulation of acetylated histone was observed when compared with control (without compound).
These data demonstrate that compounds in this invention inhibit histone deacetylases, thereby resulting in accumulation of acetylated histones.
Apoptosis assays
In various therapies such as for proliferative disorders like cancer, the selective induction of apoptosis in proliferating cells such as tumor cells is one of the desirable approaches, and can be mediated by treatment with various anti-proliferative compounds
[Blagosklonny MV, Oncogene, 23(16): 2967 (2004); Kaufmann and Eamshaw, Exp Cell Res. 256(1): 42-9 (2000)]. Programmed cell death or apoptosis is the cellular response to stress factors such as DNA damage introduced during conventional anti-cancer treatment. The concerted sequence of events during apoptosis, clearly differentiate this pathway from a non-coordinated form of cell death called necrosis. During the course of apoptosis, characteristic phenotypical cellular changes occur, which include the condensation of chromatin, the shrinkage of cells and finally the fragmentation of chromosomal DNA. One of the very early changes caused by apoptotic events occurs in the phospholipids bilayer of the plasma membrane. The phospholipid phosphatidylserine is translocated from the inner to the outer side of the plasma-membrane and, as a result, is exposed to the extracellular space. One way of detecting early apoptotic cells is to determine the amount of phosphatidyl-serine at the extracellular side of the plasma- membrane which is accomplished by the standard flow cytometric method of Annexin V staining. The phospholipids recognizing protein Annexin V binds with high affinity to these inverted and exposed phosphatidyl-serines.
The ability of the compounds in this invention to induce apoptosis was tested in Ramos Burkitt -lymphoma cells. This cell line is one of the gold standard cell lines commonly used as a tissue culture model for B cell lymphoma. Representative compounds as indicated below were added to 80,000 cells per 500 μl growth medium (RPMI1640 medium supplemented with 2 mM L-Glutamine, 10% heat-inactivated FBS, 1mM Na- Pyruvate and 10 mM HEPES) in 24 well format at various concentrations. Two days after the start of treatment, cells were collected and subjected to the Annexin V staining protocol following the instructions of the manufacturer (BD Biosciences). By using propidium iodide (PI) as a viability control, cells that stain positive for Annexin V, but negative for PI, are undergoing apoptosis. The percentage of cells in late apoptosis after treatment was derived from a standard flow cytometry (FACS) analysis [Steensma et al, Methods Mol Med 85:323-32 (2003). For example, the percentage of late apoptotic cells 48 hr after treatment with 10 μM was 84% for compound Example 3 (Λ/-Hydroxy-3-{3-[3-
(4-methylbenzenesulfonyl)ureido]-phenyl}-acrylamide). In addition, selected compounds are tested for their ability to induce apoptosis in HL-60 cells which is an acute promyelocytic leukemia cell line (data not shown). Hence, compounds disclosed in this invention can be used to treat cancers including hematologic malignancies (e.g. lymphoma and leukemia).
In vivo Xenograft Tumor Study
In data not shown, selected compounds were tested for maximal tolerated dose in normal mice and were found to be well tolerated by the mice with no obvious signs of toxicity or side effects in the dose range applied (which can be > 200 mg/kg/day).
The efficacy of the compounds of the invention can then be determined using in vivo animal xenograft studies. The animal xenograft model is one of the most commonly used in vivo cancer models.
In these studies Female athymic nude mice (Harlan), 12-14 weeks of age would be implanted subcutaneously in the flank with 5 x 106 cells of HCT116 or with 1 x 106 cells of Colo205 human colon carcinoma suspended in 50% Matrigel. When the tumor reaches the size 100 mm3, the xenograft nude mice would be paired-match into various treatment groups. The selected HDAC inhibitors would be dissolved in appropriate vehicles, such as 10%DMA/10% Cremophore/80%water and administered to xenograft nude mice intraperitonelly by daily for 14 days. The dosing volume will be 0.2-ml/20g mouse. Paclitaxol, used as positive control, will be prepared for intravenous administration in 10%Ethanol/10%Cremophore/80%water. The dosing volume for Paclitaxol will be 0.015- ml/g mouse. Tumor volume will be calculated every second day of post injection using the formula: Tumor volume (mm3) = (w2 x l)/2, where w = width and I = length in mm of an HCT116 or Colo205 carcinoma [Beverly AT, In Tumor Models in Cancer Research, published by Humana Press, New Jersey, p 593-612, 2002]. Compounds in this invention that are tested would show significant reduction in tumor volume relative to controls treated with vehicle only. The activity of histone deacetylase when measured shall be reduced and results in accumulation of acetylated histone relative to vehicle treated control group. The result will therefore indicate that compounds in this invention are efficacious in treating a proliferative disorder such as cancer.
The details of specific embodiments described in this invention are not to be construed as limitations. Various equivalents and modifications may be made without departing from
the essence and scope of this invention, and it is understood that such equivalent embodiments are part of this invention.
Claims
1. A compound of the Formula (I)
I Formula (I) wherein R is a linking moiety; R1 is selected from the group consisting of H, Ci -C6 alkyl and acyl;
M is selected from the group consisting of O, S, NH, NR4, NOH and NOR4;
R2 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR4, CONHR4, NHCOR4,
NHCOOR4, NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted, or R2 together with the nitrogen to which it is attached and a portion of R form an optionally substituted heterocycloalky group;
R3 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy,
heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR4, CONHR4, NHCOR4,
NHCOOR4' NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted;
Q is selected from the group consisting of -S(0)2-, -C(=0)- and -C(=S)-;
G is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; each R4 is independently selected from the group consisting of H, alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted; or a pharmaceutically acceptable salt or prodrug thereof. A compound according to claim 1 having the Formula (2)
Formula
(2) wherein R1 is selected from the group consisting of H, Ci ■ -Ce i alkyl and acyl;
L is a single bond or is a C1-C5 hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -0-, -S-, -S(O)- and -S(0)2- and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C C4 alkyl;
Z is selected from the group consisting of a single bond, N(R1), O, S, S(O) and
S(0)2;
A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;
B is selected from the group consisting of a single bond, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, optionally substituted alkylheteroarylene, optionally substituted C C3 alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene and optionally substituted -(CH2)m-C(0)-N(R4)- (CH2)n-, wherein n is an integer from 0 to 6, m is an integer from 0 to 6;
M is selected from the group consisting of O, S, NH, NR , NOH and NOR 4 ;.
R2 is selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR4, CONHR4, NHCOR4, NHCOOR4 NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted, or R2 together with the nitrogen to which it is attached and a portion of B form an optionally substituted heterocycloalky group;
R3 is independently selected from the group consisting of H, halogen, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl,
alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, phenoxy, benzyloxy, COOR4, CONHR4, NHCOR4, NHCOOR4, NHCONHR4, C(=NOH)R4, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, aminosulfinyl, SR4 and acyl; each of which may optionally be substituted;
Q is selected from the group consisting of -S(O)2-, -C(=0)- and -C(=S)-; G is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl; each R4 is independently selected from the group consisting of H, alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl; each of which may be optionally substituted; or a pharmaceutically acceptable salt or prodrug thereof.
3. A compound according to claim 1 or 2 having the Formula (2a)
Formula (2a) wherein R1 is selected from the group consisting of H, Ci ■ ■Cβ alkyl and acyl; L is a single bond or is a C C5 hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -0-, -S-, -S(O)- and -S(0)2- and
the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C C alkyl;
Z is selected from the group consisting of a single bond, N(R1), O, S, S(O) and S(O)2;
A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;
B is selected from the group consisting of a single bond, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, optionally substituted alkylheteroarylene, optionally substituted C C3 alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene optionally substituted heterocycloalkylene and optionally substituted -(CH2)m-C(0)-N(R4)- (CH2)n-, wherein n is an integer from 0 to 6, m is an integer from 0 to 6;
M is selected from the group consisting of O, S, NH, NR4, NOH and NOR4;
R2 is selected from the group consisting of H, Ci -C10 alkyl, alkenyi, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C4 -C9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, -C(O)OR4, -CONHR4, -NHCONHR4, C(=NOH)R4, and acyl;
R3 is selected from the group consisting of H, Ci -C-ι0 alkyl, alkenyi, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, C4 -C9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, -C(0)OR4, -CONHR4, -NHCONHR4, C(=NOH)R4, and acyl; Q is selected from the group consisting of -S(0)2-, -CO- and -C(=S)-;
G is selected from optionally substituted aryl, optionally substituted heteroaryl, alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl, wherein the substituents are independently selected from the group consisting of X, Y, R4, hydroxyl, hydroxyalkyl, alkoxy, amino, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylosulfonyl, arylsulfonyl, aminosulfonyl, -C(0)OR4, -C(0)OH, -SH, -CONHR4, -
NHCONHR4, and C(=NOH)R4;
R4 is selected from the group consisting of C C alkyl, heteroalkyl, aryl, heteroaryl and acyl;
X and Y are the same or different and are independently selected from the group consisting of H, halo, C C4 alkyl, N02, OR4, SR4, C(0)R5, and NR6R7; R5 is C C4 alkyl;
R6 and R7 are the same or different and are independently selected from the group consisting of H, Cι-C6 alkyl, C -C9 cycloalkyl, C4-C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroaryl alkyl.
or a pharmaceutically acceptable salt or prodrug thereof.
4. A compound according to claim 2 or 3 having the Formula (2b)
Formula (2b) or a pharmaceutically acceptable salt or prodrug thereof.
A compound according to any one of claims 2-4 having the Formula (2c)
Formula (2c) or a pharmaceutically acceptable salt or prodrug thereof.
6. A compound according to any one of claims 2 to 4 wherein A is optionally substituted arylene.
7. A compound according to any one of claims 2 to 4 wherein A selected from the group consisting of 1 ,4-phenylene and 1 ,3-phenylene.
8. A compound according to any one of claims 2 to 4 wherein A is 1 ,4-phenylene.
9. A compound according to any one of 2 to 8 wherein L is selected from the group consisting of a single bond, -CH2-, -(CH2)2 - and -CH=CH-.
10. A compound according to any one of claims 2 to 9 wherein L is a bond.
11. A compound according to any one of claims 2 to 9 wherein L is a group of formula -CH2-.
12. A compound according to any one of claims 2 to 9 wherein L is a group of formula -CH=CH-.
13. A compound according to any one of claims 2 to 12 wherein B is selected from the group consisting of a single bond, methylene, ethylene, propylene, alkylarylene, and heteroalkylene.
14. A compound according to any one of claims 2 to 13 wherein B is methylene.
15. A compound according to any one of claims 2 to 13 wherein B is a single bond.
16. A compound according to any one of claims 2 to 13 wherein B is ethylene.
17. A compound according to any one of claims 2 to 13 wherein B is propylene.
18. A compound according to claim 2 or 3 wherein the group BAZL is a group of formula -(CH2)π- wherein n is an integer from 1 to 7.
19. A compound according to claim 2 or 3 wherein the group BAZ is a group of formula -(CH2)- phenyl-.
20. A compound according to claim 2 or 3 wherein the group BAZL is selected from the group consisting of
1 (CH2)7 } j (CH2)6 j j (CH2)5 \ } (CH2)4 \ } (CH2)3
is a single bond
21. A compound according to any one of claims 2 to 20 wherein R2 and a portion of B together with the nitrogen to which they are attached form a heterocyloalkylene.
22. A compound according to claim 21 wherein the heterocycloalkylene is 1 ,4- piperazinylene.
23. A compound according to any one of claims 1 to 22 wherein R = H
24. A compound according to any one of claims 1 to 23 wherein M is O.
25. A compound according to any one of claims 1 to 23 wherein M is S.
26. A compound according to any one of claims 1 to 23 wherein Q is S(0)2.
27. A compound according to any one of claims 1 to 23 wherein Q is CO.
28. A compound according to any one of claims 1 to 27 wherein G is optionally substituted aryl.
29. A compound according to any one of claims 1 to 28 wherein G is phenyl.
30. A compound according to any one of claims 1 to 28 wherein G is 4-methylphenyl.
31. A compound according to any one of claims 1 to 30 wherein R2 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted arylheteroalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylheteroalkyl, optionally substituted cycloalkylalkyl and optionally substituted heterocycloalkylalkyl.
32. A compound according to any one of claims 1 to 31 wherein R2 is selected from the group consisting of H, 2-(1 H-indol-3-yl)-ethyl, 2-(2-methyl-1 H-indol-3-yl)-ethyl, pyridin-
3-ylmethyl, 3-hydroxy-propyl, 2-pyridin-2-yl-ethyl, 2-pyridin-3-yl-ethyl, pyridin-3-ylmethyl, 2-pyridin-4-yl-ethyl, benzyl, 3-phenyl-propyl, 2-phenoxy-ethyl, morphoiin-4-yl, pyridin-2-yl, phenethyl, 2-(4-bromo-phenyl)-ethyl, 2-(4-fluoro-phenyl)-ethyl, 3-imidazol-1 -yl-propyl, 2- (1 H-imidazol-4-yl)-ethyl, 1 H-Benzoimidazol-2-ylmethyl, 2-piperidin-1 -yl-ethyl, 2-pyrrolidin- 1 -yl-ethyl, 2-cyclohex-1 -enyl-ethyl, 2-ethyl-hexyl, 2-thiophen-2-yl-ethyi, 3,3-diphenyl- propyl, 2-biphenyl-4-yl-ethyl, -(4-phenoxy-phenyl, 2-(3-phenoxy-phenyl)-ethyl, 2-(2,3- dimethoxy-phenyl, 2-(2,4-dichloro-phenyl)-ethyl, cyclohexylmethyl, hexyl, isobutyl, 3- isopropoxy-propyl, 2-phenoxy-ethyl, 2-isopropoxy-ethyl, 3-methoxy-benzyl, 4- [1 ,2,3]thiadiazol-4-yl-benzyl, 2,4-dichloro-benzyl, 2-(2-methoxy-phenyl)-ethyl, 2-(3-fluoro- phenyl)-ethyl, 2-(2-fluoro-phenyl)-ethyl, 2,2-diphenyl-ethyl, 2-(4-methoxy-phenyl)-ethyl, 2- (3-chloro-phenyl)-ethyl, 4-phenyl-butyl, 3-phenyl-propyl, 3,3-diphenyl-propyl, 3-(4-methyl- piperazin-1-yl, 3-morpholin-4-yl-propyl, 3-(2-oxo-pyrrolidin-1-yl)-propyl, 3-pyrrolidin-1-yl-
propyl, tetrahydro-furan-2-ylmethyl, 1,5-dimethyl-hexyl, 2-diethylamino-ethyl and 2- dimethylamino-ethyl.
33. A compound according to any one of claims 1 to 31 wherein R2 is selected from the group consisting of H, 2-(1 H-indol-3-yl)-ethyl, 2-(2-methyl-1 H-indol-3-yl)-ethyl, pyridin- 3-ylmethyl, 3-hydroxy-propyl, 2-pyridin-2-yl-ethyl, 2-pyridin-3-yl-ethyl, pyridin-2-ylmethyl, pyridin-3-ylmethyl, 2-pyridin-4-yl-ethyl, benzyl, 3-phenyl-propyl, 2-phenoxy-ethyl, 2- morpholino ethyl, 2-phenyl ethyl, 2-(4-bromo-phenyl)-ethyl, 2-(4-fluoro-phenyl)-ethyl, 3- imidazol-1 -yl-propyl, 2-(1H-imidazol-4-yl)-ethyl, 1 H-Benzoimidazol-2-ylmethyl, 2-piperidin- 1 -yl-ethyl and 2-pyrrolidin-1 -yl-ethyl.
34. A compound according to any one of claims 1 to 31 wherein R2 is selected from the group consisting of H, 2-(1 H-indol-3-yl)-ethyl, 2-(2-methyl-1 H-indol-3-yl)-ethyl, 2- phenyl ethyl, 2-piperidin-1 -yl-ethyl and 2-pyrrolidin-1 -yl-ethyl.
35. A compound according to any one of claims 1 to 34 wherein the optional substituents are selected from the group consisting of halogen, =0, =S, -CN, -N02, -CF3, -OCF3, alkyl, alkenyi, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkenyl, heterocycloalkylalkenyl, arylalkenyl, heteroarylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, arylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycycloalkyl, alkoxyheterocycloalkyl, alkoxyaryl, alkoxyheteroaryl, alkoxycarbonyl, alkylaminocarbonyl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, phenoxy, benzyloxy, heteroaryloxy, arylalkyloxy, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, alkylsulfinyl, arylsulfinyl, aminosulfinylaminoalkyl, -COOH, -COR5, -C(0)OR5, CONHR5, NHCOR5, NHCOOR5, NHCONHR5, C(=NOH)R5 -SH, -SR5, -OR5 and acyl, wherein each R5 is independently selected from the group consisting of alkyl, alkenyi, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted;
36. A compound according to claim 1 selected from the group consisting of
8-[3-(4-methylbenzenesulfonyl)-ureido])- octanoic acid hydroxyamide,
7-[3-(4-methylbenzenesulfonyl)-ureido])- heptanoic acid hydroxyamide,
6-[3-(4-methylbenzenesulfonyl)-ureido])- hexanoic acid hydroxyamide,
6-[3-(benzenesulfonyl)-ureido])-hexanoic acid hydroxyamide,
N-Hydroxy-4-[3-(4- methylbenzenesulfonyl)ureido]methyl- benzamide,
N-Hydroxy-2-{4-[3-(4- methylbenzenesulfonyl)ureido]~phenyl}- acetamide,
N-Hydroxy-2-{3-[3-(4- methylbenzenesulfonyl)ureido]-phenyl}- acetamide,
N-Hydroxy-3-{4-[3-(4- methylbenzenesulfonyl)ureido]-phenyl}- acrylamide,
N-Hydroxy-3-{3-[3-(4- methylbenzenesulfonyl)ureido]-phenyl}- acrylamide,
6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide,
7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide,
8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide,
6-[3-Benzoyl-1-(3-phenyl-propyl)-ureido]- hexanoic acid hydroxyamide,
4-(3-Benzoyl-ureidomethyl)-N-hydroxy- benzamide,
2-[4-(3-Benzoyl-ureido)-phenyl]-N- hydroxy-acetamide,
2-[3-(3-Benzoyl-ureido)-phenyl]-N- hydroxy-acetamide,
3-[4-(3-Benzoyl-ureido)-phenyl]-N- hydroxy-acrylamide,
3-(4-{3-Benzoyl-1 -[2-(1 H-indol-3-yl)- ethyl]-ureidomethyl}-phenyl)-N-hydroxy- acrylamide,
3-[4-(3-Benzoyl-1-pyridin-3-ylmethyl- ureidomethyl)-phenyl]-N-hydroxy- acrylamide,
3-{4-[3-Benzoyl-1-(3-hydroxy-propyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
4-{3-Benzoyl-1-[2-(1 H-indol-3-yl)-ethyl]- ureidomethyl}-N-hydroxy-benzamide,
4-(3-Benzoyl-ureido)-N-hydroxy- butyramide,
4-(3-Benzoyl-1-benzyl-ureidomethyl)-N- hydroxy-benzamide,
4-[3-Benzoyl-1-(2-pyridin-2-yl-ethyl)- ureidomethyl]-N-hydroxy-benzamide,
4-[3-Benzoyl-1-(3-hydroxy-propyl)- ureidomethyl]-N-hydroxy-benzamide,
3-[4-(3-Benzoyl-1-benzyl-ureidomethyl)- phenyl]-N-hydroxy-acrylamide,
3-{4-[3-Benzoyl-1-(3-phenyl-propyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-{4-[3-Benzoyl-1-(2-phenoxy-ethyI)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
4-[3-Benzoyl-1-(3-phenyl-propyl)- ureidomethyl]-N-hydroxy-benzamide,
4-(3-Benzoyl-1-pyridin-3-ylmethyl- ureidomethyl)-N-hydroxy-benzamide,
(S)-6-[2-(3-Benzoyl-ureido)-3-(1H-indol- 3-yl)-propionylamino]-hexanoic acid hydroxyamide,
4-(4-Benzoylaminocarbonyl-piperazin-1- ylmethyl)-N-hydroxy-benzamide,
7-(3-Benzoyl-1-pyridin-2-ylmethyl- ureido)-heptanoic acid hydroxyamide,
6-(3-Benzoyl-1-pyridin-2-ylmethyl- ureido)-hexanoic acid hydroxyamide,
3-{4-[3-Benzoyl-1-(2-morpholin-4-yl- ethyl)-ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
7-(3-Benzoyl-1-benzyl-ureido)-heptanoic acid hydroxyamide,
6-(3-Benzoyl-1-benzyl-ureido)-hexanoic acid hydroxyamide,
3-{4-[3-Benzoyl-1-(2-pyridin-2-yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-[4-(3-Benzoyl-1 -phenethyl- ureidomethyl)-phenyl]-N-hydroxy- acrylamide,
3-(4-{3-Benzoyl-1-[2-(4-bromo-phenyl)- ethyl]-ureidomethyl}-phenyl)-N-hydroxy- acrylamide,
3-(4-{3-Benzoyl-1-[2-(4-fluoro-phenyl)- ethyl]-ureidomethyl}-phenyl)-N-hydroxy- acrylamide,
N-{4-[4-(2-Hydroxycarbamoyl-vinyl)- benzyl]-piperazine-1 -carbonyl}- benzamide,
3-{4-[3-Benzoyl-1 -(3-imidazol-1 -yl- propyl)-ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-(4-{3-Benzoyl-1 -[2-(1 H-imidazol-4-yl)- ethyl]-ureidomethyl}-phenyl)-N-hydroxy- acrylamide,
6-(3-Benzoyl-thioureido)-hexanoic acid hydroxyamide,
3-{4-[1 -(1 H-Benzoimidazol-2-ylmethyl)-3- benzoyl-ureidomethyl]-phenyl}-N- hydroxy-acrylamide,
3-{4-[3-BenzoyI-1-(2-pyridin-3-yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-{4-[3-Benzoyl-1-(2-pyridin-4-yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-{4-[3-Benzoyl-1 -(2-piperidin-1 -yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-{4-[3-Benzoyl-1 -(2-pyrrolidin-1 -yl- ethyl)-ureidomethyl]-phenyl}-N-hydroxy- acrylamide
or a pharmaceutically acceptable salt or prodrug thereof.
37. A compound according to claim 1 selected from the group consisting of
6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide,
8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide,
4-(3-Benzoyl-ureidomethyl)-N-hydroxy- benzamide,
3-(4-{3-Benzoyl-1 -[2-(1 H-indol-3-yl)-ethyrj- ureidomethyl}-phenyl)-N-hydroxy- acrylamide,
3-[4-(3-Benzoyl-1-phenethyl-ureidomethyl)- phenyl]-N-hydroxy-acrylamide,
6-(3-Benzoyl-thioureido)-hexanoic acid hydroxyamide,
3-{4-[3-Benzoyl-1 -(2-piperidin-1 -yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
3-{4-[3-Benzoyl-1 -(2-pyrrolidin-1 -yl-ethyl)- ureidomethyl]-phenyl}-N-hydroxy- acrylamide,
or a pharmaceutically acceptable salt or prodrug thereof.
38. A pharmaceutical composition including a compound according to any one of claims 1 to 37 and a pharmaceutically acceptable diluent, excipient or carrier.
39. Use of a compound according to any one of claims 1 to 37 in the preparation of a medicament for the treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis.
40. A use according to claim 39 wherein the disorder is a proliferative disorder.
41. A use according to claim 40 wherein the proliferative disorder is cancer.
42. A use according to claim 41 wherein the cancer is selected from breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.
43. A method of treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis in a patient the method including administration of a therapeutically effective amount of a compound according to any one of claims 1 to 37 to the patient.
44. A method according to claim 43 wherein the disorder is a proliferative disorder.
45. A method according to claim 44 wherein the proliferative disorder is cancer.
46. A method according to claim 45 wherein the cancer is selected from breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.
47. Use of a compound according to any one of claims 1 to 37 or a pharmaceutical composition according to claim 38 to modify deacetylase activity.
48. A use according to claim 47 wherein the deacetylase activity is histone deacetylase activity.
49. A use according to claim 47 wherein the deacetylase activity is class I histone deacetylase activity.
50. A use according to claim 48 or 49 wherein the histone deacetylase is HDAC1.
51. A use according to claim 48 or 49 wherein the histone deacetylase is HDAC8.
52. A method of modifying deacetylase activity including contacting the deacetylase with a compound according to any one of claims 1 to 37.
53. A method according to claim 52 wherein the deacetylase activity is histone deacetylase activity.
54. A method according to claim 52 wherein the deacetylase activity is class I histone deacetylase activity.
55. A method according to claim 53 or 54 wherein the histone deacetylase is HDAC1.
56. A method according to claim 53 or 54 wherein the histone deacetylase is HDAC8.
57. A method of treatment of a disorder that can be treated by the inhibition of deacetylase activity in a patient including administration of a therapeutically effective amount of a compound according to any one of claims 1 to 37 to the patient.
58. A method according to claim 57 wherein the deacetylase activity is histone deacetylase activity.
59. A method of treatment of a disorder that is mediated by histone deacetylase activity in a patient including administration of a therapeutically effective amount of a compound according to any one of claims 1 to 37 to the patient.
60. A method according to any one of claims 57 to 59 wherein the disorder is selected from the group consisting of Proliferative disorders (e.g. cancer); Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesis, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Progressive supranuclear palsy, Pick's disease, Intracerebral haemorrhage, Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration, Rubeotic glaucoma, Interstitial keratitis, Diabetic retinopathy; Inflammatory diseases and/or Immune system disorders including Rheumatoid Arthritis (RA), Osteoarthritis, Juvenile chronic arthritis, Graft versus Host disease, Psoriasis, Asthma, Spondyloarthropathy, Crohn's Disease, Inflammatory bowel disease , Colitis Ulcerosa, Alcoholic hepatitis, Diabetes , Sjoegrens's syndrome, Multiple Sclerosis, Ankylosing spondylitis, Membranous glomerulopathy, Discogenic pain, Systemic Lupus Erythematosus; Disease involving angiogenesis including cancer, psoriasis, rheumatoid arthritis; Psychological disorders including bipolar disease, schizophrenia, mania, depression and dementia; Cardiovascular Diseases including Heart failure, restenosis and arteriosclerosis; Fibrotic diseases including liver fibrosis, cystic fibrosis and angiofibroma; Infectious diseases including Fungal infections, such as Candida Albicans, Bacterial infections, Viral infections, such as Herpes Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.
61. A method for inhibiting cell proliferation including administration of an effective amount of a compound according to any one of claims 1 to 37.
62. A method of treatment of a neurodegenerative disorder in a patient including administration of a therapeutically effective amount of a compound according to any one of claims 1 to 37 to the patient.
63. A method according to claim 62 wherein the neurodegenerative disorder is Huntington's Disease.
64. A method of treatment of an inflammatory disease and/or immune system disorder in a patient including administration of a therapeutically effective amount of a compound according to any one of claims 1 to 37 to the patient.
65. A method according to claim 64 wherein the inflammatory disease and/or immune system disorder is rheumatoid arthritis.
66. A method according to claim 64 wherein the inflammatory disease and/or immune system disorder is systemic lupus erythematosus.
67. The use of a compound according to any one of claims 1 to 37 in the manufacture of a medicament for the treatment of cancer.
68. A use according to claim 67 wherein the cancer is a hematologic malignancy.
69. A use according to claim 68 wherein the hematologic malignancies are selected from a group consisting of B-cell lymphoma, T-cell lymphoma and leukemia.
70. A use according to claim 67 wherein the cancer is a solid tumor.
71. A use according to claim 70 wherein the solid tumor is selected from the group consisting of breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.
72. A method of treatment of a proliferative disorder in patient including administration of a therapeutically effective amount of a compound according to any one of claims 1 to 37 to the patient.
73. A method of treatment of cancer in patient including administration of a therapeutically effective amount of a compound according to any one of claims 1 to 37 to the patient.
74. A method according to claim 73 wherein the cancer is a hematologic malignancy.
75. A method according to claim 74 wherein the hematologic malignancy is selected from the group consisting of B-cell lymphoma, T-cell lymphoma and leukemia.
76. A method according to claim 73 wherein the cancer is a solid tumor.
77. A method according to claim 76 wherein the solid tumor is selected from the group consisting of breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.
78. Use of a compound according to any one of claims 1 to 37 in the manufacture of a medicament for the induction of apoptosis of tumor cells.
79. A method of induction of apoptosis of a cell including contacting the cell with an effective amount of a compound according to any one of claims 1 to 37.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51401303P | 2003-10-27 | 2003-10-27 | |
PCT/SG2004/000353 WO2005040101A1 (en) | 2003-10-27 | 2004-10-26 | Acylurea connected and sulfonylurea connected hydroxamates |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1685094A1 true EP1685094A1 (en) | 2006-08-02 |
EP1685094A4 EP1685094A4 (en) | 2007-08-22 |
Family
ID=34520162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04775672A Withdrawn EP1685094A4 (en) | 2003-10-27 | 2004-10-26 | Acylurea connected and sulfonylurea connected hydroxamates |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1685094A4 (en) |
JP (1) | JP2007509930A (en) |
AR (1) | AR046920A1 (en) |
AU (1) | AU2004284030A1 (en) |
CA (1) | CA2543570A1 (en) |
MX (1) | MXPA06004735A (en) |
TW (1) | TW200530166A (en) |
WO (1) | WO2005040101A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7884105B2 (en) | 2005-10-27 | 2011-02-08 | Janssen Pharmaceutica, N.V. | Squaric acid derivatives as inhibitors of histone deacetylase |
US8101616B2 (en) | 2006-01-19 | 2012-01-24 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8119650B2 (en) | 2006-01-19 | 2012-02-21 | Janssen Pharmaceutica N.V. | Aminophenyl derivatives as novel inhibitors of histone deacetylase |
US8138198B2 (en) | 2005-05-18 | 2012-03-20 | Angibaud Patrick Rene | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
US8163765B2 (en) | 2006-01-19 | 2012-04-24 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
US8193205B2 (en) | 2004-07-28 | 2012-06-05 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
US8268833B2 (en) | 2002-03-13 | 2012-09-18 | Janssen Pharmaceutica, N.V. | Inhibitors of histone deacetylase |
US8664223B2 (en) | 2006-01-19 | 2014-03-04 | Janssen Pharmaceutica N.V | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040094672A (en) | 2002-03-13 | 2004-11-10 | 얀센 파마슈티카 엔.브이. | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
WO2003076438A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
CA2476067C (en) | 2002-03-13 | 2011-09-20 | Janssen Pharmaceutica N.V. | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
RS51189B (en) | 2004-07-28 | 2010-10-31 | Janssen Pharmaceutica N.V. | Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase |
ITMI20041869A1 (en) | 2004-10-01 | 2005-01-01 | Dac Srl | NEW INHIBITORS OF DEACETYLASE HISTONS |
ITMI20060621A1 (en) * | 2006-03-31 | 2007-10-01 | Dac Srl | NEW CLASS OF INHIBITORS OF DEACETILASE HISTONS |
US8242175B2 (en) | 2004-10-01 | 2012-08-14 | Dac S.R.L. | Class of histone deacetylase inhibitors |
ITFI20050041A1 (en) * | 2005-03-15 | 2006-09-16 | Menarini Internat Operations Luxembourg Sa | HYDROXAMMED AS INHIBITORS OF ISTONE DEACELITASIS, THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM |
EP1874294A4 (en) * | 2005-04-20 | 2010-12-01 | Merck Sharp & Dohme | Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions |
WO2007011626A2 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7888360B2 (en) | 2006-01-19 | 2011-02-15 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
DK1981871T3 (en) | 2006-01-19 | 2012-02-13 | Janssen Pharmaceutica Nv | Heterocyclyl alkyl derivatives as novel inhibitors of histone deacetylase |
EP2142190A1 (en) * | 2007-05-04 | 2010-01-13 | Novartis Ag | Use of hdac inhibitors for the treatment of gastrointestinal cancers |
CN101417967A (en) * | 2007-10-26 | 2009-04-29 | 浙江海正药业股份有限公司 | Histone deacetylase inhibitor, compounds thereof and use thereof |
WO2009118370A1 (en) | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
WO2011009059A2 (en) * | 2009-07-17 | 2011-01-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of treating or preventing cancer |
WO2013041407A1 (en) * | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
AU2013230881A1 (en) * | 2012-03-07 | 2014-10-30 | Board Of Trustees Of The University Of Illinois | Selective histone deactylase 6 inhibitors |
US9409858B2 (en) | 2012-03-07 | 2016-08-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
AU2014260605B2 (en) * | 2013-04-29 | 2016-07-14 | Chong Kun Dang Pharmaceutical Corp. | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same |
WO2015017546A1 (en) | 2013-07-30 | 2015-02-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
EP3769757A3 (en) * | 2013-10-18 | 2021-10-06 | The General Hospital Corporation | Imaging histone deacetylases with a radiotracer using positron emission tomography |
WO2015137750A1 (en) * | 2014-03-12 | 2015-09-17 | Chong Kun Dang Pharmaceutical Corp. | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same |
CN113288888B (en) * | 2021-05-28 | 2023-02-03 | 烟台邦杰生物科技有限公司 | Compounds with vasodilating activity |
CN115703730A (en) * | 2021-08-16 | 2023-02-17 | 中国科学院上海药物研究所 | Sulfonylurea compound, preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004143053A (en) * | 2002-10-22 | 2004-05-20 | Senju Pharmaceut Co Ltd | beta-AMINOHYDROXAMIC ACID DERIVATIVE AND USE THEREOF |
-
2004
- 2004-10-26 WO PCT/SG2004/000353 patent/WO2005040101A1/en active Application Filing
- 2004-10-26 EP EP04775672A patent/EP1685094A4/en not_active Withdrawn
- 2004-10-26 TW TW093132561A patent/TW200530166A/en unknown
- 2004-10-26 AU AU2004284030A patent/AU2004284030A1/en not_active Abandoned
- 2004-10-26 AR ARP040103893A patent/AR046920A1/en unknown
- 2004-10-26 JP JP2006537946A patent/JP2007509930A/en active Pending
- 2004-10-26 CA CA002543570A patent/CA2543570A1/en not_active Abandoned
- 2004-10-26 MX MXPA06004735A patent/MXPA06004735A/en not_active Application Discontinuation
Non-Patent Citations (7)
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8455498B2 (en) | 2002-03-13 | 2013-06-04 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
US9556161B2 (en) | 2002-03-13 | 2017-01-31 | Janssen Pharmaceutica Nv | Inhibitors of histone deacetylase |
US9533979B2 (en) | 2002-03-13 | 2017-01-03 | Janssen Pharmaceutica Nv | Amino-derivatives as novel inhibitors of histone deacetylase |
US9150560B2 (en) | 2002-03-13 | 2015-10-06 | Janssen Pharmaceutica Nv | Inhibitors of histone deacetylase |
US8916554B2 (en) | 2002-03-13 | 2014-12-23 | Janssen Pharmaceutica, N.V. | Amino-derivatives as novel inhibitors of histone deacetylase |
US8697717B2 (en) | 2002-03-13 | 2014-04-15 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
US8268833B2 (en) | 2002-03-13 | 2012-09-18 | Janssen Pharmaceutica, N.V. | Inhibitors of histone deacetylase |
US8343988B2 (en) | 2002-03-13 | 2013-01-01 | Janssen Pharmaceutica, N.V | Inhibitors of histone deacetylase |
US8524711B2 (en) | 2002-03-13 | 2013-09-03 | Janssen Pharmaceutica N.V. | Amino-derivatives as novel inhibitors of histone deacetylase |
US8193205B2 (en) | 2004-07-28 | 2012-06-05 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
US8524728B2 (en) | 2004-07-28 | 2013-09-03 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
US8592441B2 (en) | 2004-07-28 | 2013-11-26 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
US9150543B2 (en) | 2004-07-28 | 2015-10-06 | Janssen Pharmaceutica N. V. | Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase |
US9636341B2 (en) | 2004-07-28 | 2017-05-02 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
US8377935B2 (en) | 2005-05-18 | 2013-02-19 | Janssen Pharmaceutica N.V. | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
US8138198B2 (en) | 2005-05-18 | 2012-03-20 | Angibaud Patrick Rene | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
US7884105B2 (en) | 2005-10-27 | 2011-02-08 | Janssen Pharmaceutica, N.V. | Squaric acid derivatives as inhibitors of histone deacetylase |
US8664223B2 (en) | 2006-01-19 | 2014-03-04 | Janssen Pharmaceutica N.V | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8163765B2 (en) | 2006-01-19 | 2012-04-24 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
US9078896B2 (en) | 2006-01-19 | 2015-07-14 | Janssen Pharmaceutica, N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8119650B2 (en) | 2006-01-19 | 2012-02-21 | Janssen Pharmaceutica N.V. | Aminophenyl derivatives as novel inhibitors of histone deacetylase |
US8101616B2 (en) | 2006-01-19 | 2012-01-24 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
Also Published As
Publication number | Publication date |
---|---|
WO2005040101A1 (en) | 2005-05-06 |
AR046920A1 (en) | 2006-01-04 |
JP2007509930A (en) | 2007-04-19 |
CA2543570A1 (en) | 2005-05-06 |
MXPA06004735A (en) | 2006-12-14 |
AU2004284030A1 (en) | 2005-05-06 |
EP1685094A4 (en) | 2007-08-22 |
TW200530166A (en) | 2005-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005040101A1 (en) | Acylurea connected and sulfonylurea connected hydroxamates | |
US10736881B2 (en) | Benzimidazole derivatives: preparation and pharmaceutical applications | |
US20070167499A1 (en) | Biaryl linked hydroxamates: preparation and pharmaceutical applications | |
US8143282B2 (en) | Heterocyclic compounds | |
EP2208721B1 (en) | Histone deacetylase inhibitor, composition and use thereof | |
WO2006101456A1 (en) | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors | |
US7019003B2 (en) | Peptide deformylase inhibitors | |
WO2006101454A1 (en) | Benzothiophene derivatives: preparation and pharmaceutical applications | |
EP0764632B1 (en) | Selective beta3 adrenergic agonists | |
US11858919B2 (en) | HDAC1,2 inhibitors | |
EP1673349B1 (en) | Benzimidazole derivatives: preparation and pharmaceutical applications | |
US20080070954A1 (en) | Acylurea Connected And Sulfonylurea Connected Hydroxamates | |
AU2006201177B2 (en) | Heterocyclic compounds | |
AU2004274382B2 (en) | Benzimidazole derivatives: preparation and pharmaceutical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060529 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070723 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100504 |